Nonsense Mediated RNA Decay Promotes Survival of Cells with Defective Splicing by Cheruiyot, Abigael Jeruto
Washington University in St. Louis 
Washington University Open Scholarship 
Arts & Sciences Electronic Theses and 
Dissertations Arts & Sciences 
Spring 5-15-2020 
Nonsense Mediated RNA Decay Promotes Survival of Cells with 
Defective Splicing 
Abigael Jeruto Cheruiyot 
Washington University in St. Louis 
Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds 
 Part of the Biology Commons, and the Cell Biology Commons 
Recommended Citation 
Cheruiyot, Abigael Jeruto, "Nonsense Mediated RNA Decay Promotes Survival of Cells with Defective 
Splicing" (2020). Arts & Sciences Electronic Theses and Dissertations. 2173. 
https://openscholarship.wustl.edu/art_sci_etds/2173 
This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open 
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an 






WASHINGTON UNIVERSITY IN ST. LOUIS 
Division of Biology and Biomedical Sciences 
Molecular Cell Biology 
 
Dissertation Examination Committee: 














A dissertation presented to  
The Graduate School  
of Washington University in 
partial fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 
 
May 2020 















© 2020, Abigael Cheruiyot
ii 
 
Table of Contents 
List of figures  ............................................................................................................................... vi 
List of Tables  ............................................................................................................................. viii 
Acknowledgements  ..................................................................................................................... ix 
Abstract  ...................................................................................................................................... xiii 
Chapter 1: NMD as a Guardian of the Central Dogma and a Target for Treating Disease ...1 
Introduction  .....................................................................................................................................2 
pre-mRNA splicing and the consequences of mis-splicing  ............................................................4 
A simplified mechanism of pre-mRNA splicing  ................................................................4 
Defective splicing and associated diseases  .........................................................................5 
Nonsense mediated RNA decay (NMD)  .........................................................................................6 
Proteins involved in NMD  ..................................................................................................6 
Mechanisms of NMD in mammalian systems  ....................................................................8 
Physiological functions of NMD  ......................................................................................11 
NMD in disease and as a potential therapeutic target  .......................................................12 
The role of RNA processing in regulating R-loops to promote genome maintenance  .................15 
R-loop formation and regulation  .......................................................................................15 
Defective splicing and R-loops  .........................................................................................16 
Potential role of NMD in R-loops Regulation  ..................................................................18 
References  .....................................................................................................................................19 
Chapter 2: Nonsense Mediated RNA Decay Is a Unique Vulnerability of Cells with 
Defective Splicing  ........................................................................................................................42 
Abstract  .........................................................................................................................................43 
Introduction  ...................................................................................................................................43 
Results  ...........................................................................................................................................45 
A novel reporter system for NMD analysis in individual cells  ........................................45 
A genome-wide CRISPR/Cas9 knockout screen identifies novel NMD-promoting 




SF3B promotes NMD in human cells in an EJC-dependent,  
but splicing-independent, manner  .....................................................................................49 
NMD activity is attenuated in cells with aberrant splicing  ...............................................51 
Cancer cells harboring spliceosome mutations are preferentially sensitive to NMD 
attenuation  .........................................................................................................................52 
R-loops are important for the hypersensitivity of spliceosome mutant  
cells to NMD disruption  ....................................................................................................55 
Discussion  .....................................................................................................................................56 
Acknowledgments  .........................................................................................................................60 
Author Contributions  ....................................................................................................................60 
Materials and Methods  ..................................................................................................................62 
Key reagents, oligo sequences, genetically modified K562 SF3B1K666N cells,  
SMG1 inhibitor  .................................................................................................................62   
Cell culture, transfection, lentivirus production and infection  .........................................62 
Generation of a fluorescence- and bioluminescence-based NMD reporter  ......................63 
Assays for NMD of the fluorescence/bioluminescence-based reporter  ............................64 
Knockdown of NMD factors  ............................................................................................65 
Pooled genome-wide CRISPR/Cas9 knockout screen to identify new NMD factors 
 and regulators  ...................................................................................................................65 
Data analysis and hit identification and validation  ...........................................................66 
lN-boxB tethering reporter and NMD analysis  ................................................................68 
Cell viability analysis  ........................................................................................................68 
Immunofluorescence to detect R-loops and gH2AX  ........................................................70 
Detection of R-loops in U2OS cells using slot blot analysis  ............................................70 
Immunoblotting .................................................................................................................71 
BrdU incorporation and cell cycle analysis  ......................................................................72 
Metaphase chromosome spreads  .......................................................................................72 
DNA fiber assay  ................................................................................................................73 





Chapter 3: Compound C Inhibits Nonsense-mediated RNA Decay Independently  
of AMPK  ....................................................................................................................................112 
Abstract  .......................................................................................................................................113 
Introduction  .................................................................................................................................113 
Results  .........................................................................................................................................116 
CC inhibits NMD activity in human cells  .......................................................................116 
CC stabilizes physiological NMD targets  .......................................................................118 
CC inhibits NMD independent of AMPK  ......................................................................119 
CC does not inhibit the kinase activity of SMG1, but it reduces the protein levels of 
multiple NMD factors  .....................................................................................................119 
CC augments the expression and stability of the NMD target ATF4, but ATF4 is 
dispensable for autophagy induced by CC  ......................................................................120 
Discussion  ...................................................................................................................................122 
Materials and methods  ................................................................................................................124 
Key reagents  ....................................................................................................................124 
Cell culture, transfection, lentivirus and adenovirus production and infection  ..............126 
NMD Reporter assays  .....................................................................................................126 
Analysis of the expression and stability of endogenous NMD targets  ...........................127 
Knockdown and knockout of AMPKα or ATF4 in human cells  ....................................129 
Immunoprecipitation and in vitro kinase assay  ..............................................................130 
Immunofluorescence staining to detect LC3B foci  ........................................................130 
Electron Microscopy and quantification of autophagosomes  .........................................130 
Acknowledgments  .......................................................................................................................132 
References  ...................................................................................................................................142 
Chapter 4: Conclusions and Future Directions  .....................................................................153 
Conclusions  .................................................................................................................................154 
Future Directions  ........................................................................................................................157 
How does SF3B promote NMD?  ....................................................................................157 
How do cancer-associated splicing factor mutations attenuate NMD?  ..........................158 
How do dysregulated splicing and disruption of NMD increase R-loops? .....................159 
Developing small molecule inhibitors of NMD  ..............................................................162 
v 
 
Targeting NMD and other pathways to treat cancers with defective splicing .................163 


















List of Figures 
Chapter 1: Introduction to RNA Surveillance and Its Role in Genome Maintenance 
Figure 1.1: A schematic representation of the main steps of splicing by the major 
spliceosome  .........................................................................................................................5 
Figure 1.2: A schematic representation of an EJC-dependent model of NMD                    
in human cells  ...................................................................................................................10 
Figure 1.3: A Schematic representation of R-loop formation and regulation  ...................16 
Chapter 2: Nonsense Mediated RNA Decay Is a Unique Vulnerability of Cells with 
Defective Splicing 
Figure 2.1: A new reporter system for analyzing NMD in individual human cells  ..........75 
Figure 2.2: A genome-wide CRISPR/Cas9 knockout screen to identify novel NMD 
factors and regulators  ........................................................................................................77 
Figure 2.3: SF3B complex promotes NMD in an EJC-dependent, but splicing-
independent, manner  .........................................................................................................79 
Figure 2.4: Cells expressing mutant spliceosome factors rely more on NMD                      
for survival  ........................................................................................................................82 
Figure 2.5: Elevated R-loop formation is a major underlying mechanism for the 
hypersensitivity of spliceosome mutant cells to NMD inhibition  ....................................85 
Figure S2.1: A new reporter system for analyzing NMD in individual human cells  .......87 
Figure S2.2: A genome-wide CRISPR/Cas9 knockout screen to identify novel NMD 
factors and regulators  ........................................................................................................88 
Figure S2.3: SF3B complex promotes NMD in an EJC-dependent, but splicing-
independent, manner  .........................................................................................................90 
Figure S2.4: Cells expressing mutant spliceosome factors rely more on                             
NMD for survival  ..............................................................................................................91 
vii 
 
Figure S2.5: Elevated R-loop formation is a major underlying mechanism for the 
hypersensitivity of spliceosome mutant cells to NMD inhibition  ....................................94 
Chapter 3: Compound C Inhibits Nonsense-mediated RNA Decay Independently of AMPK 
Figure 3.1: CC inhibits NMD in human cells  .................................................................133 
Figure 3.2: CC stabilizes endogenous NMD targets  .......................................................135 
Figure 3.3: CC inhibits NMD independently of AMPK inhibition  ................................137 
Figure 3.4: CC reduces protein levels of multiple NMD factors, but does not inhibit 
SMG1 kinase activity  ......................................................................................................139 
Figure 3.5: CC induces autophagy independently of the expression and stabilization of 






List of Tables 
Chapter 2: Nonsense Mediated RNA Decay Is a Unique Vulnerability of Cells with 
Defective Splicing 
Table 2.1: List of key resources and reagents used  ..........................................................94 
Table 2.2: Sequence Identities of PCR primers, sgRNAs, and shRNAs  ..........................97 
 
Chapter 3: Compound C Inhibits Nonsense-mediated RNA Decay Independently of AMPK 
Table 3.1: Key Reagents used in the study  .....................................................................124 








I would like to thank my mentor, Zhongsheng You. From our first conversation during the 
interview process to the end of my graduate school, Zhongsheng has believed in me, encouraged 
me and constantly advocated for my career development. With his guidance and patience, I have 
learned to think critically, to ask the right questions, to perform the critical experiments and 
effectively communicate my work. I am very grateful for his support.  
I would like to thank other members of the You lab, who made the lab a fun and cooperative 
environment to work. I offer special thanks to Shan Li and Andrew Nickless for teaching me all 
the technical skills early during my graduate school, for being good role models, and for 
collaborating with me. Sharad Paudyal, Won Koh, Delphine Lemacon Sangotokun, Lingzhen 
Kong, Zheng Yang, Ying Li, and Ke Tan provided important insights in my work and made the 
lab a lively place to work.  
I offer special thanks to my committee members for their insightful ideas, recommendations, 
comments, and for always making time in their busy calendars to talk or meet. I thank our 
program coordinator, Stacy Kiel for listening, advising, and making sure I did everything in time. 
I also thank MCB program directors for their advice along the way, and for being great student 
advocates. I thank the Cell Bio department for their full support during my graduate school. 
I would like to give special thanks to Kenya Scholar Access Program (KenSAP) and the greater 
KenSAP community for accepting me into this family, helping me successfully apply for 
colleges in the US, and offering mentorship whenever I needed it. 
I have received immense support from my wonderful group of friends. Brian Wadugu and Smriti 
Bajracharya, my longtime friends from college and Wash U, are the reasons I considered 
x 
 
applying to Wash U. I thank other longtime friends who encouraged me from far, Annie, Kukua, 
Solomon and Chishala. I also made some new friends at Wash U. Mary Mathyer, John Dean, 
Samarth Hedge, Trent Evans, and Madeline Christine have been unwavering friends. We have 
helped each other enjoy graduate school and life in Saint Louis, during the highs and lows, over 
the past few years. I am very grateful for the friendship. 
I would like to thank my family for their love and constant support. I am grateful that my parents 
supported my education from an early age. My dad’s passion for science inspired me to pursue 
the sciences, and my mom’s dream of me studying abroad encouraged me to look for the best 
opportunities for my studies worldwide. My brothers and sisters have been a source of strength 
and inspiration in my career and life. I thank them for the love they have for me, and for not 
complaining too much when I am away from home longer than we would like. I also thank my 
host family in Maine, Steve Collins and his family for welcoming me to Maine, for making 
Maine winter fun, and for supporting me long after graduation from Colby. I have also had 
incredible support from my family-in law, the Harvey and McWhorter families, who have made 
Missouri feel like home. Their homes provided me with a much-needed break from school. I 
thank my husband and best friend, Joseph Harvey. I am very grateful that Joseph has been by my 
side throughout graduate school. Apart from being very supportive in my pursuit for a career in 
science, Joseph has taught me how to communicate my work eloquently, as he is very eloquent 
himself. I am very grateful for his unwavering support, encouragement, and patience, especially 
when I had to work long hours. I am very fortunate to have him by my side as we forge a future 
together. 
Lastly, I am grateful to HHMI for funding portions of my graduate work through the HHMI 



































ABSTRACT OF THE DISSERTATION 
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Nonsense mediated RNA decay (NMD) is an RNA surveillance pathway present in all 
eukaryotes that detects and degrades nonsense mRNAs, which contain pre-mature translation 
termination codons. Nonsense mRNAs are prevalent when pre-mRNA splicing is altered or 
defective. Interestingly, defective pre-mRNA splicing is emerging as a major driver of cancer 
development, including development of myelodysplastic syndrome (MDS), leukemia, and some 
solid tumors. Moreover, pre-mRNA splicing is also thought to enhance NMD in human cells, 
although it’s still unclear whether and how splicing or splicing factors promote NMD. The role 
of NMD in regulating mis-spliced mRNA and the link between NMD and RNA splicing, suggest 
that understanding the process of NMD in the context of normal and defective splicing may hold 
some clues on developing therapies to treat cancers with dysregulated splicing. To better 
understand the process of NMD, we have developed a novel NMD reporter system to measure 
NMD activity in individual human cells and used it to perform a genome-wide CRISPR/Cas9 
KO screen to identify genes that promote NMD. We found that the SF3B spliceosome complex 
promotes NMD without splicing of the target mRNA, suggesting that recruitment of certain 
xiv 
 
spliceosome factors, but not pre-mRNA splicing per se, promotes NMD. In the context of 
defective splicing, we found that expression of cancer-associated spliceosome mutants (including 
mutant SF3B1) attenuate NMD. Importantly, cancer cells harboring spliceosome mutations were 
remarkably sensitive to inhibition of NMD. Therefore, inhibition of NMD is a novel potential 
therapeutic strategy to treat cancers with defective splicing. This finding suggests that small 
molecule inhibitors of NMD are needed to facilitate development of therapies that target the 
NMD pathway. In this dissertation, we have evaluated the use of two different compounds to 
inhibit NMD. SMG1i directly targets SMG1, the only kinase in the NMD pathway, while 
Compound C, a commonly used AMPK inhibitor, inhibits NMD indirectly probably by down-
regulating NMD factors. Compound C is, however, non-specific, but its derivatives may generate 
specific NMD inhibitors. Collectively, our studies shed some new light on the process of NMD 
in the context of normal or defective splicing, uncover NMD as a novel vulnerability of cancers 
with defective splicing, and provide promising lead compounds for developing therapies that 







Chapter 1:  
NMD as a Guardian of the Central Dogma 







The central dogma of molecular biology dictates the flow of genetic information between DNA, 
RNA and protein1. This implies that genetic information must be faithfully replicated during 
DNA replication, accurately transcribed to RNA and some RNA need to be accurately translated 
to protein, which are the primary effectors of cellular processes. In eukaryotic cells, pre-mRNA 
(precursor messenger RNA) splicing is an important step of gene expression, where the intronic 
sequences of RNA are identified and removed to make a mature messenger RNA (mRNA)2. This 
process greatly contributes to the diversity of the transcriptome and the proteome, especially in 
metazoans where about 60% of genes are alternatively spliced to generate many mRNA 
isoforms3.  Increased transcriptome diversity is, however a double-edged sword. While this 
feature increases the utility of the genome, it also presents a greater opportunity for errors in the 
transcriptome and the proteome, which may have negative impacts on the cell, or may contribute 
to formation of genetic disorders and cancers4,5. Maintaining the quality and quantity of the 
transcriptome is, therefore a major challenge to metazoans.  Consequently, cells have evolved 
elaborate RNA surveillance and degradation pathways, including nonsense mediated RNA decay 
(NMD)6,7,8. As the name suggests, NMD was discovered as an RNA surveillance mechanism that 
targets and degrades nonsense mRNAs, which are the mRNAs that possess pre-mature 
translation termination codons (PTCs)9,10. NMD is now thought to serve both a quality control 
function, by targeting mutant mRNAs with PTCs, and a general gene expression function, by 
targeting about 10% of mRNAs encoding functional full-length proteins to facilitate various 
developmental process and cellular homeostasis11,12,13,14,15,16. While pre-mRNA splicing and 
NMD appear distinct, there is evidence that the two processes are functionally and 
mechanistically connected. NMD degrades PTC-containing mRNAs resulting from erroneous 
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splicing, and about one third of RNAs produced by alternative splicing17. It is apparent that 
coupling alternative splicing to NMD is yet another mechanism of gene regulation where 
numerous genes, particularly splicing factors, regulate their RNA levels by promoting production 
of PTC-containing mRNA isoforms of their genes18,19,20. Mechanistically, pre-mRNA splicing 
seems to enhance efficiency of mammalian NMD21. It is thought that the exon junction 
complexes (EJCs) that are deposited upstream exon-exon junctions during splicing can be used 
to determine whether a termination codon is pre-mature and activate NMD22,23,24,25,26. However, 
it is not clear whether splicing per se ,or the recruitment of splicing factors is important for 
NMD. The relationship between NMD and splicing needs to be better explored to understand the 
mechanisms of NMD and the roles of these two pathways in maintaining the quality and 
abundance of RNA.  
RNA processing, such as pre-mRNA splicing and RNA surveillance may have a previously 
unappreciated role in genome maintenance. Emerging evidence suggest that RNA-binding 
proteins and splicing factors prevent RNA from annealing to DNA during transcription, which 
would form stable DNA/RNA hybrids and subsequently displace one strand of DNA (a structure 
known as R-loop)27. While R-loops are important for some cell biological processes, aberrant R-
loops are a threat to the integrity of the genome, as they may become obstacles during DNA 
replication and generate DNA breaks28,29. Indeed, the depletion of RNA binding proteins, RNA 
helicases, and many splicing factors cause R-loop mediated genomic instability29,30. It was also 
found that depleting NMD factors results in genomic instability, although the mechanisms 
responsible are still unclear31,32. The bona fide roles of splicing and RNA surveillance in 
regulating the transcriptome, and these new roles of RNA processing pathways in genome 




pre-mRNA splicing and the consequences of mis-splicing 
A simplified mechanism of pre-mRNA splicing 
Splicing of pre-mRNA is a highly dynamic and complex process that involves several 
ribonucleoprotein (snRNPs) and over 150 proteins33,34. While splicing is conserved in 
eukaryotes, human spliceosome contains both a major spliceosome, which is present in lower 
eukaryotes, and a minor spliceosome, which is not conserved35. Mechanism of splicing by the 
major spliceosome, which consists of 5 small nuclear RNAs (U1, U2, U4, U5, U6 snRNAs), is 
the best understood36. To correctly excise introns from RNA, the spliceosome must recognize 
core splicing signals within the intron, which include the 5’ splice site (5’ss), the 3’ splice site 
(3’ss), and the branch point37. The stepwise splicing process begins by U1 snRNP binding to the 
5’ss, forming complex E (Figure 1.1). U2 snRNP then binds to the branch point, forming 
complex A, which subsequently binds a pre-formed tri-snRNP complex U4/U6.U5 to form 
complex B. Major rearrangements, including dissociation of U1 and U4 are required to activate 
complex B to form complex Bact, which supports the first catalytic step needed to cleave the 5’ 
end of the intron. The resulting complex is known as complex C, and it supports the second 
catalytic reaction, which cleaves the 3’ end of the intron and ligates the exons. Upon ligation of 
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Figure 1.1. A schematic representation of the main steps of splicing by the major 
spliceosome. 
 Pre-mRNA splicing is performed by five snRNP complexes (U1, U2, U4, U5, U6) and about 
150 proteins (omitted for simplicity). Splicing is done over many steps beginning from 
sequential binding of snRNP, remodeling of the complexes and 2 catalytic steps that lead to 
ligation of exons, release of intron lariat, and recycling of snRNP complexes. 
 
Defective splicing and associated diseases 
As a vital and complex step of gene expression in eukaryotes, splicing is a highly regulated 
process. However, errors during splicing can still occur due to mutations on the RNA cis-
regulating elements, core splicing components, or regulatory factors38,39. Mutations that alter pre-
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mRNA sequence may alter the choice of the 5’ss or 3’ss, generating different spliced 
isoforms38,39. Examples of diseases arising from mutations on the RNA that causes altered 
splicing include β+-thalassaemia, which is caused by mis-spliced β-globin gene 40,41,42; Duchenne 
and Becker muscular dystrophy, which is caused by mis-spliced DMD gene43; frontotemporal 
dementia and parkinsonism associated with chromosome 17 (FTDP-17), which is caused by mis-
spliced MAPT gene44 ; and laminopathies caused by mis-spliced LMNA gene45. In addition to 
mutations in pre-mRNA, mutations that occur on the spliceosome proteins themselves also cause 
many diseases and cancers. U2 snRNP components and related proteins are mutated in 
hematological malignancies and some solid tumors. Approximately 50% of myelodysplastic 
syndrome (MDS), 20% of acute myeloid leukemia (AML) and 60% of chronic myelomonocytic 
leukemia (CMML) harbor heterozygous somatic mutations in spliceosome genes SF3B1, 
U2AF1, SRSF2, and ZRSR2, which cause largely distinct changes in RNA splicing and gene 
expression46,47,48,49,50,51,52,53. Mutations in components of U4/U6.U5 tri-snRNP PRPF3, PRPF4, 
PRPF6, PRPF8, PRPF31, and SNRNP200 are associated with retinitis pigmentosa, a retinal 
degeneration disease54. 
 
Nonsense mediated RNA decay (NMD) 
Proteins involved in NMD 
The first few NMD factors were identified in S.cerevisiae55. In these seminal studies, it was 
observed that frame-shift mutations and nonsense mutations caused rapid turnover of resulting 
mRNAs, and that the UP-Frameshift (UPF) proteins were responsible for this turnover. Genetic 
screens in C. elegans and S.cerevisiae resulted in identification of SMG1-7 and UPF1-3 proteins 
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as NMD factors56,57. The S.cerevisiae UPF1-3 are orthologs of C. elegans SMG 2-4. Orthologs 
of all SMG proteins have been identified and defined as NMD factors in several species, 
including plants and mammals58. Two genome-wide RNAi screen in C. elegans later identified 4 
additional NMD factors conserved in eukaryotes; NBAs, DHX34, GNL and SEC1359,60. It was 
also found that SR proteins (proteins with RNA recognition motifs and serine arginine-rich 
domains) enhance NMD, and that SRSF1 particularly promotes NMD by promoting UPF1 
binding to RNA61,62. Additional RNA helicases were also found to promote NMD, including 
DDX5, DDX17, RUVBL1, and RUVBL263,64. Exon junction complexes (EJCs) deposited during 
splicing enhance NMD in mammalian cells, as presence of an EJC downstream of a stop codon 
is one of the best understood mechanism of identifying a pre-mature stop codon (PTC) from a 
normal stop codon 21.  EJCs are however dispensable for NMD in other organisms, such as C. 
elegans and S. cerevisiae, and Drosophilla65,66,67.   It is apparent that all the mechanisms of NMD 
that have been described so far require the function of UPF1, but the requirements of other NMD 
factors varies62,68,13,69. Therefore, although NMD is conserved among all eukaryotes, there exist 
significant differences in the mechanisms of NMD in different species, and the mechanisms may 
vary depending on the kind of NMD target. Because a majority of known NMD factors in 
mammalian systems were identified through sequence homology to C. elegans and S.cerevisiae 
factors, it is likely that there are unknown NMD factors and regulators unique for NMD in 
mammalian systems. In an effort to identify factors involved in NMD in human cells, some 
studies have employed protein interaction approaches, where proteins binding to phosphorylated 
UPF1 or SMG1 were identified using SILAC or immuno-precipitation assays. These studies 
identified eIF3 as a prominent protein interacting with UPF1, and SMG8-9 as proteins 
interacting with SMG170,71. However, given that NMD factors have other NMD-independent 
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roles, these methods may identify interacting proteins that are not necessarily important for 
NMD. In support of the idea that the list of NMD factors in mammalian systems is likely 
incomplete, recent RNAi and CRISPR Cas9 knockout screens in human cells have identified 
additional genes that potentially function in the NMD pathway, including ICE1, which facilitates 
NMD by promoting binding of UPF3B to EJC72. Defining the roles of these potential NMD 
factors will facilitate a better understanding of NMD in mammalian systems. 
Mechanisms of NMD in mammalian systems 
NMD from yeast to human requires mRNA translation73,74. It is thought that inefficient 
translation termination can trigger NMD, although certain features on the RNA are additionally 
required to activate NMD. In humans, the presence of an EJC on an mRNA downstream of a 
translation termination codon (stop codon), otherwise known as 3’UTR EJC, strongly enhances 
NMD23,69,75,76. This has led to the proposed EJC-dependent NMD model, although EJC-
independent NMD models also exists (Figure 1.2)21,68,25. EJCs are deposited during splicing at 
20-24 nucleotides upstream of an exon-exon junction, and remain associated to the mRNA even 
after the mRNA is exported to the cytoplasm77,78. The EJC core is composed of 4 proteins: 
eIF4A3, RBM8A (also called Y14), MAGOH, and MLN51 (also called Barentz, BTZ, or 
CASC3)79,80. The EJC core is usually associated with auxiliary proteins, including UPF3B, a 
known NMD factor81,24. During translation, processive translocation of the ribosome on mRNA 
removes proteins on the mRNA, including EJCs. Since the ribosome does not translocate past the 
stop codon, the protein complexes downstream the stop codon (the 3’ UTR), remain on the 
mRNA. The EJC-dependent NMD model posits that if an EJC is 50-55 nucleotides downstream 
of the stop codon, NMD is activated10,74. To activate NMD, SMG1 complex (SMG1-SMG8-
SMG9) and UPF1 are recruited to the terminating ribosome via interactions with translation 
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termination release factors eRF1and eRF3, forming the so-called SURF complex71,82. 
Subsequently, UPF2 is recruited to the EJC via its interaction with UPF3B, and both recruit the 
SURF complex to the EJC, forming the so-called DECID complex24,83. Interaction between the 
SURF complex and the EJC in the DECID complex is required to activate SMG1 kinase to 
phosphorylate UPF1, which commits the RNA for degradation through NMD82,84,85. 
Phosphorylated UPF1 facilitates recruitment of SMG5, SMG6 (also called EST1A), and SMG7 
via 14-3-3 domains on these proteins, which bind to the phospho-residues on UPF186,87,88. SMG5 
and SMG7 recruit deandenylation and decapping complexes86,89,90. De-capped and/or de-
adenylated RNA is degraded by exonucleases, including XRN191. SMG6 possesses RNA 
endonuclease activity and directly cleaves NMD-targeted RNAs92,93,94. The SMG5-SMG7 and 
the SMG6 pathways of RNA degradation appear to be partially redundant in human cells86,95. 
The EJC-independent model of NMD is less well understood compared to the EJC-dependent 
model, but there is sufficient evidence that some RNA targets are degraded without following the 
EJC rule, or in the absence of 3’UTR EJC68,96,25. Consistent with this EJC-independent model of 
NMD, artificially tethering UPF1 to the 3’UTR of an mRNA is sufficient to induce NMD97. 
Moreover, NMD not only targets nonsense mRNAs containing pre-mature stop codons (PTCs), 
but also many physiological transcripts with certain NMD-inducing features, including upstream 
open reading frames (uORFs), inclusion of PTCs-containing exons, introns in 3’ UTR, and 
exceedingly long 3’ UTRs (greater than 1kb)21,98,99. Non-mutant NMD targets that have 
exceedingly long 3’UTRs do not have EJCs in the 3’UTR, yet they are still degraded by NMD, 






Figure 1.2. A schematic representation of the EJC-dependent model for NMD in human 
cells.  
NMD ensues during translation when the ribosome pre-maturely terminates at a PTC that is 
located 50-55 nucleotides upstream of an EJC. SMG1 and UPF1 are recruited by association 
with the terminating factors to form the SURF complex. EJC-associated UPF2 and UPF3B 
recruit the SURF complex to form the DECID complex, which facilitates phosphorylation of 
UPF1. Phosphorylated UPF1 recruits SMG5, SMG7, and SMG6, which subsequently recruit 




However, 3’UTR length does not necessarily predict RNA degradation by NMD, suggesting that 
the length of the 3’UTR alone is not sufficient to induce NMD100,16,15. Therefore, it is still 
unclear how NMD targets these RNAs. It is thought that presence of poly-adenylate binding 
protein (PABP), which binds to poly-A tail of mRNA, close to translation termination codon 
antagonizes NMD by promoting efficient translation termination101,102. This suggests that 
mRNAs with long 3’UTRs may be targeted by NMD due to inefficient translation termination, 
because the long 3’UTR places the stop codon far from PABP. However, mRNAs can assume a 
loop configuration, where the poly-A tail and the cap of the mRNA are brought into close 
proximity to each other, reducing the distance between PABP and the stop codon, despite the 
RNA having a long 3’UTR103. In the mRNAs with long 3’UTR, NMD can also be activated by 
presence of many UPF1 proteins downstream of a stop codon, because UPF1 non-specifically 
binds to mRNA104.  However, NMD activated this way can be inhibited by binding of certain 
proteins immediately downstream of the stop codon, such as polypyrimidine tract-binding 
protein 1 (PTBP1), and heterogenous nuclear ribonucleoprotein L (hnRNPL)104,105. Therefore, 
the balance between NMD-inducing and antagonizing features on the mRNA may determine 
whether this mRNA is targeted for degradation by EJC-independent NMD. The degradation of 
the mRNA itself still utilizes the proteins required for RNA degradation in EJC-enhanced NMD. 
Physiological functions of NMD  
NMD is essential in development of mammalian systems, as the knockout of NMD factors 
UPF1, UPF2, SMG1, or SMG6 is embryonic lethal in mice106,107,108,109. Studies in embryonic 
stem cells with NMD factor knockout showed that lack of NMD prevented cells from 
differentiating109. In certain differentiation steps, NMD is down-regulated. Examples include 
differentiation of the endoderm layer and neuronal cells110,111,112. NMD also promotes immune 
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cell maturation by degrading PTC-containing RNAs resulting from imprecise recombination 
between variable (V), diversity (D), and joining (J) segments, which happens in almost two-
thirds of all recombinations113.  The competition between NMD and (STAU1)-mediated mRNA 
decay (SMD), due to the requirement of UPF1 in both pathways, promotes myogenesis114. NMD 
is an important mechanism of cellular stress response, as a number of cellular stresses, such as 
hypoxia, amino acid depravation, reactive oxygen species, and increased calcium can blunt 
NMD115,11,116,117. This blunting of NMD promotes expression of NMD-targeted mRNAs 
important for stress response and establishing cellular homeostasis118. NMD plays a major role in 
regulating many splicing factors, including SR-containing splicing factors (SRSF 
family)119,120,121. Some of these splicing factors can promote alternative splicing of their own 
RNAs to produce PTC-containing RNAs that are targeted by NMD, thus auto-regulating their 
own protein abundance, while others regulate related splicing factors20. These observations 
demonstrate that fine-tuning NMD is crucial for normal cell physiology. 
NMD in disease and as a potential therapeutic target 
NMD is thought to modulate the phenotypic outcome of about 1/3 of genetic disorders that are 
caused by nonsense mutations122,123. How NMD affects the outcomes of these diseases depend 
on the location of the PTC on the gene (whether it is on NMD-sensitive, insensitive region), the 
function of the full-length and truncated gene product, and the efficiency of NMD124,125,126. 
Depending on the location of a PTC on the gene, NMD affects the pattern of inheritance of the 
disease. If a PTC is located on NMD-sensitive region, NMD degrades the RNA and the 
heterozygous carrier of this mutation will rely on the function of the WT allele, promoting 
autosomal recessive inheritance124,125.  However, if a PTC is in NMD-insensitive region of the 
gene, then the truncated protein resulting from this mutation will accumulate in the cell, causing 
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autosomal dominant inheritance124,125. Examples of diseases showing distinct patterns of 
inheritance depending on the location of the PTC include β-thalassemia127, susceptibility to 
mycobacterial infection128, von Willebrand disease129, Becker disease and Thomsen disease130, 
and Leber congenital amaurosis131. In addition to affecting the pattern of inheritance, NMD can 
either make the disease outcome less or more severe, depending on whether the truncated protein 
has dominant negative effects or some normal function. For example, NMD-sensitive nonsense 
mutations in the collagen type I alpha 1 (COL1A1) and collagen type II alpha 1 (COL2A1) genes 
cause haplo-insufficiency and a milder form of osteogenesis imperfecta (OI), while missense 
mutations that are not targeted by NMD are dominant negative and cause the more severe form 
of OI132,133,134. In contrast, some NMD-insensitive nonsense mutations in Duchenne muscular 
dystrophy (DMD) have partial normal function, and patients with these mutations have a milder 
form of DMD, compared to patients with NMD-sensitive nonsense mutations135,136. This 
suggests that NMD worsens the phenotypic outcome of DMD by degrading nonsense mRNAs 
that encode truncated proteins with partial normal function. Therefore, inhibition of NMD is a 
potential therapeutic approach to treat such disorders. 
Mutations of NMD factors themselves are also associated with disease. For instance, mutations 
in UPF3B gene is associated with intellectual disability in humans137,138. Sequencing analysis 
identified UPF3B mutations in 2 families with Lujan–Fryns syndrome, one family with FG 
syndrome, and several other families with schizophrenia and autism spectrum 
disorder137,139,140,141. Moreover, deletion of genomic region containing UPF2 gene were found in 
11 patients with intellectual disability142. These deletions caused gene expression changes that 
were similar to those seen in UPF3B mutations, suggesting that the dysregulation of the NMD 
pathway is likely an important factor in the development of these diseases142. Deletion of a 
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region of chromosome 1 that consists of the EJC gene RBM8A has also been linked to 
intellectual disability143. Consistent with these observations, a UPF3B-null mouse exhibited 
defects in learning, and prepulse inhibition common in patients with schizophrenia and other 
brain disorders144. 
The effects of NMD on cancer development seem to be context-specific. Many tumor suppressor 
genes, such as BRCA1, BRCA2, TP53, and Rb have NMD-sensitive mutations145,146,147,148. It 
appears that tumor suppressors are more likely to harbor NMD-sensitive nonsense mutations, 
while oncogenes are more likely to harbor missense mutations149. Therefore, intact NMD may 
promote tumorigenesis by down-regulating tumor suppressor proteins. In other cases, disabling 
NMD seems to promote tumorigenesis or tumor progression. For example, somatic loss-of-
function mutations in UPF1 are commonly found in pancreatic adenosquamous carcinomas and 
lung inflammatory myofibroblastic tumours, suggesting NMD downregulation may promote 
development of these cancers 150,151. Inhibiting NMD may also promote tumor growth in the 
tumor microenvironment. The tumor microenvironment is characterized by stresses, such as 
hypoxia and ER stress, and as such, cancer cells need to adapt to this environment in order to 
proliferate152.  Because NMD blunting promotes cellular response to stress, inhibition of NMD 
may promote tumor growth by promoting adaptation of tumor cells to the stress in the tumor 
microenvironment153.  
NMD is a potential target for developing therapies to treat genetic disorders and cancers. As 
discussed above, some genetic disorders, such as Duchenne muscular dystrophy (DMD), may 
benefit from inhibition of NMD to allow for expression of truncated proteins with partial normal 
function, which reduce the severity of the disease135. Moreover, inhibiting NMD and promoting 
translation read-through allows for production of full length proteins, which would fully restore 
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protein function to treat such genetic disorders. As a proof of concept, antisense oligonucleotide-
mediated knockdown of UPF3B increased production of dystrophin mRNA (from DMD gene) in 
a mouse model of DMD, and coagulation factor IX mRNA in a mouse model of hemophilia154. 
Furthermore, combination of translation read-through and UPF3B knockdown lead to production 
of full-length functional coagulation factor IX protein in the mouse model of hemophilia154. 
However, the use of translation read-through drugs is associated with toxicity155. Therefore, 
more studies are needed to devise a safer method of translation read-through. NMD inhibition 
also has a potential to improve immunotherapy, as nonsense mRNAs arising from frameshift 
mutations and mis-splicing would encode novel peptides, which may promote neo-antigen 
production necessary for immunotherapy156. A proof of concept study showed that targeted 
inhibition of NMD in subcutaneous and metastatic tumor models, using tumor-targeted NMD 
factor siRNAs, reduced tumor size due to immune recognition156. A recent analysis also showed 
that a better response to immunotherapy was associated with patients who had more nonsense 
mRNAs that evaded NMD, suggesting that increasing nonsense mRNAs may improve immune 
response157. Small molecule inhibitors of NMD have been recently developed, and have shown 
promising effects on restoring protein expression from nonsense mRNAs and some anti-cancer 
effects in cell lines and mouse models, but the safety and efficacy of NMD inhibitors in to 
treating genetic disorders and cancers has not yet been demonstrated in clinical trials158,159. 
Therefore, more studies are needed to develop many specific inhibitors of NMD to explore the 
therapeutic benefits of NMD inhibition in treating certain genetic disorders and cancer. 
The role of RNA processing in regulating R-loops to promote genome maintenance 
R-loop formation and regulation 
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R-loops are three stranded nucleic acids structures composed of displaced ssDNA and 
RNA:DNA hybrid that often form during transcription when nascent RNA reanneals to template 
DNA (Figure 1.3)160.  Due to this unique structure, R-loops are detected in cells primarily by 
using S9.6 antibody that has high specificity for RNA:DNA hybrids, although other studies have 
utilized catalytic-dead RNase H1, or foot-printing assays161,162,163. 
  
Figure 1.3. Schematic representation of R-loop formation and regulation. 
R-loops are co-transcriptional three-stranded nucleic acid structures consisting of an RNA:DNA 
hybrid and a displaced RNA. Efficient RNA processing (including splicing and RNA export) and 
regulated transcription prevent formation of R-loops. Once they are formed, R-loops can be 
removed by the helicase activity of many RNA:DNA helicases, and the activity of RNase H 
nucleases that remove the RNA moiety on the RNA:DNA hybrid. Not illustrated are the DNA 
repair and related proteins, such as BRCA1/2, FANCM, and Topoisomerase 1 that regulate R-




Immunoprecipitation of R-loops combined with high-throughput sequencing has contributed to 
mapping genomic regions where R-loops are enriched. Although this is still an active area of 
research, the  general features that seem to pre-dispose to R-loop formation include high G/C 
ratio in non-template strand, high transcription, and polyA tracts164,165,166. R-loops are ubiquitous 
in chromosomes, constituting 5-8% of the genome167. Consistently, R-loops have several 
physiological functions, including class switch recombination during lymphocyte development, 
control of methylation of CpG island promoters, and transcription termination168,164,161. Aberrant 
R-loops are, however, a major threat to genome maintenance, as they have been linked to 
increased mutations, hyper-recombination, rearrangements, and DNA damage due to 
transcription-replication collisions caused by transcription and/ or replication stress29,169,170. R-
loops, therefore, need to be regulated in cells. Several factors that remove R-loops or prevent 
their formation have been identified. RNase H proteins specifically degrade the RNA in the 
RNA:DNA hybrid171. A number of helicases have also been implicated in R-loop removal, 
including DDX1, DDX19, DDX21, DDX23, DHX9, AQR, and SETX172,173,174,175,176,177. 
Interestingly, depletion of each of these helicases causes R-loop induction, suggesting a non-
redundant role in R-loop metabolism. Additionally, RNA processing proteins, primarily 
members of the spliceosome complex and mRNA export, such as SF3B1, SRSF1, PIAS, 
SNRPA1, Nrl1 and THO/TREX are also required for R-loop metabolism178,179,180,181. 
Transcription efficiency also seem to affect the level of R-loops in cells, as inefficient or too high 
transcription can increase R-loops27,182. Finally, proteins involved in genome maintenance such 
as, BRCA1/2, FANCM, and Topoisomerase 1 also play a role in preventing aberrant R-
loops183,184,185. 
Defective splicing and R-loops 
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Heterozygous somatic mutations in the splicing genes SF3B1, U2AF1, SRSF2, and ZRSR2 are 
found in approximately 50% of myelodysplastic syndrome (MDS), 20% of acute myeloid 
leukemia (AML) and 60% of chronic myelomonocytic leukemia (CMML)46,47,48,49,50,51,52,53. 
Because all these genes are involved in the 3’ splice site recognition, these mutations cause mis-
splicing in cells, but the patterns of mis-splicing appear to be distinct186,187,188,189. The different 
patterns of mis-splicing caused by each mutation raises the possibility that mis-splicing alone is 
not the underlying mechanism for how the mutations in splicing factors contribute to MDS and 
leukemia etiology. Other studies have observed increased genomic instability in cells harboring 
mutations in MDS-associated splicing factors190,191,192. Recent studies now suggest that the 
genomic instability observed in cells harboring splicing factor mutations are likely due to 
increased R-loops, although future studies are needed to mechanistically determine how each of 
the mutations increase R-loops193,194,195. 
Potential role of NMD in R-loops Regulation 
Several key factors in the NMD pathway seem to play a role in genome maintenance, as their 
depletion causes DNA damage, but the mechanisms are not well understood196,197,198. 
Downregulation of UPF1 helicase in HeLa cells, causes ATR-mediated cell cycle arrest at early 
S-phase31.  Moreover, depletion of UPF1, SMG1, and SMG6 in HeLa cells results in increased 
association of TERRA to telomeres and telomere loss, suggesting a role of these NMD factors in 
displacing TERRA from telomeres199. This latter evidence suggest that the NMD/NMD factors 
may regulate R-loops, because TERRA is known to form R-loops at telomeres200. More studies 
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Nonsense-mediated RNA decay (NMD) is an evolutionarily conserved pathway that targets and 
degrades aberrant mRNAs with premature translation termination codons (PTCs), which are 
prevalent in cells with defective splicing. Previous studies have also implicated splicing in the 
NMD process as removal of introns from pre-mRNA in human cells attenuates its degradation by 
NMD. However, it remains unclear whether and how splicing factors or the splicing process 
itself promote NMD.  By carrying out a genome-wide CRISPR/Cas9 knockout screen using a 
novel NMD reporter system, we identified a previously unrecognized function of the heptameric 
SF3B spliceosome complex in promoting NMD that is completely separate from its role in 
splicing. We also found that cancer cells with spliceosome gene mutations common in 
myelodysplastic syndrome (MDS) and other cancer cells, have overall attenuated NMD activity. 
Further inhibition of NMD in spliceosome mutant cells caused heightened sensitivity, which 
results from an accumulation of R loops that contain RNA:DNA hybrid structures. Together, our 
findings shed new light on the functional interplay between NMD and splicing and suggest a 
novel therapeutic strategy for MDS and other cancers with spliceosome mutations based on the 
synthetic lethality between NMD inhibition and aberrant splicing.  
 
Introduction 
In metazoans, pre-mRNA splicing generates diversity in the transcriptome, but also presents a 
major source of aberrant RNAs when dysregulated1,2. Incorrect splice site selection, intron 
retention and exon exclusion threaten the fidelity of gene expression, which can cause many 
genetic disorders, such as b-thalassemia, frontotemporal dementia and laminopathies, and 
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cancer3,4,5,6,7,8. Abnormal splicing is particularly prevalent in myelodysplastic syndrome (MDS) 
and other cancers with recurring mutations in splicing factors9,10. Approximately 50% of MDS, 
20% of acute myeloid leukemia (AML) and 60% of chronic myelomonocytic leukemia (CMML) 
harbor heterozygous somatic mutations in the spliceosome genes SF3B1, U2AF1, SRSF2, and 
ZRSR2, which are involved in the early stage of spliceosome assembly and cause distinct 
changes in RNA splicing and gene expression9,10,11,12,13,14,15,16,17. Many solid tumors, including 
uveal melanoma, breast, lung and pancreatic cancers, also harbor spliceosome gene 
mutations18,19,20,21. The inherent vulnerability of the splicing process and its dysregulation in 
disease conditions necessitate mechanisms to detect and control the fate of mis-spliced 
transcripts. Nonsense mediated RNA decay (NMD) plays a key role in RNA surveillance by 
specifically targeting abnormal mRNAs with premature translation termination codons (PTCs) 
for degradation22. NMD also regulates gene expression by degrading physiological transcripts 
with certain NMD-inducing features, including upstream open reading frames (uORFs), PTC-
containing exons, introns in the 3’ untranslated region (UTR), and exceedingly long 3’ 
UTRs22,23,24. Consequently, NMD modulates the severity of many genetic diseases and regulates 
various developmental processes and responses to cellular stress25,26,27,28,29,30,31. In addition to 
eliminating alternatively spliced or mis-spliced transcripts, NMD may be mechanistically linked 
to RNA splicing in mammals, as removal of introns from target pre-mRNAs attenuates their 
degradation by NMD32,33,34. It is believed that splicing-mediated deposition of exon junction 
complexes (EJCs) facilitates the recognition of PTCs in mRNA, although an EJC-independent 
NMD pathway also exists22,35. A key step of NMD is the recruitment of core NMD factors UPF1 
and SMG1 to the terminating ribosome by eRF1 and eRF3, leading to phosphorylation of UPF1 
by SMG1, a member of the PIKK family of protein kinases that also include ATM, ATR, DNA-
45 
 
PKcs and mTOR36,37. This phosphorylation leads to recruitment of SMG5, SMG6 and SMG7 to 
target mRNA via phospho-specific interactions, which in turn either directly cleaves the mRNA 
(SMG6) or recruits nucleolytic activities for RNA degradation (SMG5 and SMG7)38,39. Despite 
extensive research in this area, our understanding of the functional interplay between NMD and 
splicing remains limited, and the exact role of NMD in cells with dysregulated splicing remains 
to be determined.    
In this study we identify a previously unrecognized function of the SF3B spliceosome complex 
in NMD, and a synthetic lethal relationship between splicing dysregulation and NMD disruption. 
By performing a genome-wide CRISPR/Cas9 knockout screen using a novel NMD reporter 
system, we have identified a number of new factors that promote NMD, including components of 
the SF3B spliceosome complex. Further studies uncovered a role of SF3B in promoting NMD 
that requires EJC, but not splicing of the target mRNA. Interestingly, cells expressing mutants of 
SF3B1 or U2AF1 that are frequently found in MDS and cancer exhibited attenuated NMD 
activity. Furthermore, we found that spliceosome mutant cells are hypersensitive to NMD 
disruption. Remarkably, this sensitivity could be rescued by ectopic expression of RNaseH1, 
which removes R loops, a cellular structure formed during transcription that contains a 
RNA/DNA hybrid and displaced ssDNA40,41. Together our results have uncovered novel roles of 
splicing factors in NMD and identified a new strategy for treating MDS and other cancers with 
defective splicing by targeting the NMD pathway.   
 
Results 
A novel reporter system for NMD analysis in individual cells 
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In our effort to screen for additional NMD factors and regulators, we developed a new reporter 
system that can rapidly and accurately measure NMD activity in individual mammalian cells. 
This new reporter system (Fig. 2.1A) is built on a bioluminescence-based NMD reporter that we 
developed previously, which consists of two separate, but highly homologous, transcription units 
that are inserted in tandem into a single vector30,42. Each unit in the original reporter contains a 
CMV promoter, a T cell receptor-β (TCR β) minigene containing three exons and two introns, a 
HA tag-encoding sequence inserted in exon 1, and a polyadenylation signal. The first unit, which 
contains the open reading frame (ORF) of the CBR luciferase and its natural stop codon in exon 
2 of the TCR β minigene, expresses a nonsense mRNA that is targeted for degradation by NMD. 
The second unit, which serves as an internal control for the expression of the first unit, contains 
the ORF of the CBG99 luciferase (without a stop codon) in the same position in exon 2 of the 
TCR β minigene. This reporter can be used to measure NMD activity in a population of cells 
based on the ratio of the products of the two fusion reporter genes at the levels of RNA, protein, 
or the luciferase activity of CBR and CBG30,42,43. In order to develop a reporter that can analyze 
NMD activity in individual cells, we inserted the ORFs of mCherry and EGFP (without stop 
codons) immediately upstream of CBR and CBG, respectively, into the original reporter (Fig. 
2.1A). The increase and decrease in the mCherry/EGFP signal ratio represent NMD repression 
and enhancement, respectively. Both the fluorescent proteins (mCherry and EGFP) and 
luciferases (CBR and CBG) in the reporter are functional (see below). Thus, this new reporter is 
expected to allow for accurate NMD analysis in individual live cells through fluorescence 
detection, while still retaining the ability to measure NMD efficiency in a group of cells via 
bioluminescence detection.  
47 
 
To validate the new NMD reporter, we generated a U2OS cell line stably expressing the reporter 
(hereafter referred to as U2OS reporter cells) through stable transfection and clone validation. As 
expected, while the reporter cells exhibited robust EGFP signal, little mCherry signal was 
detected by fluorescence imaging (Fig. 2.1B). Treatment of the reporter cells with caffeine, 
which inhibits NMD by decreasing enzymatic activity of the SMG1 protein kinase, dramatically 
increased mCherry signal (Fig. 2.1B). Flow cytometry analysis also showed an increase in the 
mCherry/EGFP fluorescence ratio after caffeine treatment, leading to a shift of the cell 
population in a dot plot (Fig. 2.1C). These results were corroborated by western blot and RT-
qPCR analyses of the levels of protein and RNA, respectively, of the two fusion reporter genes 
(Fig. 2.1D and E). Furthermore, shRNA- or sgRNA-mediated depletion of SMG1 or its direct 
substrate UPF1, or UPF2 also resulted in increased mCherry/EGFP ratio at the levels of protein, 
RNA and fluorescence activity (Fig. 2.1F-H, Fig. S2.1A-C), further validating the reporter. 
Together, these data demonstrate that our new reporter is a specific, robust and convenient 
system for analyzing NMD activity at both the single-cell and population levels.  
 
A genome-wide CRISPR/Cas9 knockout screen identifies novel NMD-promoting factors in 
human cells  
Using the new NMD reporter system described above we next performed a genome-wide 
CRISPR/Cas9 knockout screen to identify new NMD factors and regulators. To do this, we 
generated a U2OS reporter cell line expressing Cas9 and infected them with lentiviruses 
expressing the GeCKOv2 human sgRNA library to knock out individual genes in cells. 
Fluorescence-activated cell sorting (FACS) was then performed to collect cells with inhibited 
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NMD activity (0.22% of infected cells with increased mCherry/EGFP ratio) (Fig. 2.2A and B). 
Genomic DNA was then isolated from the collected cells as well as a fraction of infected but 
unsorted cells (baseline control), and the integrated sgRNA inserts in the genome were amplified 
by PCR. After the addition of Illumina sequencing tags via a PCR method, samples were 
subjected to Next-Gen sequencing and analysis in order to obtain read counts for each sgRNA in 
the library. MAGeCK analysis was then performed to rank genes based on the enrichment of 
their respective sgRNAs in the collected NMD-inhibited cells. Notably, among the 15 top ranked 
hits, six are known to promote NMD, including three known NMD factors (UPF1, SMG6, 
RUVBL1), two components of EJC (eIF4A3, RBM8A), and a spliceosome factor that facilitates 
EJC assembly on mRNA (CWC22) (Fig.2. 2C and D). Moreover, Gene Set Enrichment Analysis 
(GSEA) of the overall screen result indicates that NMD, spliceosome and mRNA translation are 
among the most enriched pathways (Fig. 2.2E). These data further validate our new reporter 
system and the quality of the genome-wide CRISPR/Cas9 screen.   
Importantly, our screen identified many potential novel factors that promote NMD in human 
cells, providing a rich resource for future elucidation of the mechanism and regulation of the 
NMD pathway. In the present study, we validated the 9 genes among the top 15 hits that were 
not known to be involved in NMD. These genes are involved in the early stage of spliceosome 
assembly during splicing (SF3B1, SF3B5, SF3A3, PRPF19, RNF113A, DGCR14)44,45,46,47, 
regulation of pyruvate dehydrogenase activity (PDP2)48, cilia function (DNAAF2)49, or unknown 
processes (TRAM1L1). Using two independent sgRNAs for each gene that are distinct from that 
in the original GeCKOv2 library, we examined the effects of knockdown of these factors on 
NMD of our reporter. Western blot results show that depletion of each factor increased the 
expression of the HA-mCherry-CBR-TCR(PTC) fusion protein and the HA-mCherry-CBR-
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TCR(PTC)/HA-EGFP-CBG-TCR(WT) ratio (Fig. S2.2A and B), suggesting that these factors 
promote NMD. To complement this experiment, we examined in Calu-6 cells the effect of 
depletion of these factors on the stability of p53 mRNA, which contains an endogenous PTC and 
is known to be degraded by NMD36,50. Depletion of the aforementioned nine factors individually 
resulted in increased stability of p53 mutant mRNA, consistent with the results of our reporter 
assay (Fig. S2.2C). Furthermore, depletion of these factors also increased the stability of several 
physiological NMD targets in Calu-6 cells, including ATF4, PIM3, and UPP1, but not the 
stability of ORCL, which is not a NMD target (Fig. S2.2D-G)50,51,52. These observations 
independently verify the CRISPR screen results, although further characterization is needed to 
define the functions of these factors in promoting NMD. 
 
SF3B promotes NMD in human cells in an EJC-dependent, but splicing-independent, 
manner 
In human cells splicing is believed to promote NMD by depositing EJC on mRNA that facilitates 
upstream PTC recognition22,53,54,55. However, it remains to be determined whether the entire 
splicing process is necessary for NMD or whether the recruitment of EJC factors to mRNA by a 
subset of spliceosome factors during splicing promotes NMD. Further analysis of our NMD 
screening hits revealed an enrichment of components of the SF3B complex (Fig. S2.2H). To 
untangle the function of SF3B in NMD and in splicing, we employed an intronless, tethering 
reporter system consisting of a lN-fused NMD factor and a target mRNA with boxB sites in the 
3’ UTR. It has been shown previously that the recruitment of a lN-fused NMD factor to the 
cognate boxB sites leads to degradation of the target mRNA by NMD53,56,57,58. To test whether 
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tethering SF3B components to a mRNA can trigger NMD, we first generated a U2OS cell line 
stably expressing an intronless reporter mRNA containing the EGFP ORF and 4 boxB sites in 
the 3’ UTR (Fig. 2.3A). As expected, no cryptic splicing was detected in this reporter mRNA in 
cells (Fig. S2.3A). As a control for this tethering system, we also generated a U2OS cell line 
stably expressing a reporter mRNA with scrambled boxB sites (boxB’) in the 3’ UTR that are 
deficient in lN binding. Expression of lN fusion proteins in cells was controlled by a 
doxycycline inducible system. To assess the stability of the reporter mRNA, actinomycin D was 
used to block transcription, and the amount of reporter mRNA remaining before and after 
actinomycin D treatment was analyzed by RT-qPCR. Consistent with published reports, 
expression of lN-fused UPF3B (a known NMD factor) (lN-UPF3B) resulted in accelerated 
degradation of the boxB reporter mRNA, while expression of lN or UPF3B alone had no effect 
(Fig. 2.3B). Expression of lN, UPF3B or lN-UPF3B did not affect the stability of the boxB’ 
reporter transcript (Fig. 2.3B). Importantly, the decay of the boxB reporter mRNA after lN-
UPF3B induction was completely abrogated by sgRNA/Cas9-mediated depletion of UPF1 or a 
core EJC factor eIF4A3 (Fig. 2.3C, D).  Treating cells with a specific small molecule inhibitor of 
SMG1 (SMG1i), which does not inhibit related kinases, such as ATR, at the used concentrations 
(Fig. S2.3B-D, Bailis et al., manuscript in preparation), also prevented the degradation of the 
boxB reporter mRNA (Fig. 2.3E). Together, these results further validate the degradation of the 
reporter mRNA by NMD.  
Using this tethering system, we next determined whether components of the SF3B complex can 
promote NMD independently of splicing. Remarkably, expression of lN-SF3B1, lN-SF3B5, or 
lN-SF3B6 all resulted in accelerated degradation of the boxB reporter mRNA, in comparison 
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with expression of lN or untagged proteins alone (Fig. 2.3F-H). Expression of these lN-fusion 
proteins had no effects on the stability of the boxB’ reporter mRNA (Fig. 2.3F-H). In contrast to 
SF3B factors, expression of lN-tagged SNRNP40 (a component of U5 snRNP complex) did not 
affect the stability of boxB or boxB’ reporter mRNAs (Fig. 2.3I), demonstrating the specificity 
of the role of SF3B in NMD. Importantly, the degradation of the boxB reporter mRNA induced 
by lN-SF3B1, lN-SF3B5 or lN-SF3B6 was completely abrogated by treatment with SMG1i or 
depletion of UPF1 using sgRNA/Cas9, confirming that the degradation of the tethered reporter 
transcript is mediated by NMD (Fig. 2.3J and K). Depletion of eIF4A3 using sgRNA/Cas9 also 
blocked the decay of the boxB reporter RNA induced by lN-SF3B1, lN-SF3B5 or lN-SF3B6, 
suggesting that SF3B complex promotes NMD in an EJC-dependent manner (Fig. 2.3L). In 
further support of this idea, depletion of the spliceosome factor CWC22 (also a top hit in our 
NMD screen), which facilitates EJC assembly on mRNA through its direct interaction with 
eIF4A354,59,60, prevented the degradation of the tethered boxB reporter transcript (Fig. 2.3M).  
Taken together, these results suggest that SF3B complex possesses a function that directly 
promotes NMD independently of its role in splicing and that SF3B likely acts upstream of 
CWC22 to facilitate EJC assembly and subsequent NMD.  
 
NMD activity is attenuated in cells with aberrant splicing 
The identification of multiple spliceosome factors as top hits in our genome-wide CRISPR 
screen and the novel function of SF3B complex in NMD described above motivated us to 
investigate whether dysregulated splicing, which can result from spliceosome gene 
mutations9,10,11,12,13,14,15,16, affects NMD activity. Heterozygous mutations in SF3B1 occur 
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frequently in MDS, CMML, AML and solid tumors, with SF3B1K700E being the most prominent 
mutation9,11,12,61,62,63,64. To determine whether mutant SF3B1K700E impacts NMD activity, we 
expressed Flag-SF3B1K700E or Flag-SF3B1WT in U2OS cells that contain the lN-UPF3B-boxB 
based tethering reporter system described above. The effects on NMD of the tethered reporter 
were assessed via RT-qPCR. As shown in Fig. 2.4A, cells expressing Flag-SF3B1K700E, but not 
Flag-SF3B1WT, exhibited a reduced level of degradation of the reporter RNA, suggesting that 
NMD activity is attenuated in the presence of this spliceosome mutant. Because the RNA 
binding activity of SF3B1K700E is apparently not affected by the mutation65, the inhibitory effect 
of this mutant on NMD is likely an indirect consequence of splicing dysregulation, which may 
cause mis-splicing of NMD factors or saturating levels of NMD substrates. In further support of 
this idea, we found that NMD of the lN-UPF3B-tethered reporter mRNA was also partially 
repressed in cells expressing U2AF1S34F, another spliceosome mutation frequently found in MDS 
and cancer (Fig. 2.4B)66. Furthermore, treating cells with the splicing modulator pladienolide B 
(PB) also caused inhibition of the degradation of the tethered NMD reporter (Fig. S2.4A). Taken 
together, these observations suggest that NMD is attenuated in cells with perturbed splicing.  
 
Cancer cells harboring spliceosome mutations are preferentially sensitive to NMD 
attenuation  
The high levels of nonsense mRNAs observed in cells with spliceosome mutations16,17 and the 
role of NMD in the clearance of these potentially deleterious transcripts raise the possibility that 
these mutant cells depend on NMD for survival10. The attenuated NMD activity in spliceosome 
mutant cells may also make them more vulnerable to further NMD disruption. In support of this 
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idea, we found that SF3B1K700E-expressing U2OS cells exhibited much more reduced viability 
after shRNA-mediated knockdown of UPF1, compared to cells expressing a comparable level of 
SF3B1WT (Fig. 2.4C). Similarly, U2OS cells expressing U2AF1S34F were also much more 
sensitive to UPF1 knockdown than cells expressing U2AF1WT (Fig. 2.4D). These results suggest 
that a synthetic lethal relationship exists between splicing alterations induced by spliceosome 
mutations and NMD disruption and that NMD can be targeted for selective elimination of 
spliceosome mutant cells. In further support of this idea, we found that SF3B1K700E-expressing 
U2OS cells were much more sensitive to SMG1i, compared to SF3B1WT-expressing cells (Fig. 
2.4E). K562 leukemia cells expressing U2AF1S34F also displayed heightened sensitivity to 
SMG1i, compared to cells expressing U2AF1WT (Fig. 2.4F). Furthermore, SMG1i preferentially 
killed K562 cells containing a knock-in SF3B1K666N mutation compared to the isogenic SF3B1WT 
control cells (Fig. 2.4G, Fig. S2.4B). Together these data suggest the possibility that NMD is a 
therapeutic vulnerability for cancer cells with spliceosome mutations such as MDS. It was 
previously reported that spliceosome mutant cells are sensitive to splicing modulators such as 
PB, sudemycin, E7107, and H3B-880017,66,67,68. Consistent with published results, U2OS or 
K562 cells expressing SF3B1K700E, U2AF1S34F, or SF3B1K666N all exhibited elevated sensitivity 
to PB (Fig. 2.4E-G). Interestingly, SMG1i appeared to have better selectivity in killing these 
spliceosome mutant cells, compared to PB (Fig. 2.4E-G).  
To explore the cellular processes responsible for the sensitivity of spliceosome mutant cells to 
NMD inhibition, we first examined the effects of SMG1i treatment on cell cycle progression and 
DNA replication by performing flow cytometry analysis on K562 cells expressing U2AF1S34F or 
SF3B1K666N after pulse-labeling with BrdU. As shown in Fig. 2.4H and I, prolonged SMG1i 
treatment caused an increase in the G2/M population in both control WT cells and spliceosome 
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mutant cells; however, this effect was much greater in mutant cells than in WT cells. Similarly, 
although SMG1i treatment reduced BrdU incorporation in both WT and spliceosome mutant 
cells, this effect was much greater in mutant cells than in WT cells (Fig. S2.4C and D). These 
data suggest that the combination of splicing dysregulation and NMD inhibition compromises 
cell cycle progression and DNA replication. To further assess the effects of NMD inhibition on 
DNA replication in spliceosome mutant cells, we performed DNA fiber analysis of nascent DNA 
after a sequential IdU/CIdU pulse-labeling procedure69,70. In the DNA tracts with both IdU and 
CldU signals, the average length of the CIdU tracts represents the overall speed of fork 
elongation, while the ratio of CIdU/IdU tract lengths reflects the “smoothness” of fork 
progression with a ratio < 1 indicative of fork obstruction that occurs during CldU incorporation 
(forks stalled/collapsed during IdU incorporation are less likely to proceed to have subsequent 
CIdU incorporation and thus are excluded from analysis.)71,72,73. As shown in Fig. 2.4J and K, 
SMG1i treatment reduced the overall speed of fork progression, with a greater effect in 
spliceosome mutant cells than in control WT cells. SMG1i treatment also caused much more 
reduction in the CIdU/IdU ratio in spliceosome mutant cells than in control WT cells (Fig. 2.4L 
and M), indicative of replication obstruction. Defects in replication often cause fork collapse, 
resulting in chromosomal instability. Consistent with the observed replication defects, we also 
detected a higher level of chromosome abnormalities, including chromosomal breaks and 
fusions, in K562 cells expressing U2AF1S34F or SF3B1K666N after SMG1i treatment, compared to 
control cells expressing WT proteins (Fig. 2.4N and O). Taken together, these data suggest that 
disruption of NMD in spliceosome mutant cells causes an elevated level of replication 
obstruction, leading to slowed replication, cell cycle arrest and chromosomal instability. These 
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effects are likely in part responsible for the observed hypersensitivity of spliceosome mutant 
cells to NMD inhibition.   
 
R-loops are important for the hypersensitivity of spliceosome mutant cells to NMD 
disruption  
To better understand the molecular mechanisms for the sensitivity of spliceosome mutant cells to 
NMD disruption, we investigated the possible involvement of R-loops (a structure containing a 
RNA:DNA hybrid and a displaced ssDNA) that are known to be elevated in spliceosome mutant 
cells74,75,76. Although R-loops participate in a number of physiological processes, abnormal R-
loop formation can interfere with DNA replication and transcription, causing DNA damage, 
genomic instability and cell death77. Consistent with their high basal levels of R-loops, 
spliceosome mutant cells exhibit intrinsic DNA damage, cell cycle arrest and chromosomal 
instability (Fig. 2.4H-O)78,79,80,81,82. NMD factors have been shown to regulate levels of telomeric 
repeat-containing RNA (TERRA) on telomeres, suggesting that they may play a role in R-loop 
regulation at telomeres83. Notably, we observed that SMG1i treatment or UPF1 depletion caused 
a marked increase in overall R-loop levels in cells (without spliceosome mutations) (Fig. 2.5A 
and B, Fig. S2.5A and C). UPF1 depletion and SMG1i treatment also caused increased H2AX 
phosphorylation (gH2AX), a marker of DNA damage (Fig. S2.5B and D). These increased levels 
of both R-loops and gH2AX were largely rescued by overexpression of RNase H1 that removes 
R-loops (Fig. S2.5E-H). Thus, both spliceosome mutations and NMD disruption cause aberrant 
R-loop formation and DNA damage. This raises the possibility that the combination of 
spliceosome mutations and NMD inhibition causes even more abnormal R-loops and DNA 
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damage. Indeed, SMG1i treatment and U2AF1S34F or SF3B1K700E mutations exhibited additive 
effects on the levels of R-loops andCgH2AX in U2OS cells (Fig. 2.5C, D, F, G). These effects 
were largely rescued by overexpression of RNaseH1 (Fig. 2.5C, D, F, G). Remarkably, the 
selective killing effect of SMG1i on spliceosome mutant K562 cells was also largely rescued by 
RNase H1 overexpression, indicating that R loops are a major underlying mechanism for the 
sensitivity of spliceosome mutants to NMD inhibition (Fig. 2.5E and H). Taken together, the 
results described above strongly suggest that disruption of NMD in spliceosome mutant cells 
causes further increase in R loops, leading to replication defects, DNA damage, chromosomal 
instability and cell death. 
 
Discussion 
In this study, we have identified a novel function of the SF3B spliceosome complex in promoting 
NMD in human cells and a synthetic lethal relationship between splicing dysregulation and 
NMD disruption. By performing a genome-wide CRISPR/Cas9 knockout screen using a new 
fluorescence-based reporter system that can measure NMD activity in individual cells, we have 
identified many putative new factors or regulators, including components of the SF3B 
spliceosome complex and other factors required for early spliceosome assembly, in the human 
NMD pathway (Fig. 2.1, Fig. 2.2, Fig. S2.1, Fig. S2.2). These hits, together with those identified 
previously in CRISPR/Cas9 knockout and siRNA knockdown screens using different reporter 
systems, provide a rich resource for future characterization of the mechanism and regulation of 
NMD in human cells84,85. Using a RNA tethering-based reporter system we uncovered a 
previously unrecognized function of the SF3B complex in promoting NMD, separate from its 
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role in pre-mRNA splicing. Interestingly, NMD activity is partially attenuated in cells harboring 
mutations in SF3B1 or U2AF1, which are common in MDS and cancer. These spliceosome 
mutant cells are preferentially sensitive to NMD disruption, suggesting that NMD is a unique 
therapeutic vulnerability for malignancies with defective splicing.   
The identification of a role of the SF3B complex in NMD that is separable from its splicing 
function sheds new light on the process of NMD. Because both introns and EJC assembly are 
important for NMD of multiple reporters, it is believed that pre-mRNA splicing plays a crucial 
role in NMD in mammals, at least for some transcripts. However, it remains unclear whether 
NMD of those transcripts requires the complete process of splicing, or whether the association of 
certain spliceosome factors to pre-mRNA (which then facilitates EJC assembly) during splicing 
promotes NMD. In support of the latter possibility, we found that tethering of multiple 
components of the SF3B complex, but not a later splicing factor SNRNP40, to the 3’ UTR of an 
intronless reporter RNA induced NMD (Fig. 2.3F-K). This RNA degradation requires the core 
EJC factor eIF4A3 as well as CWC22 that directly recruits EJC factors to RNA (note that both 
eIF4A3 and CWC22 are also among the top hits identified in our CRISPR screen) (Fig. 2.2C, D; 
Fig. 2.3L, M). These findings suggest that the splicing of pre-mRNA per se is not required for 
NMD; rather, the recruitment of EJC factors to mRNA by a subset of spliceosome factors during 
splicing facilitates nonsense mRNA recognition and degradation. This model is also in line with 
the fact that several verified top hits in our screen (SF3A3, PRPF19, RNF113A, DGCR14) are 
spliceosome factors required for early steps of splicing86,87. Interestingly, we note that a recent 
siRNA-based genome-wide screen by Hogg and colleagues using a different NMD reporter 
system also identified multiple spliceosome factors among the top hits of potential NMD factors 
or regulators, including four members of the SF3B complex85. Further work is needed to 
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determine precisely how SF3B and possibly other spliceosome factors promote EJC assembly 
and subsequent NMD.  
We found that NMD activity is attenuated under conditions where cells express certain mutant 
splicing factors. Somatic, heterozygous mutations in spliceosome genes such as SF3B1, U2AF1, 
SRSF2 and ZRSR2 frequently occur in patients with MDS, AML, CMML as well as solid 
tumors62,88,89,90,91,92. These mutations cause largely distinct patterns of alterations in splicing and 
gene expression, but a shared feature is the generation of numerous aberrant nonsense mRNAs, 
which normally rely on NMD for clearance9,16,17. Interestingly, our results suggest that the 
activity of NMD is partially attenuated in cells expressing SF3B1(K700E) or U2AF1(S34F) 
(Figs. 2.4A, B), which is in agreement with a previous observation that the levels of certain 
NMD factor transcripts (which are themselves NMD targets) are increased in spliceosome 
mutant cells9,93. Perturbation of splicing by PB, which directly binds to the SF3B complex, also 
suppressed NMD activity (Fig. S2.4A). The inhibitory effect of dysregulated splicing on NMD 
likely results indirectly from abnormal splicing/expression of NMD factors (e.g., UPF3A and 
SMG794), and/or high levels of nonsense mRNAs that saturates the NMD machinery. However, 
some splicing factor mutants can also stimulate NMD of certain target transcripts in a sequence-
specific manner, as exemplified by SRSF2P95H 95.  
The prevalence of aberrant nonsense mRNAs and the attenuated NMD activity observed in 
spliceosome mutant cells raise the possibility that partial disruption of NMD can selectively kill 
these cells. Indeed, we found that cells expressing spliceosome factor mutants were much more 
sensitive to SMG1 inhibition or UPF1 knockdown, compared with cells expressing WT proteins 
(Fig. 2.4C-G). This preferential sensitivity is correlated with cell cycle arrest, DNA replication 
defects, DNA damage and chromosomal instability (Fig. 2.4H-O). Remarkably, the sensitivity of 
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spliceosome mutant cells to SMG1 inhibition could be rescued by RNaseH1 overexpression (Fig. 
2.5E and H), suggesting that R loops are a major underlying mechanism of the synthetic 
lethality. In support of this idea, we found that SMG1 inhibition and spliceosome mutations in 
combination caused an additive effect on R loop formation (Fig. 2.5A-C, F, Fig. S2.5A and C 
)76,81,82. This effect on R loops is in line with that on gH2AX, which is induced by abnormal R 
loop levels (Fig. 2.5D and G). Thus, our data strongly suggest that inhibition of NMD in 
spliceosome mutant cells causes a further increase in R loop levels, which in turn causes 
heightened DNA damage, chromosomal instability and cell death.  
The synthetic lethal relationship identified here between splicing dysregulation and NMD 
inhibition suggests that NMD is an attractive target for treating MDS and cancer with 
spliceosome mutations. Based on the observation that spliceosome mutant cells are sensitive to 
further splicing perturbation, a major effort has been focused on developing splicing modulators 
such as E7107 and H3B-8800¾both of which bind to SF3B1¾as therapies for MDS, AML and 
CMML96,97,98,99,100. However, clinical trials with these compounds either were suspended due to 
toxicity, or did not achieve objective responses97,98,99,100. Our results suggest that NMD 
inhibition, more specifically SMG1 inhibition, is an alternative strategy for treating MDS and 
cancers with defective splicing (Fig. 2.4E-G). It is worth noting that although complete 
disruption of NMD appears to be lethal, its attenuation is tolerated and occurs normally in certain 
developmental processes and in response to cellular stress28,101,102,52. Beyond the cell-
autonomous effects described in this study, NMD inhibition also has the potential to induce anti-
cancer immunity by increasing the production of cancer neoantigens encoded by mis-spliced 
nonsense mRNAs in spliceosome mutant cells103,104,105. In addition to splicing modulation and 
NMD inhibition, spliceosome mutant cells are also sensitive to inhibition of ATR, another 
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SMG1-related kinase in the PIKK family82,106,107. Of note, SMG1i described in this study is 
highly specific for SMG1 (manuscript in preparation). At the concentrations used for NMD 
inhibition in this study, SMG1i does not inhibit ATR (Fig. S2.3D). It will be important to 
directly compare different therapeutic strategies for MDS and cancers with defective splicing and 
test the potential of combination treatment with spliceosome modulators, SMG1i and ATRi.   
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Materials and Methods 
Key reagents, oligo sequences, genetically modified K562 SF3B1K666N cells, SMG1 inhibitor 
The key reagents used in this study are listed in Table 2.1. The sequences of sgRNAs, RT-qPCR 
primers and oligos for CRISPR/Cas9 knock-in are listed in Table 2.2. Genetically modified K562 
SF3B1K666N cells were generated using CRISPR-Cas9 technology. Briefly, 200,000-400,000 
K562 cells were transiently co-transfected with 150 ng of sgRNA (Synthego), 75 ng Cas9 
protein (Berkeley Macrolab), 100 pmol of ssODN donor (hSF3B1.K666N.anti.ssODN), and 200 
ng pMaxGFP expression plasmid (Lonza, #13429329) via nucleofection (Lonza, 4D-
NucleofectorTM X-unit) using solution P3 (Lonza, #V4XP-3024), program FF-120 in small 
cuvettes according to the manufacturer's recommended protocol.  To obtain heterozygous clones, 
two ssODN donors were used: one donor containing the desired modification and a blocking 
modification to prevent subsequent editing after incorporation of the desired modification, and 
another donor containing only a silent blocking modification in order to prevent editing by non-
homologous end joining on the second allele. Five days post nucleofection, cells were single-cell 
sorted by FACS to enrich for GFP+ (transfected) cells, clonally selected, and verified for the 
desired targeted modification via targeted deep sequencing and analysis with CRIS.py108. The 
SMG1i used in this study is an ATP-competitive sulfonamide compound developed by Amgen, 
Inc. The SMG1i inhibits SMG1 enzymatic activity with an IC50 of 0.3 nM and has at least 100-
fold selectivity over other PI3K kinase family members (Bailis et al., manuscript in preparation). 
 
Cell culture, transfection, lentivirus production and infection 
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Human cell lines were cultured in DMEM (Sigma, D5796) (for U2OS, HEK293T and Calu-6) or 
in RPMI 1640 medium (Gibco, 1187) (for K562) supplemented with 10% fetal bovine serum 
(FBS), 100 units/ml penicillin, 100 µg/ml streptomycin in a 5% CO2 incubator at 37 °C.  
Human GeCKOv2 CRISPR knockout pooled library (Addgene # 1000000049) and lenti-Cas9 
plasmid were obtained from addgene (Addgene # 52962), a gift from Feng Zhang109,110. The 
library was amplified in DH5a cells on 100 agar plates (15 cm). Deep Sequencing results 
indicate 98% coverage of all the sgRNAs in the designed library. To generate lentiviruses 
expressing shRNA, Cas9, sgRNA-Cas9, or the GeCKOv2 sgRNA library, HEK 293T cells were 
transfected with lentiviral vectors and packaging vectors (pCMV-VSVG and psPAX2, Addgene 
# 8454 and 12260, respectively), using the Mirus TransIT-LT1 transfection reagent. Cell culture 
medium containing lentiviruses was collected 48 and 72h after transfection, filtered (0.45 µm 
filter, Millipore Sigma #SLHV033RS) and used to infect target cells in the presence of 8 µg/mL 
polybrene.  
Transfection of sgRNA-Cas9 plasmids into Calu-6 cells for individual gene validation was done 
using Lipofectamine 3000 transfection reagent (ThermoFisher Scientific), according to 
manufacturer’s protocol. Cells were selected with puromycin (3 µg/mL) 48 hours after 
transfection. RNA stability was analyzed 6 days after transfection via an actinomyin D chase 
assay, as described previously30,43.  
 
Generation of a fluorescence- and bioluminescence-based NMD reporter  
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The fluorescence/bioluminescence-based NMD reporter system used for the genome-wide 
CRISPR/Cas9 screen in this study was generated by inserting ORFs of mCherry and EGFP 
immediately upstream of CBR and CBG, respectively, into our previously described 
bioluminescence-based NMD reporter30,42. Complete annotated sequence of the reporter is 
available upon request. U2OS cells stably expressing this NMD reporter system was generated 
by co-transfecting the NMD reporter plasmid and pMXs-puro vector that encodes a puromycin-
resistance gene into U2OS cells, using Mirus TransIT-LT1 transfection reagent. After selection 
with puromycin (1.5 µg/mL), single clones expressing the reporter were isolated and validated by 
examining the effects of depletion of known NMD factors or caffeine treatment on NMD of the 
integrated reporter. 
 
Assays for NMD of the fluorescence/bioluminescence-based reporter 
Multiple assays were used to measure NMD activity using our new fluorescence/ 
bioluminescence-based reporter. For live cell imaging, mCherry and GFP fluorescence signals in 
U2OS reporter cells plated in 3.5 cm glass-bottomed dishes (MatTek corporation) were acquired 
using a Nikon Eclipse TiE inverted microscope with MetaMorph software, as described 
previously111. For flow cytometry, resuspended single U2OS reporter cells were analyzed on a 
FACS machine (Sony, Synergy HAPS 1) to separate cell populations based on mCherry and 
GFP signals. For western blots, anti-HA antibodies were used to detect reporter fusion proteins 
HA-mCherry-CBR-TCR(PTC) and HA-EGFP-CBG-TCR(WT). For RT-qPCR, total RNA was 
isolated using RNAqueous™ Total RNA Isolation Kit from ThermoFisher Scientific (AM1912), 
or TRIzol™ reagent from ThermoFisher Scientific (15596). Trace DNA contamination was 
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removed using TURBO DNA-free™ Kit from ThermoFisher Scientific (AM1907), followed by 
reverse transcription to synthesize cDNA using PrimeScript RT kit from Clontech (RR037A). 
qPCR was performed using a two-step PCR protocol (melting temperature: 95°C; 
annealing/extension temperature: 60°C; cycle number: 40) on an ABI V117 real-time PCR 
system with PowerUp SYBR Green Master Mix (ThermoFisher Scientific, A25742). The mRNA 
levels of the housekeeping gene GAPDH was used for normalization. The sequences of the 
primers used are listed in Table 2.2. 
 
Knockdown of NMD factors 
To knock down NMD factors in U2OS reporter cells for reporter validation, lentiviruses 
expressing previously validated shRNAs targeting UPF1 or SMG1 were used30. A shRNA 
targeting firefly luciferase (shLuc) was used as a control. The sequences of shRNA used are 
listed in Table 2.2. U2OS reporter cells were infected with shRNA and incubated for 4 days 
before NMD reporter analysis. Depletion of the proteins was confirmed via western blot analysis 
using anti-SMG1 (Cell Signaling Technology, 9149), and anti-UPF1 (Cell Signaling 
Technology, 12040) antibodies. Tubulin (Santa Cruz, sc8035) was used as a loading control. 
 
Pooled genome-wide CRISPR/Cas9 knockout screen to identify new NMD factors and 
regulators  
U2OS reporter cells were infected with lentiviruses expressing Cas9, and then selected with 
blasticidin (10 µg/mL) for 5 days to establish the U2OS reporter Cas9 cell line. This cell line was 
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validated by examining the effects of sgRNAs targeting SMG1 or UPF2 on NMD of the reporter. 
To carry out the screen, U2OS reporter Cas9 cells were infected with lentiviruses expressing the 
GeCKOv2 library (containing two sub-libraries) at a MOI of less than 1 with a 500x coverage of 
the library. Six days after infection, FACS was performed to collect cells with increased 
mCherry to EGFP ratio, indicative of NMD inhibition. Genomic DNA was extracted using 
PureLink Genomic DNA kit (ThermoFisher Scientific, K182001) followed by two PCR 
reactions to prepare samples for Illumina Next-Gen sequencing. The first PCR was used to 
amplify out sgRNA inserts in the cells, and the second PCR was used to add Illumina sequencing 
tags as well as indexes for sample identification. To improve complexity of the library required 
for deep sequencing, a mixture of 5 forward primers with staggered nucleotides immediately 
upstream of the sgRNA sequences was used in the second PCR. The sequences of primers used 
are listed on Table 2.2. All PCR reactions were performed using Phusion Hot Start II High-
Fidelity DNA Polymerase (ThermoFisher Scientific, F549L). PCR samples were sequenced 
using the Illumina HiSeq 2500 platform. As a baseline control for the abundance of sgRNAs in 
the collected cells, a fraction of unsorted cells were subjected to the same procedure of genomic 
DNA isolation, PCR and Next-Gen Sequencing. 
 
Data analysis and hit identification and validation 
A custom Perl script was used to determine the read counts for each sgRNA and map the 
sgRNAs to their gene IDs in the reference GeCKOv2 library. The script is available upon 
request. Only the sgRNAs with at least 10 reads in each sample was used for further analysis. 
Analysis of genes enriched in FACS-collected cells (with inhibited NMD) compared to baseline 
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control was performed using MAGeCK, a computational tool designed to rank genes based on 
the enrichment of individual sgRNAs as well as the number of enriched sgRNAs for each 
gene112.   
To validate genes identified in the screen, 2 gRNAs from a different human gRNA library 
(AVANA library)113 for each of the 9 genes were cloned into the pLentiCRISPR V2 vector that 
also expresses Cas9 (Addgene, #52961). Two non-targeting gRNAs were also cloned into the 
same vector to serve as controls. All the sequences for the gRNAs used are listed in Table 2.2. 
Lentiviruses containing each gRNA were generated and infected into U2OS reporter Cas9 cells 
to deplete expression of individual genes. NMD activity was then analyzed by western blot to 
determine the ratio of HA-mCherry-CBR-TCR(PTC) to HA-EGFP-CBG-TCR(WT). Since the 
ratio was similar for both non-targeting controls, the relative NMD activity was normalized to 
one non-target control (sgNT-1). As an independent NMD analysis system for further validation, 
human pulmonary adenocarcinoma Calu-6 cells that express a PTC-containing p53 mRNA was 
used36,50,30,43. The same sgRNAs-Cas9 in pLentiCRISPR V2 described above were transfected 
into Calu6 cells, followed by 48 hours of puromycin selection, to deplete expression of the top 
ranked 9 genes individually. Six days after transfection, cells were treated with actinomycin D (5 
µg/mL) for 6 hours to inhibit transcription. RNA samples were collected immediately before and 
after actinomycin D treatment. RT-qPCR was performed for p53 mRNA to measure the percent 
mRNA remaining after addition of actinomycin D.  In addition to p53 mRNA, the RNA stability 
of several known non-mutant NMD targets, including ATF4, PIM3, and UPP1, and a control that 




lN-boxB tethering reporter and NMD analysis 
The EGFP-4boxB reporter construct was generated based on the Globin 4boxB tethering reporter 
developed by Dr. Niels Gehring and colleagues53. The 3’UTR containing four boxB sites were 
cloned into pEGFP-C1 vector to replace the 3’ UTR of the EGFP transcription cassette. The 
resulting EGFP-4boxB expression cassette was then sub-cloned into the pCDH lentiviral vector 
at Xba I and Sal I sites. A construct with scrambled boxB (boxB’) sequences was also generated 
as a control. To generate a dox-inducible lN-UPF3B expression construct, the lN-V5-UPF3B 
ORF in pCl-neomycin-lN-V5-UPF3B (also a gift from Dr. Gehring) was PCR amplified and 
inserted into the pCW lentiviral vector.  lN-fused SF3B1, SF3B5, SF3B6 or SNRNP40 
inducible expression constructs in pCW were generated by replacing UPF3B in pCW-lN-
UPF3B. Note that all these constructs contain a V5 tag sequence immediately downstream of lN 
in all the constructs. pCW-lN-V5 expressing lN alone, pCW-UPF3B, pCW-V5-SF3B1, pCW-
V5-SF3B5, pCW-V5-SF3B6 and pCW-V5-SNRNP40 without lN were also generated as 
controls. Inducible U2OS cell lines expressing lN, lN-fused or lN-unfused UPF3B, SF3B1, 
SF3B5, SF3B5, or SNRNP40 were generated by lentivirus infection. Stable expression of EGFP-
4boxB or EGFP-4boxB’ reporters in these cells lines were generated by lentiviral infection. 
Expression of the inducible proteins was induced by 1 to 2 µg/mL doxycycline for 48 hours. The 
stability of EGFP-4boxB or EGFP-4boxB’ reporter transcripts was determined by RT-qPCR 
analysis of RNA samples before or after 6 hours of actinomycin D treatment.  
 
Cell viability analysis 
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U2OS cells stably expressing Flag-SF3B1WT or Flag-SF3B1K700E were generated by lentiviral 
infection. To assess the sensitivity of these cells to SMG1i or PB, cells were plated in triplicates 
at similar density and 24 hours later treated with DMSO, SMG1i or PB. K562 cells with 
inducible expression of U2AF1WT or U2AF1S34F were generated previously114. To assess the 
sensitivity of these cells to SMG1i or PB, cells were grown in T25 flasks in the presence or 
absence of 250 ng/mL doxycycline for 48 hours. An equal number of induced or uninduced cells 
were then plated and treated with SMG1i, PB, or DMSO. K562 cells with SF3B1K666N knock-in 
mutation were generated using the CRISPR/Cas9 technique. The sensitivity of these cells and 
their parental K562 cells to SMG1i or PB was also evaluated. In all these experiments, alamar 
blue assay was performed 3 days after addition of SMG1i or PB. Relative viability of SMG1i- or 
PB-treated cells were obtained after normalization to DMSO-treated cells. To determine the 
effect of RNase H1 over-expression on cell sensitivity to SMG1i, K562 cells with inducible 
U2AF1WT or U2AF1S34F, or with SF3B1K666N knock-in mutation were infected with lentiviruses 
generated from empty pCDH vector (EV), or pCDH-RNase H1 (RNH1). Cell viability in EV, or 
RNH1-expressing cells after SMG1i treatment was then measured as described above. 
To determine the sensitivity of spliceosome mutant cells to UPF1 depletion, U2OS cells stably 
expressing SF3B1WT, SF3B1K700E, U2AF1WT, or U2AF1S34F were infected with UPF1 shRNA, or 
with shLuc control. Twenty hours after infection, an equal number of cells were plated and 
alamar-Blue assay was performed on day 3 to day 6 post infection. To determine cell growth 
from day 3 to day 6, the values obtained from alamar blue assay were normalized to day 3 for 
each cell line. To determine the relative cell viability of cells expressing WT versus mutant 
splicing factors after UPF1 depletion, values from cells infected with shUPF1 were normalized 




Immunofluorescence to detect R-loops and gH2AX 
U2OS cells were treated with DMSO, or SMG1i (5 µM) for 24 hours, or infected with 
shUPF1/shLuc and incubated for 5 days. U2OS cells stably expressing SF3B1WT, SF3B1K700E, 
U2AF1WT, or U2AF1S34F were infected with LacZ control, or RNase H1 adenovirus and then 
treated with SMG1i (1 µM) for 3 days. For immunofluorescence to detect S9.6 nuclear signal 
and gH2AX, cells plated on cover-slips were first permeabilized with PBS containing 0.2% 
Triton, washed with PBS and fixed with 4% PFA, and then blocked with 10% goat serum in 
PBS. Cells were then incubated with antibodies against S9.6 (1:100, Millipore Sigma, 
MABE1095) and gH2AX (1:500, Cell Signaling Technology, 9718) for 2 hours at room 
temperature. Cells were washed with PBS containing 0.1% Triton, and then incubated with 
Alexa Fluor 488-conjugated goat anti-mouse antibody (1:500, ThermoFisher, A-11001) and 
Alexa Fluor 568-conjugated goat anti-rabbit (1:500, ThermoFisher, A-11011) for 1 hour. Cells 
were counter-stained with Hoecsht (ThermoFisher, H3570). Images were acquired using Nikon 
Ti-E fluorescence microscope and Metamorph software (Molecular Devices). Nuclear signal of 
S9.6 and gH2AX were quantified using ImageJ software.  
 
 Detection of R-loops in U2OS cells using slot blot analysis  
U2OS cells were treated with DMSO, or SMG1i (5 µM) for 24 hours, or infected with 
shUPF1/shLuc and incubated for 5 days. Genomic DNA was then extracted using 
phenol/chloroform/isoamyl alcohol. 2 µg genomic DNA was treated with buffer alone or with 1 
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unit RNase H enzyme (NEB, MO297S) for 2 hours at 37 °C. 200 ng to1 µg genomic DNA was 
then slotted directly to 2 nylon membranes. One membrane, used as loading control was 
incubated in DNA denaturing buffer (0.5 M NaOH, 1.5 M NaCl) for 10 min and neutralized for 
10 min in 0.5 M Tris-HCl pH 7.2, 1.5 M NaCl. Both membranes were UV-crosslinked, blocked 
with casein buffer, and then incubated with S9.6 antibody (Millipore Sigma, MABE1095) to 
detect R-loops, or with anti-ssDNA antibody (Millipore Sigma, MAB3868) to detect total DNA. 
Images were obtained using ChemiDoc imaging system, and the S9.6/ssDNA signal was 
quantified using ImageJ software. To determine if RNase H1 can remove R-loops in cells, U2OS 
cells were infected with adenovirus expressing LacZ control, or RNase H1. After respective 
UPF1 knockdown/SMG1i treatment, genomic DNA was then extracted and slot blot analysis 
was performed as described above.  
 
Immunoblotting  
Detection of all the proteins was done using SDS-PAGE and immunoblotting using the Odyssey 
Infra-red Imaging System as described before115. Briefly, cells were lysed using 50 mM Tris, 
10% glycerol, 2% SDS, 5% β-mercaptoethanol. Protein lysates were run on SDS-PAGE gels and 
transferred to a PVDF membrane, blocked with casein buffer and incubated with the indicated 
primary antibodies (see Table 2.1). DyLight 800- and DyLight 680-conjugated secondary 
antibodies were used to detect the primary antibodies, and signals were acquired using Odyssey 




BrdU incorporation and cell cycle analysis 
Cell proliferation and cell cycle analysis was performed by flow cytometry after BrdU 
incorporation, as described before69. K562 cells expressing inducible U2AF1WT or U2AF1S34F, or 
with SF3B1K666N knock-in mutation were treated with 1 µM SMG1i for 3 days, and then 
incubated with BrdU (20 µM) for 30 min. Subsequently, cells were washed with cold PBS and 
fixed with 70% ethanol overnight. DNA was denatured using 2 N HCl/0.5% Triton X-100 for 30 
minutes in room temperature, and then neutralized with 0.1 M sodium tetraborate, pH 8.5. Cells 
were then incubated overnight with mouse anti-BrdU antibody (1:00, BD Biosciences, 347580) 
in PBS + 0.5% Tween 20 + 1% BSA. After washing with PBS + 1% BSA, cells were incubated 
with Alexa Fluor 488-conjugated goat anti-mouse IgG (1:500, ThermoFisher, A-11001) for 1 h. 
After washing with PBS + 1% BSA, cells were re-suspended in PBS containing propidium 
iodide (20 µg/ml) and RNase A (200 µg/ml) and incubated at 37°C for 30 min. Flow cytometry 
was performed using BD FACSCalibur Flow Cytometer and cell cycle profile was analyzed with 
FlowJo software. 
 
Metaphase chromosome spreads  
Metaphase chromosome spreads to evaluate genomic instability following SMG1i treatment 
were performed as previously described70. K562 cells expressing inducible U2AF1WT or 
U2AF1S34F, or SF3B1K666N knock-in mutation were treated with 1 µM SMG1i for 2 days. Cells 
were then washed and incubated in fresh medium for another 2 days. In the last 4 hours, cells 
were incubated with 10 µM nocodazole. Cells were then collected, washed with PBS, and re-
suspended with10 ml of pre-warmed hypotonic solution (10 mM KCl, 10% FBS) and incubated 
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for 10 min at 37 °C. Cells were fixed by adding 500 µl of cold fixation buffer (1V acetic acid: 3V 
methanol), and washed in the same buffer 4 times before overnight incubation in the same buffer 
at 4 °C. The nuclei were then spread on pre-chilled slides, air-dried overnight, and mounted with 
Prolong Gold Antifade reagent (ThermoFisher, P36930) containing Hoechst (ThermoFisher, 
H3570). Images were acquired using Nikon Ti-E fluorescence microscope. Fifty randomly 
selected metaphases per experiment (total of 3 experiments) were scored for chromosomal 
aberrations.  Statistical analysis was done using GraphPad Prism 6.    
 
DNA fiber assay 
A DNA fiber assay to determine replication fork speed was performed as previously described70. 
K562 cells expressing inducible U2AF1WT or U2AF1S34F, or SF3B1K666N knock-in mutation were 
treated with 1 µM SMG1i for 3 days. Cells were then incubated with 20 µM 5-iodo-2′-
deoxyuridine (IdU, Sigma-Aldrich) for 30 minutes, followed by incubation with 400 µM 5-
chloro-2′-deoxyuridine (CldU, Sigma-Aldrich) for 30 minutes. Cells were then collected and 
washed with cold PBS, and then re-suspended at a concentration of 4 million cells per mL. A 
total of 2 uL of the cell solution was combined with 8 uL of lysis buffer (200 mM Tris.HCl pH 
7.5; 50 mM EDTA; 0.5 % SDS) on a glass slide. Cells were allowed to settle on the slide for 5 
minutes and then tilted at 20-45° angle to allow DNA to slowly spread on the slide. The resulting 
DNA spreads were air-dried, fixed in 3:1 methanol/acetic acid and stored at 4 °C. DNA fibers 
were denatured using 2.5 N HCl for 1 hr, washed with PBS and blocked with 5% BSA in PBS-T 
(PBS + 0.1% Tween-20) for 1 hr. CldU and IdU tracks were detected with rat anti-BrdU 
antibody (1:50, Abcam, ab6326), and mouse anti-BrdU antibody (1:50, BD Biosciences, 
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347580), respectively. Secondary antibodies (anti-rat Alexa 488, (1:100, ThermoFisher, A-
11077) and anti-mouse Alexa 546 (1:100, Thermofisher, A21123) were used to detect CldU and 
IdU. Antibody incubations was performed in a humid 37°C chamber for 1 hr for primary 
antibodies, and 45 min for secondary antibodies. The slides were air-dried and mounted with 
Prolong Gold Antifade reagent (ThermoFisher, P36930). Fluorescence images of IdU and CldU 
tracks were captured using an inverted microscope (Nikon Ti-E) and Metamorph software 
(Molecular Devices). The IdU and CldU tract lengths were measured using ImageJ software, and 
the pixel length values were converted into micrometers using the scale bars created by the 
microscope. Fork speed mas measured as total length of CldU tract in the tracts containing both 





Figure 2.1. A new reporter system for analyzing NMD in individual human cells. 
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A. Schematic diagram of a multicolored, fluorescence- and bioluminescence-based NMD 
reporter.  
B. Fluorescence imaging of the NMD reporter in U2OS reporter cells after treatment with H2O 
or caffeine (10 mM) for 24 hrs. 
C. FACS analysis of U2OS reporter cells treated with H2O or caffeine (10 mM) for 24 hrs. In 
the merged panel, green dots are H2O-treated cells whereas red dots are caffeine-treated cells. 
D. Western blot of the protein products (HA-tagged) of the NMD reporter after 24-hr treatment 
of U2OS reporter cells with H2O or caffeine (10 mM). 
E. Ratios of mCherry-containing reporter mRNA to EGFP-containing reporter mRNA in U2OS 
reporter cells treated with H2O or caffeine (10 mM) for 24 hrs. The mCherry/EGFP mRNA 
ratio of the H2O control was normalized to 1. Data represent the mean ± SD of three 
independent experiments. **p ≤ 0.01 (paired t-test). 
F. Western blot of the protein products of the NMD reporter in U2OS reporter cells after 
shRNA-mediated knockdown of SMG1 or UPF1. 
G. Ratio of mCherry-containing reporter mRNA to EGFP-containing reporter mRNA in U2OS 
reporter cells after shRNA-mediated knockdown of SMG1 or UPF1. The mCherry/EGFP 
mRNA ratio of the shLuc control was normalized to 1. Data represent the mean ± SD of three 
independent experiments. **p ≤ 0.01 (paired t-test). 
H. FACS analysis of U2OS reporter cells after shRNA-mediated knockdown of SMG1 or UPF1. 
In the merged figure, green dots represent control shLuc cells, and red dots represent 




Figure 2.2. A genome-wide CRISPR/Cas9 knockout screen to identify novel NMD factors 
and regulators. 
A. Workflow of the CRISPR/Cas9 knockout screen.  
78 
 
B. FACS analysis of Cas9-expressing U2OS reporter cells infected with the two GeCKOv2 
sgRNA sub-libraries, or a non-targeting sgRNA control. The gating represents the collected 
cell population with attenuated NMD activity. 
C. A bubble plot showing results of gene enrichment analysis obtained from MAGeCK analysis. 
The x-axis represents gene IDs of all targeted genes. The bubble size represents the number 
of gRNAs enriched for the target gene.  
D. The list of top 15 gene hits as ranked by MAGeCK analysis. 









Figure 3. SF3B complex promotes NMD in an EJC-dependent, but splicing-independent, 
manner. 
A. A schematic of a tethering reporter that recapitulates NMD in human cells. The 3’ UTR of 
the reporter construct contains 4 boxB sites. A reporter with scrambled boxB (boxB’) 
sequences in the 3’ UTR was used as a control.  
B. Left, western blot analysis of UPF3B or lN-UPF3B proteins (both V5-tagged) after 
induction with doxycycline (1 ug/mL). Right, stability of boxB or boxB’ reporter mRNA in 
cells expressing lN, UPF3B, or lN-UPF3B. RNA decay analysis was performed by 
measuring RNA before and after actinomycin D treatment. Percent mRNA remaining was 
calculated as the mRNA remaining as a percent of RNA before actinomycin D treatment. 
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Data represent the mean ± SD of three independent experiments. **p ≤ 0.01, *p ≤ 0.05 
(unpaired t-test). 
C. Left, western blot analysis of UPF1 knockdown and lN-UPF3B induction in cells expressing 
the boxB reporter mRNA. Right, effects of UPF1 knockdown on the stability of boxB 
reporter mRNA in cells expressing lN or lN-UPF3B. Data represent the mean ± SD of three 
independent experiments. ***p ≤ 0.001 (unpaired t-test). 
D. Left, western blot analysis of eIF4A3 knockdown and lN-UPF3B induction in cells 
expressing the boxB reporter mRNA. Right, effects of eIF4A3 knockdown the stability of 
boxB reporter mRNA in cells expressing lN or lN-UPF3B. Data represent the mean ± SD of 
three independent experiments. **p ≤ 0.01 (unpaired t-test). 
E. RNA decay analysis of boxB reporter mRNA in lN- or lN-UPF3B expressing cells after 
treatment with DMSO or SMG1i (1 µM). Data represent the mean ± SD of three independent 
experiments. **p ≤ 0.01 (unpaired t-test). 
F–I. Left, western blot analysis of lN-tagged or untagged spliceosome factors (SF3B1, SF3B5, 
SF3B5 or SNRNP40) in cells after induction with doxycycline (2 ug/mL). Middle and right, 
stability of boxB or boxB’ reporter mRNA in cells expressing lN, or lN-tagged or -untagged 
spliceosome factors. Data represent the mean ± SD of three independent experiments. *p ≤ 
0.05 (unpaired t-test). 
J.  Effects of SMG1i (1 µM) or DMSO on the stability of boxB reporter mRNA in cells 
expressing lN, lN-SF3B1, lN-SF3B5 or lN-SF3B6. Data represent the mean ± SD of three 
independent experiments. ***p ≤ 0.001; **p ≤ 0.01 (unpaired t-test). 
K-M. Left, western blot analysis of knockdown of UPF1, eIF4A3 or CWC22, and expression of 
lN-SF3B1, lN-SF3B5 or lN-SF3B6 in cells expressing the boxB reporter mRNA. Right, 
effect of knockdown of UPF1, eIF4A3 or CWC22 on the stability of the boxB reporter 
mRNA in cells expressing lN, lN-SF3B1, lN-SF3B5 or lN-SF3B6. Data represent the 








Figure 2.4. Cells expressing mutant spliceosome factors rely more on NMD for survival. 
A-B. Left, western blot analysis of lN-UPF3B in boxB reporter cells expressing Flag-tagged 
SF3B1WT/K700E (A) or U2AF1WT/S34F (B). Right, effects of SF3B1WT/K700E or U2AF1WT/S34F 
overexpression on the stability of boxB reporter mRNA in cells in the presence of lN-
UPF3B. Data represent the mean ± SD of three independent experiments. **p ≤ 0.01 
(unpaired t-test). 
C-D. Left, western blot analysis of UPF1 knockdown in U2OS cells expressing Flag-tagged 
SF3B1WT/K700E (C) or U2AF1WT/S34F (D). Right, effects of UPF1 knockdown on the viability 
of U2OS cells expressing SF3B1WT/K700E (C) or U2AF1WT/S34F (D). Data represent the mean 
± SD of three independent experiments. ***p ≤ 0.001; **p ≤ 0.01 (unpaired t-test). 
E.  Left, western blot analysis of Flag-tagged SF3B1WT or SF3B1K700E overexpression in U2OS 
cells. Middle and right, effects of SMG1i or PB treatment (3 days) on the viability of U2OS 
cells expressing SF3B1WT or SF3B1K700E. Data represent the mean ± SD of three independent 
experiments. **p ≤ 0.01; *p ≤ 0.05 (unpaired t-test). 
F. Left, western blot analysis of inducible expression of Flag-tagged U2AF1WT or U2AF1S34F in 
K562 cells. Middle and right, effects of SMG1i or PB treatment (3 days) on the viability of 
K562 cells expressing U2AF1WT or U2AF1S34F. Data represent the mean ± SD of three 
independent experiments. **p ≤ 0.01; *p ≤ 0.05 (unpaired t-test). 
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G. Effects of SMG1i or PB treatment (3 days) on the viability of K562 cells with or without 
SF3B1K666N knock-in mutation. Data represent the mean ± SD of three independent 
experiments. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05 (unpaired t-test). 
H-I. Effects of SMG1i treatment (1 µM, 3 days) on the G2-M population of the K562 cells 
expressing U2AF1WT/S34F (H) or K562 cells with or without SF3B1K666N knock-in mutation 
(I). Data represent the mean ± S.E.M of three independent experiments. ***p ≤ 0.001; **p ≤ 
0.01; *p ≤ 0.05 (unpaired t-test). 
J-M. Effects of SMG1i treatment (1 µM, 3 days) on DNA replication speed (J, K) or fork 
progression (L, M) in K562 cells expressing U2AF1WT/S34F (J, L) or K562 cells with or 
without SF3B1K666N knock-in mutation (K, M). Upper, experimental scheme for DNA fiber 
assay. Lower, distribution of CldU tract lengths or CIdU/IdU ratio. Green bars represent the 
median ± S.E.M of two independent experiments. A total of 150 tracts analyzed per sample. 
****p ≤ 0.0001; ***p ≤ 0.001; **p ≤ 0.01 (Mann Whitney test). 
N-O. Effects of SMG1i treatment (1 µM, 2 days followed by 2 days of recovery) on 
chromosomal integrity in K562 cells expressing U2AF1WT/S34F (N) or K562 cells with or 
without SF3B1K666N knock-in mutation (O). Upper, experimental scheme of metaphase 
spread assay. Lower, distribution of chromosomal aberrations per mitosis. Red bars represent 
the mean ± S.E.M of two independent experiments. A total of 150 metaphases analyzed per 




Figure 2.5. Elevated R-loop formation is a major underlying mechanism for the 
hypersensitivity of spliceosome mutant cells to NMD inhibition 
A. R-loop analysis of SMG1i-treated cells. U2OS cells were treated with SMG1i (5 µM) for 24 
hours and then immunofluorescence was performed to detect nuclear S9.6 signal. Left, 
representative images showing nuclear signal of S9.6. Right, Quantification of nuclear S9.6 
signal. Red bars represent the mean ± S.E.M of two independent experiments. A total of 130 
nuclei analyzed per sample. ****p ≤ 0.0001 (Mann Whitney test). 
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B. R-loop analysis of U2OS cells after shRNA-mediated knockdown of UPF1. U2OS cells were 
infected with shLuc/UPF1 and then incubated for 5 days. Immunofluorescence was 
performed to detect nuclear S9.6 signal. Left, representative images showing nuclear signal 
of S9.6. Right, Quantification of nuclear S9.6 signal. Red bars represent the mean ± S.E.M of 
two independent experiments. A total of 130 nuclei analyzed per sample. ***p ≤ 0.001 
(Mann Whitney test). 
C. R-loop analysis of U2OS cells stably expressing U2AF1 WT/S34F. Cells were infected with 
adenovirus expressing lacZ control or RNH1 and then treated with SMG1i (1 µM) for 3 days. 
Red bars represent the mean ± S.E.M of two independent experiments. A total of 150 nuclei 
analyzed per sample. ****p ≤ 0.0001 (Mann Whitney test). 
D. Immunofluorescence analysis of gH2AX in U2OS cells stably expressing U2AF1 WT/S34F. 
Cells were infected with adenovirus expressing lacZ control or RNH1 and then treated with 
SMG1i (1 µM) for 3 days. Red bars represent the mean ± S.E.M of two independent 
experiments. A total of 150 nuclei analyzed per sample. ****p ≤ 0.0001 (Mann Whitney 
test). 
E. Cell viability analysis of K562 cells stably expressing EV/RNH1 after induction of U2AF1 
WT/S34F and treatment with indicated amounts of SMG1i for 3 days. Data represent the 
mean ± SD of three independent experiments. **p ≤ 0.01; *p ≤ 0.05 (unpaired t-test). 
F. R-loop analysis of U2OS cells stably expressing SF3B1 WT/K00E. Cells were infected with 
adenovirus expressing lacZ control or RNH1 and then treated with SMG1i (1 µM) for 3 days. 
Red bars represent the mean ± S.E.M of two independent experiments. A total of 150 nuclei 
analyzed per sample. ****p ≤ 0.0001 (Mann Whitney test). 
G. Immunofluorescence analysis of gH2AX in U2OS cells stably expressing SF3B1 
WT/K700E. Cells were infected with adenovirus expressing lacZ control or RNH1 and then 
treated with SMG1i (1 µM) for 3 days. Red bars represent the mean ± S.E.M of two 
independent experiments. A total of 130 nuclei analyzed per sample. ****p ≤ 0.0001 (Mann 
Whitney test). 
H. Cell viability analysis of K562 control/SF3B1-K666N knock-in cells stably expressing 
EV/RNH1, treated with indicated amounts of SMG1i for 3 days. Data represent the mean ± 





Figure S2.1. A new reporter system for analyzing NMD in individual human cells. 
A. Western blot analysis of the protein products of the NMD reporter in Cas9-expressing U2OS 
reporter cells after sgRNA-mediated depletion of UPF2. 
B. Ratios of mCherry-containing reporter mRNA to EGFP-containing reporter mRNA in Cas9-
expressing U2OS reporter cells after UPF2 depletion. The mCherry/EGFP mRNA ratio of 
the sgNT control was normalized to 1. Data represent the mean ± SD of three independent 
experiments. *p ≤ 0.05 (paired t-test). 









A. Western blot analysis of the protein products of the NMD reporter in Cas9-expressing U2OS 
reporter cells after sgRNA-mediated depletion of the 9 top-ranked genes individually. Two 
sgRNAs that are distinct from that in the original GeCKOv2 library were used for 
knockdown.  
B. Quantified results of the samples depicted in A. The ratios of the sgNT (nontargeting) control 
was normalized to 1. Data represent the mean ± SD of three independent experiments. ***p 
≤ 0.001; **p ≤ 0.01; *p ≤ 0.05 (paired t-test).   
C. Effects of depletion of the 9 top-ranked genes individually on the stability of endogenous 
PTC-containing p53 mRNA in Calu-6 cells. Cells were transfected with sgRNA-Cas9 
constructs and incubated for 6 days, and then treated with actinomycin D for 6 hours to 
inhibit transcription. Total mRNA was collected before and after actinomycin D treatment. 
p53 mRNA levels were measured using RT-qPCR. Data represent the mean ± SD of three 
independent experiments. *p ≤ 0.05; **p ≤ 0.01; (paired t-test).   
D-G. Effects of depletion of the 9 top-ranked genes individually on the stability of known NMD 
targets ATF4 (D), UPP1 (E), and PIM3 (F) in Calu-6 cells. ORCL (G) is non-NMD target 
control. Samples were generated as depicted in C.  Data represent the mean ± SD of three 
independent experiments. ****p ≤ 0.0001; ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05 (paired t-
test).   
H. Comparison of the enrichment of NMD factor genes and spliceosomal complex genes in 




Figure S2.3. SF3B complex promotes NMD in an EJC-dependent, but splicing-
independent, manner. 
A. No cryptic splicing was detected in boxB or boxB’ tethering reporter RNA. Total RNA was 
extracted from U2OS cells expressing boxB or boxB’ reporter mRNAs, followed by RT 
using a oligo dT primer. PCR was then used to generate cDNAs with primers that anneal to 
5’UTR and 3’UTR of the boxB or boxB’ reporter transcripts.  
B. Western blot analysis of the protein products of the new NMD reporter after treatment with 
SMG1i at indicated concentrations for 24 hours. 
C. Ratios of mCherry-containing reporter mRNA to EGFP-containing reporter mRNAs in 
U2OS cells treated with 1 µM SMG1i for 24 hours. DMSO-treated cells were normalized to 
1. Data represent the mean ± SD of three independent experiments. **p ≤ 0.01 (paired t-test). 
D. Western blot analysis of phosphor-CHK1 (phosphor serine 345), total CHK1, and gH2AX in 
U2OS cells pre-treated with the indicated concentrations of SMG1i for 24 hours, and then 




Figure S2.4. Cells expressing mutant spliceosome factors rely more on NMD for survival. 
A. Left, western blot analysis of induced lN-UPF3B in cells expressing the boxB reporter 
mRNA after treatment with 1 nM PB for 24 hours. Right, effects of PB treatment on the 
stability of boxB reporter mRNA in the presence of lN-UPF3B.  
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B. Genetically modified K562 SF3B1K666N expresses 50% SF3B1WT mRNA and 50% 
SF3B1K666N mRNA. Sequence fragment density reads from RNA sequencing of K562 cells 
with or without SF3B1K666N knock-in mutation aligned in IGV. The control cells express 
100% SF3B1WT mRNA. The knock-in cells express 50% mRNA containing the C to G 
mutation at position 1998 (that changes K at 666 to N, colored bars on the left) and 100% 
mRNA containing the blocking modifications (that do not change the amino acid) to prevent 
additional editing by Cas9 (colored bars on the right). 
C. Upper, effects of SMG1i treatment (1 µM, 3 days) on the cell cycle and DNA replication of 
K562 cells expressing U2AF1WT or U2AF1S34F. Treated cells were pulsed labeled with BrdU 
for 30 min before being harvested for propidium iodide staining and flow cytometry. Lower, 
percentages of cells in different cell cycle phases after SMG1 treatment. Data represent the 
mean ± S.E.M. of three independent experiments. 
D.  Upper, effects of SMG1i treatment (1 µM, 3 days) on the cell cycle and DNA replication of 
K562 cells with or without SF3B1K666N knock-in mutation. Treated cells were pulsed labeled 
with BrdU for 30 min before being harvested for propidium iodide staining and flow 
cytometry. Lower, percentages of cells in different cell cycle phases after SMG1 treatment. 





Figure S2.5. Elevated R-loop formation is a major underlying mechanism for the 
hypersensitivity of spliceosome mutant cells to NMD inhibition 
A. R-loop analysis using slot blot assay. U2OS cells were treated with SMG1i (5 µM) for 24 
hours and then genomic DNA was collected for R-loop analysis. Total genomic DNA 
with/without RNase H (RNH) digestion were slotted on a membrane and S9.6 antibody was 
used to detect R-loops. ssDNA was used to detect total genomic DNA. 
B. Western blot analysis of gH2AX in U2OS cells treated with SMG1i as described in A, above. 
C. R-loop analysis of U2OS cells after shRNA-mediated knockdown of UPF1. Total genomic 
DNA with/without RNase H (RNH) digestion were slotted on a membrane and S9.6 antibody 
was used to detect R-loops. ssDNA was used to detect total genomic DNA. 




E. R-loop analysis of U2OS cells treated with SMG1i (5 µM) for 24 hours after lacZ, or RNH1 
adenovirus infection for 48 hours.  
F. Western blot analysis of gH2AX in U2OS infected with adenovirus-lacZ, or RNH1, and then 
treated with SMG1i, as described in E. 
G. R-loop analysis of U2OS cells after shRNA-mediated knockdown of UPF1 and infection 
with adenovirus-lacZ, or RNH1 for 48 hours.  
H. Western blot analysis of gH2AX in U2OS cells after UPF1 KD and infection with 
adenovirus-lacZ, or RNH1, as described in G. 
I. Western blot analysis of RNH1 over-expression in U2OS cells expressing U2AF1WT, 
U2AF1S34F, SF3B1WT, or SF3B1K700E, infected with adenovirus lacZ control, or adenoivurs 
RNH1. 
J. Western blot analysis of RNH1 in K562 cells stably expressing RNase H1 after induction of 
U2AF1 WT/S34F 






 Table 2.1. List of key resources and reagents used. 
Key Reagents and Resources Table 
Reagent or Resource Source Identifier 
   
NMD reporters and other plasmids   
pBS-(HA-CBR-TCR(PTC))-(HA-CBG-
TCR(WT)) 
Generated in You lab N/A 
pBS-(HA-CBR-TCR(PTC)) Generated in You lab N/A 
pBS-(HA-CBG-TCR(WT)) Generated in You lab N/A 
pBS-(HA-mCherry-CBR-TCRβ(PTC)) Generated in You lab N/A 
pBS-(HA-EGFP-CBG-TCRβ(WT)) Generated in You lab N/A 
pBS-(HA-mCherry-CBR-TCR(PTC))-(HA-
EGFP-CBG-TCR(WT)) 
Generated in You lab N/A 
lentiGuide-Human GeCKOv2  Addgene Cat#10000
00049 
pLenti-Cas9 Blast  Addgene Cat#52962 
pCMV-VSVG  Addgene Cat#8454 
psPAX2 Addgene Cat#12260 
pLentiCRISPR V2  Addgene Cat#52961 
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pCl-ƛN-V5-UPF3B Gift from Dr. Niels 
Gehring 
N/A 
pCW-ƛN-V5-UPF3B Cloned from pCl-ƛN-V5 -
UPF3B 
N/A 
pCI-globin-4boxB Gift from Dr. Niels 
Gehring 
N/A 
pCDH-GFP-4boxB Cloned from pCI-globin-
4BOXB 
N/A 
pCDH-GFP-scrambled-4boxB (boxB') Generated in You lab N/A 
pCW-UPF3B Generated in You lab N/A 
pCW-Cas9-puro Addgene Cat#50661 
pCW-ƛN-V5 Generated in You lab N/A 
pCW-ƛN-V5-SF3B5 Generated in You lab N/A 
pCW-V5-SF3B5 Generated in You lab N/A 
pEGFP-C1-GFP-SF3B6-FLAG Addgene Cat#86870 
pCW-ƛN-V5-SF3B6 Generated in You lab N/A 
pCW-V5-SF3B6 Generated in You lab N/A 
pCDNA3.1-FLAG-SF3B1-WT Addgene Cat#82576 
pCDNA3.1-FLAG-hSF3B1-K700E Addgene Cat#82577 
pCDH-FLAG-SF3B1-WT Generated in You lab N/A 
pCDH-FLAG-SF3B1-K700E Generated in You lab N/A 
pCW-ƛN-V5-SF3B1 Generated in You lab N/A 
pCW-V5-SF3B1 Generated in You lab N/A 
pSPlit-OC-SNRNP40 Addgene Cat#51741 
pCW-V5-SNRNP40 Generated in You lab N/A 
pCW-ƛN-V5-SNRNP40 Generated in You lab N/A 
pCDNA3.1-FLAG-U2AF1-WT Obtained from Walter lab N/A 
pCDNA3.1-FLAG-U2AF1-S34F Obtained from Walter lab N/A 
pCDH-FLAG-U2AF1-WT Generated in You lab N/A 
pCDH-FLAG-U2AF1-S34F Generated in You lab N/A 
pMaxGFP  Lonza™ Cat#13429
329 
   
Antibodies   
Mouse anti-HA antibody Biolegend Cat#90150
7  
Rabbit anti-SMG1 Cell Signaling 
Technology  
Cat#9149  
Rabbit anti-UPF1 Cell Signaling 
Technology  
Cat#12040 
Mouse anti-tubulin Santa Cruz Cat#sc-
8035 
Rabbit anti-SF3B1 Cell Signaling 
Technology  
Cat#14434 




Rabbit anti-V5 Cell Signaling 
Technology  
Cat#13202 
Mouse anti-β-Actin  Cell Signaling 
Technology  
Cat#3700 
Rabbit anti-UPF2 Novus Biologicals Cat#NB2-
20813 
Rabbit anti-CWC22 Abclonal Cat#A1311
6 
Rabbti anti-eIF4A3 Abclonal Cat#A4338 







Mouse anti-S9.6 Millipore Sigma Cat#MAB
E1095 
Mouse anti-ssDNA Millipore Sigma Cat#MAB
3868 
Rabbit anti-Rnase H1 Gene Tex Cat#GTX1
17624 
Mouse monoclonal anti-BrdU, Clone B44 BD PharMingen Cat#34758
0 
Rabbit monoclonal Phospho-Chk1 (S345) Cell Signaling 
Technology  
Cat#2348 
Mouse monoclonal anti-Chk1 Santa Cruz Cat#sc-
8408 
Rat monoclonal anti-BrdU [BU1/75 (ICR1)] Abcam Cat# 
ab6326 
Alexa Fluor 488-conjugated goat anti-mouse ThermoFisher Scientific Cat#A-
11001 
Goat anti-Rabbit IgG (H+L) Cross-Adsorbed 
Secondary Antibody, DyLight 680 
ThermoFisher Scientific Cat#35568 
Goat anti-Mouse IgG (H+L) Cross-Adsorbed 
Secondary Antibody, DyLight 800 
ThermoFisher Scientific Cat# SA5-
10176  
Alexa Fluor 488-conjugated goat anti-rat ThermoFisher Scientific Cat#A-
11077 
Alexa Fluor 546-conjugated goat anti-mouse ThermoFisher Scientific Cat#A-
21123 
Alexa Fluor 568-conjugated goat anti-rabbit ThermoFisher Scientific Cat#A-
11011 
   
Chemicals   
Actinomycin D Sigma-Aldrich Cat#A1410 
Caffeine Sigma-Aldrich Cat#C0750 




Lipofectamine 3000 Reagent ThermoFisher Scientific Cat#L3000
015 
RNAqueous™ Total RNA Isolation Kit  ThermoFisher Scientific Cat#AM19
12 
TRIzol™ reagent  ThermoFisher Scientific Cat#15596 
TURBO DNA-free™ Kit ThermoFisher Scientific Cat#AM19
07 
PrimeScript RT kit Clontech Cat#RR03
7A 
PowerUp SYBR Green Master Mix  ThermoFisher Scientific Cat#A2574
2 
PureLink Genomic DNA kit  ThermoFisher Scientific Cat#K1820
01 
Phusion Hot Start II High-Fidelity DNA 
Polymerase 
ThermoFisher Scientific Cat#F549L 
SMG1 inhibitor (SMG1i) Amgen N/A 




5-Iodo-2′-deoxyuridine (IdU) Sigma-Aldrich Cat#I7125 
5-Chloro-2′-deoxyuridine (CldU) Sigma-Aldrich Cat#C6891 
BrdU ThermoFisher Cat#B2315
1 
Hoechst 33342 ThermoFisher Cat#H3570 
Propidium Iodide MP Biomedicals Cat#19545
8 
Prolong Gold Antifade reagent  ThermoFisher Cat#P3693
0 
Solution P3 Lonza™ Cat#V4XP
-3024 
   
Purified Protein   
Cas9-NLS Berkeley Macrolab N/A 
 
Table 2.2. Sequence Identities of PCR primers, oligo, sgRNAs, and shRNAs. 
sgRNA, shRNA, primer and oligo sequences 
Name of primer Sequence 
  







p53-F GAGGTTGGCTCTGACTGTACC  















RT-PCR Primers for 
boxB/boxB' 
 
GFP-5'-UTR-F GTTTAGTGAACCGTCAGATCG  
GFP-3'-UTR-R GAAATTTGTGATGCTATTGC 
  
























Reverse Index 2 CAAGCAGAAGACGGCATACGAGATTCTAAGCGTGACTG
GAGTTCAGACGTGTGCTCTTCCGATCTtctactattctttcccctgcact
gt 
Reverse index 3 CAAGCAGAAGACGGCATACGAGATCTGTCATGTGACTG
GAGTTCAGACGTGTGCTCTTCCGATCTtctactattctttcccctgcact
gt 
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The nonsense mediated RNA decay (NMD) pathway safeguards the integrity of the 
transcriptome by targeting mRNAs with premature translation termination codons (PTCs) for 
degradation. It also regulates gene expression by degrading a large number of non-mutant RNAs 
(including mRNAs and noncoding RNAs) that bear NMD-inducing features. Consequently, 
NMD has been shown to influence development, cellular response to stress, and clinical outcome 
of many genetic diseases. Small molecules that can modulate NMD activity provide critical tools 
for understanding the mechanism and physiological functions of NMD, and they also offer 
potential means for treating certain genetic diseases and cancer. Therefore, there is an intense 
interest in identifying small-molecule NMD inhibitors or enhancers. It was previously reported 
that both inhibition of NMD and treatment with the AMPK-selective inhibitor Compound C 
(CC) induce autophagy in human cells, raising the possibility that CC may be capable of 
inhibiting NMD. Here we show that CC indeed has a NMD-inhibitory activity. Inhibition of 
NMD by CC is, however, independent of AMPK activity. As a competitive ATP analog, CC 
does not affect the kinase activity of SMG1, an essential NMD factor and the only known kinase 
in the NMD pathway. However, CC treatment down-regulates the protein levels of several NMD 
factors. The induction of autophagy by CC treatment is independent of ATF4, a NMD target that 
has been shown to promote autophagy in response to NMD inhibition. Our results reveal a new 





First discovered in S. cerevisiae, nonsense mediated mRNA decay (NMD) is an evolutionarily 
conserved RNA quality control pathway that targets aberrant RNAs with PTCs for 
degradation[1]. Translation of PTC-containing mRNAs generates aberrant protein products, 
which may have pathological effects on the cell. Therefore, NMD plays an important protective 
role in the cell. It is believed that NMD modulates the clinical outcome of approximate 1/3 of 
human genetic disorders and many forms of cancer caused by mutations that lead to nonsense 
mRNAs[2]. In addition to downregulating mutant transcripts, more recent studies indicate that 
NMD also regulates the expression of ~10% of mRNAs bearing NMD-inducing features (e.g. 
PTCs caused by alternative splicing or programmed intron retention, upstream open reading 
frames (uORFs), intron-containing 3’ UTRs, exceedingly long 3’ UTRs), as well as many 
noncoding RNAs[3, 4]. Consequently, NMD as well as its dynamic regulation play an important 
role in many physiological processes, such as embryonic development, neurogenesis, 
myogenesis and stress responses[3, 5-9].  
Small-molecule inhibitors or enhancers of NMD offer critical tools for dissecting the NMD 
pathway and its physiological functions. They also have the potential for treating certain genetic 
disorders and cancer[2, 10]. While active NMD renders many dominant mutations recessive by 
degrading transcripts encoding abnormal proteins with dominant activities, it can exacerbate the 
phenotypes of many disorders by preventing the synthesis of truncated protein products with 
normal function[10]. Therefore, inhibition of NMD is an attractive therapeutic approach for 
treating certain diseases where the protein products of the corresponding nonsense mRNAs are 
fully or partially functional. Furthermore, NMD inhibitors can be combined with drugs that 
promote translation readthrough at PTCs (e.g. PTC124 and aminoglycosides such as G418 and 
gentamicin) to produce full-length protein products[11-13]. As a proof of concept, co-treatment 
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with NMD inhibitor NMDI14 and G418 restored full-length p53, and subsequent cell death in 
cells expressing nonsense p53 mRNA[14]. Similar effects have been observed for siRNA-
mediated depletion of UPF1 and gentamicin in promoting the production of full length CFTR 
protein in cell lines derived from cystic fibrosis patients that carry nonsense mutations in the 
gene[15]. Inhibition of NMD also has the potential to improve cancer immunotherapy[16]. In 
cancer cells, nonsense mRNAs produced by aberrant splicing or frame-shift mutations encode 
proteins with novel epitopes, therefore, NMD inhibition is expected to increase the levels of 
cancer antigens for immune detection[16]. Several NMD inhibitors with different mechanisms of 
action have been previously identified. NMDI-1 disrupts the interaction of the NMD factors 
UPF1 and SMG5, whereas NMDI-14 disrupts the interaction of UPF1 with SMG7[14, 17]. 
Pateamine A inhibits the function of the EJC factor eIF4III in NMD[18]. Cardiac glycosides (e.g. 
ouabain, digoxin, digitoxin, lanatoside C and proscillaridin) and 5-azacytidine have been shown 
to inhibit NMD indirectly by increasing intracellular calcium levels and by inducing MYC 
expression, respectively[19, 20]. 
In this study, we have identified compound C (6-[4-(2-Piperidin-1-ylethoxy) phenyl]-3-pyridin-
4-ylpyrazolo [1,5-a] pyrimidine) as a new cell-permeable, small-molecule inhibitor of NMD in 
human cells. Compound C (CC) was first identified as an inhibitor of the metabolic sensor kinase 
AMPK in a chemical screen[21]. CC inhibits the kinase activity of AMPK by competing with 
ATP for binding, with Ki of 109 ± 16 nM in the absence of AMP[21]. The binding of CC to 
AMPK also prevents its activation by AICAR or metformin, the most prescribed drug for type II 
diabetes[21]. Interestingly, CC was also identified in a functional screen in zebrafish as a 
compound (Dorsomorphin) that perturbs dorsoventral axis formation[22]. CC exerts this activity 
by inhibiting bone morphogenetic protein (BMP) type 1 receptors ALK2, ALK3, and ALK6, 
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preventing BMP-mediated SMAD 1/5/8 phosphorylation, target gene transcription and 
osteogenic differentiation[22]. In addition to AMPK and ALKs, CC was found to inhibit several 
other kinases, including ERK8, MNK1, PHK, MELK, DYRK isoforms, HIPK2, Src, and Lck, 
with similar or even greater potency[23]. Thus, CC is a selective, but not specific, inhibitor of 
AMPK, although it is widely used as a tool for AMPK studies[24-29]. A recent study shows that 
CC can induce autophagy, which would be contrary to the finding that activation of AMPK, but 
not its inhibition, promotes autophagy[30-32]. However, the ability of CC to induce autophagy is 
AMPK-independent[30]. Interestingly, disruption of NMD activity also results in activation of 
autophagy, which is, in part, due to the stabilization of the transcripts of ATF4, a transcription 
factor that promotes expression of multiple autophagy genes including LC3B and ATG5[33]. 
These observations prompted us to test the possibility that CC inhibits NMD, which in turn leads 
to autophagy induction. By examining the effects of CC on a highly effective NMD reporter as 
well as endogenous NMD target transcripts, we demonstrate that CC indeed possesses a 
previously unrecognized activity in inhibiting NMD in human cells. The ability of CC to 
suppress NMD is not mediated through the inhibition of AMPK or SMG1, the only known 
kinase in the NMD pathway, but it down-regulates protein levels of several core NMD factors. 
Although CC treatment causes upregulation and stabilization of the NMD target ATF4, this 
effect is apparently not responsible for the induction of autophagy by CC.  
Results 
CC inhibits NMD activity in human cells 
To determine whether CC can modulate NMD efficiency in human cells, we used a previously-
developed bioluminescence-based reporter system, which can accurately measure NMD activity 
in mammalian cells using multiple assays[19]. This reporter contains two transcription units that 
117 
 
express a PTC-containing TCRβ minigene fused to CBR luciferase (CBR-TCRβ(PTC)) and a 
wild type TCRβ minigene fused to CBG luciferase (CBG-TCRβ(WT)), respectively (Fig 3.1A). 
NMD activity is measured as the ratio of CBR-TCRβ(PTC) to CBG-TCRβ(WT) at the levels of 
mRNA, protein, or luciferase activity, with an increase in the ratio representing NMD 
inhibition[19]. To determine the effects of CC on NMD, we treated human U2 osteosarcoma 
(U2OS) cells stably expressing the reporter with CC and then measured NMD activity by 
bioluminescence imaging. CC inhibited NMD in a dose- and time-dependent manner, with ~ 3-
fold inhibition of NMD of the reporter observed after 24-hr treatment with CC at 10 µM, a 
concentration commonly used to inhibit AMPK in vivo and in vitro (Figs 3.1B and C). This level 
of inhibition is similar to that caused by treatment with caffeine (10 mM, 24 hrs), an inhibitor of 
SMG1 (Fig 3.1B)[17], or by shRNA-mediated knockdown of NMD factors such as SMG1, 
UPF1 and UPF2[19].  
To confirm the results obtained from bioluminescence imaging, we measured CBR and CBG 
mRNA and protein levels using RT-qPCR and western blot, respectively. Consistent with the 
results of bioluminescence imaging, CC treatment increased the ratio of CBR-TCRβ(PTC) to 
CBG-TCRβ(WT) at both mRNA and protein levels (Figs 3.1D and E). Treating the human lung 
cancer cell line Calu-6 or non-transformed BJ human fibroblasts with CC also resulted in NMD 
inhibition as measured by the NMD reporter (Figs 3.1F and G), indicating that the effect of CC 
on NMD is not a cell line-specific phenomenon. 
To further validate that CC is a bona fide inhibitor of NMD, we determined its effects on the 
stability of the endogenous mutant p53 mRNA in Calu-6 cells, which contains a PTC 
mutation[34]. To do this, cells were first treated with CC for 24 hrs. Subsequently, the 
transcription inhibitor actinomycin D was added to block new mRNA synthesis for 6 hrs. RT-
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qPCR was then performed to measure the levels of the p53 mutant mRNA immediately before 
and after actinomycin D treatment. As shown in Fig 3.2A, CC stabilized the PTC-containing p53 
mRNA, further supporting the idea that CC inhibits NMD. 
CC stabilizes physiological NMD targets 
In addition to eliminating mutant mRNAs, NMD also regulates gene expression by targeting 
many non-mutant physiological transcripts for degradation[35]. To further illustrate the effects of 
CC on NMD, we determined whether CC can also stabilize physiological NMD targets. The 
SC35 (SRSF2) gene encodes three splicing variants, two of which (SC35C and SC35D) are 
targets of NMD[36]. We found that CC treatment increased the levels of SC35C and SC35D, but 
had no effect on SC35WT that is not targeted by NMD (Fig 3.2B), consistent with the results 
obtained from the NMD reporter described above. In further support of the idea that CC inhibits 
NMD, CC also stabilized endogenous NMD targets such as PIM3, UPP1, FRS2, and PISD, but 
had no effect on ORCL and HPRT, which are not NMD targets (Fig 3.2C)[3, 37]. Previous 
studies have shown that transcripts of several NMD factors including SMG1, UPF1, UPF2, 
SMG5, SMG6, and SMG7 are themselves targets of NMD, a feature that allows for 
autoregulation of the NMD pathway[38, 39]. We predicted that inhibition of NMD by CC would 
cause stabilization of these transcripts. Indeed, CC stabilized the mRNA of these NMD factors 
(Fig 3.2D). CC treatment also increased the steady-state levels of these transcripts except UPF2 
(Fig 3.2E). UPF3B mRNA, which is not a NMD target, was not stabilized by CC, although its 
steady-state level increased (Fig 3.2D), suggesting that CC exerted additional effects on NMD 
factor transcripts. Taken together, these data strongly suggest that CC has a previously 
unrecognized activity in inhibiting NMD in human cells.  
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CC inhibits NMD independent of AMPK 
CC has been widely used as an inhibitor of AMPK, although it also targets several other 
kinases[23]. To determine whether CC inhibits NMD through AMPK, we used siRNAs to knock 
down both isoforms of the catalytic subunit of AMPK (AMPKα1 and AMPKα2) in U2OS cells. 
As expected, AMPK depletion reduced the phosphorylation of acetyl-CoA carboxylase1 (ACC1) 
at serine 79, a direct AMPK phosphorylation site (Fig 3.3A)[40]. However, AMPK knockdown 
did not influence the inhibitory effects of CC on NMD, suggesting that CC inhibits NMD 
independently of AMPK (Fig 3.3B). To rule out the possibility that the residual AMPK present 
in the knockdown cells was sufficient to mediate CC’s effects on NMD, we generated AMPKα-
KO cells lacking both AMPKα1 and AMPKα2 using the CRISRP/Cas9 technology (Fig 3.3C). 
No significant differences in the extent of NMD inhibition were observed between WT and 
AMPKα-KO cells after CC treatment (Fig 3.3D), indicating that AMPK inhibition is not 
responsible for CC’s effect on NMD. Interestingly, we found that forced activation of AMPK 
using 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) did not enhance, but actually 
attenuated NMD activity (Figs 3.3E and 3.3F). These results strongly suggest that CC inhibits 
NMD independently of AMPK activity and that activation, but not inhibition, of AMPK 
suppresses NMD.  
CC does not inhibit the kinase activity of SMG1, but it reduces the protein levels of 
multiple NMD factors  
As a competitive ATP analog[21], CC is known to inhibit several other kinases in addition to 
AMPK[23]. One possible mechanism by which CC inhibits NMD involves the inhibition of 
SMG1, which is the only known protein kinase that directly phosphorylates the RNA helicase 
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UPF1 to promote NMD[34]. To test this possibility, we performed an in vitro kinase assay to 
determine whether CC can inhibit the kinase activity of SMG1. We immunoprecipitated His-
tagged wild type (WT) or a kinase dead (DA) mutant of SMG1 expressed in 293T cells[34]. A 
purified recombinant GST-p53N fusion protein containing a N-terminal segment of p53 was 
used as a model substrate for SMG1 (Fig 3.4A)[41]. As shown before, SMG1(WT), but not 
SMG1(DA), efficiently phosphorylated GST-p53N (Fig 3.4B)[41]. This kinase activity was 
abolished by caffeine, a known inhibitor of SMG1[17]. However, SMG1 kinase activity was not 
affected by CC at 10 µM, a concentration that efficiently inhibited NMD in cells (Figs 3.4B and 
3.1). This result suggests that the inhibitory effects of CC on NMD do not result from SMG1 
inhibition.  
We next asked whether CC affected the protein levels of NMD factors, which would impact 
NMD activity. Interestingly, we found that CC markedly reduced the protein levels of 3 core 
NMD factors including UPF1, SMG5, and SMG6 (Figs 3.4C and 3.4D). CC treatment did not 
affect the protein levels of SMG1, UPF2, SMG7 and UPF3B, indicating the effects of CC are 
specific for a subset of NMD factors (Figs 3.4C and 3.4D). This downregulation of the protein 
levels of multiple NMD factors may in part underlie the inhibitory effects of CC on NMD.   
CC augments the expression and stability of the NMD target ATF4, but ATF4 is 
dispensable for autophagy induced by CC  
Our investigation of the effects of CC on NMD was initially inspired by the observations that 
both CC treatment and NMD disruption induce autophagy[30, 33]. The autophagy-inducing 
activity of CC in cells is unexpected as AMPK, which CC inhibits, has been shown to promote 
autophagy[42]. To investigate the relationships between CC, NMD, and autophagy, we first 
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determined whether CC could induce autophagy under our experimental conditions. U2OS cells 
were treated with 10 µM CC and the induction of autophagy was assessed. Consistent with 
published findings, both western blot and immunofluorescence staining results show a dramatic 
increase in the levels of LC3B-II, a surrogate marker of autophagosome formation, after CC 
treatment (Figs 3.5A and B)[43]. Using transmission electron microscopy (TEM), we also 
detected a marked increase in autophagosome formation after CC treatment (Figs 3.5C and D). 
Knockdown of the NMD factor SMG1 or UPF1 also resulted in accumulation of LC3B-II, in 
agreement with previous observations (Fig 3.5E)[33]. These data indicate that both CC and 
NMD disruption do indeed induce autophagy. Given the inhibitory effects of CC on NMD 
activity described above, these observations suggest the possibility that NMD inhibition is part of 
the mechanism for the autophagy-inducing activity of CC. 
It has been shown that the induction of autophagy in response to NMD inhibition is in part 
mediated by ATF4, a direct NMD target[33]. Upon NMD inhibition, the stabilization of ATF4 
mRNA leads to increased ATF4 protein levels, which promote autophagy by activating the 
expression of autophagy genes including LC3B and ATG5[44]. To determine whether ATF4 
contributes to CC-induced autophagy, we first examined whether CC treatment causes 
stabilization and increase of ATF4 mRNA. RT-qPCR results indicate that CC treatment indeed 
increased both the stability and the steady-state levels of ATF4 mRNA (Figs 3.5F and G), 
leading to a dramatic increase in ATF4 protein levels (Fig 3.5H). To determine whether this 
ATF4 upregulation is important for autophagy induction after CC treatment, we knocked down 
ATF4 using siRNA in cells and then examined LC3B-II accumulation after CC treatment. 
Depletion of ATF4 expression did not significantly abrogate LC3B-II accumulation (Fig 3.5I). 
To rule out the possibility that the residual ATF4 protein in the knockdown cells is sufficient for 
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autophagy activation, we generated ATF4-knockout cells using CRISPR/Cas9 (Fig 3.5J). No 
significant differences were observed between parental cells and ATF4-knockout cells in LC3B-
II accumulation after CC treatment, further supporting the idea that ATF4 is dispensable for 
autophagy activated by CC (Fig 3.5K).  
Discussion 
This study identifies CC as an inhibitor of NMD activity in human cells (Figs 3.1 and 3.2). Using 
both knockdown and knockout approaches, we show that the effect of CC on NMD is not 
mediated through the inhibition of the key metabolic regulator AMPK, adding another important 
“off-target” activity to CC (Figs 3.3A-D)[23, 28, 45]. Interestingly, activation of AMPK by 
AICAR causes NMD attenuation (Figs 3.3E and F), raising the possibility that cellular metabolic 
state can influence NMD activity. In addition to AMPK, CC has been shown to inhibit several 
other protein kinases including ALK2, ALK3, ALK6, ERK8, MNK1, PHK, MELK, DYRK, 
HIPK2, Src, and Lck [22, 23]. SMG1 is the only protein kinase among the identified NMD 
factors and thus could be a potential target of CC. However, CC did not inhibit the kinase 
activity of SMG1 in vitro at the concentration that efficiently abrogates NMD in cells (Fig 3.4B). 
Interestingly, we found that CC treatment reduced the protein levels of three core NMD factors 
including UPF1, SMG5, and SMG6 (Figs 3.4C and D). The downregulation of these NMD 
factors may in part underlie the repression of NMD by CC. The mRNA levels of UPF1, SMG1, 
SMG5, SMG6 and SMG7, however, were higher in CC-treated cells (which was at least in part 
caused by the stabilization of these transcripts as a result of NMD inhibition) (Fig 3.2E)[38, 39, 
46]. These observations raise the possibility that CC affects the mRNA translation or the stability 
of these NMD proteins. Several miRNAs including miR128, miR125, and miR433 have been 
shown to regulate NMD factors[6, 47, 48]; it will be interesting to determine in the future 
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whether these miRNAs play a role in the CC-induced downregulation of NMD factors and 
attenuation of NMD efficiency.  
At the cell level, both CC treatment and NMD inhibition induce autophagy (Fig 3.5)[30, 33]. The 
ability of CC to inhibit NMD suggests that NMD attenuation is part of the mechanism for the 
activation of autophagy by CC. Previously, it has been shown that autophagy induction after 
NMD inhibition is mediated in part by the stabilization of the mRNA of ATF4, a NMD target 
that promotes the transcription of the key autophagy factors LC3B and ATG5[33, 44]. However, 
we found that although CC treatment also induced and stabilized ATF4 transcripts, ATF4 was 
dispensable for autophagy induction by CC (Fig 3.5). Future work is needed to identify relevant 
NMD targets that promote autophagy in the presence of CC.  
Our finding that CC inhibits NMD may have important implications for the use of CC as a 
chemical biology tool and as a potential therapeutic agent. The ability of CC to inhibit NMD 
may represent a mechanism for the many cellular phenotypes observed for CC. For example, in 
addition to autophagy, CC has been shown to induce apoptosis in many cancer cell lines and in 
vivo tumor models[28, 49-52]. Because NMD appears to be essential for human cells, its 
inhibition likely accounts partially for the effects of CC on cancer cell viability. CC has also 
been shown to induce cell differentiation, which was previously attributed in part to its inhibition 
of BMP type 1 receptors[53-55]. Because downregulation of NMD has been shown to promote 
multiple differentiation processes (e.g. embryonic stem cell differentiation, neurogenesis and 
myogenesis) by regulating the levels of many target mRNAs, including that involved in the BMP 
and TGF-β pathways in specific contexts[6, 7, 56, 57], it is possible that NMD inhibition could 
contribute to CC-induced cell differentiation. On the other hand, the effects of CC on many other 
targets also limit its use as an inhibitor of NMD in research. Thus, caution needs to be taken 
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when interpreting results of CC treatment. In spite of its many off-target activities, CC or its 
derivatives with low toxicity may be effective in treating certain diseases by inhibiting NMD, as 
NMD inhibition may alleviate the symptoms of certain genetic disorders (e.g. β-thalassemia, 
cystic fibrosis, Hurler’s syndrome, and Duchenne muscular dystrophy) that are caused by 
nonsense mutations in a single gene whose mutant protein products retain full or partial 
function[10]. Abrogation of NMD has also been suggested to induce antitumor immunity due to 
the expression of cancer antigens encoded by nonsense mRNAs[16, 58]. Thus, CC or its 
derivatives may have the potential of improving immunotherapy for cancers that contain an 
increased level of nonsense mRNAs as a result of a high mutation load. Further investigation of 
the mechanism of action of CC in NMD inhibition will facilitate the development of CC or its 
derivatives as a therapeutic agent and aid our understanding of the physiological functions of 
NMD.  
Materials and Methods 
Key Reagents 
The key reagents used in this study, including plasmids, siRNAs, sgRNAs, antibodies, and 
chemicals are listed in Table 3.1. 
Table 3.1 Key Reagents used in the study 
Reagent Source Identifier 
Reporter and other plasmids 
pBS-(CBR-TCR(PTC))-
(CBG-TCR(WT)) 
Generated in lab N/A 
pBS-(CBR-TCR(PTC)) Generated in lab N/A 
pBS-(CBG-TCR(WT)) Generated in lab N/A 
pAdenoX-PRLS-ZsGreen1 Clontech Cat#632258 
pLenti-Cas9 Blast  Addgene 52962 
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pCMV-VSVG Addgene 8454 
pPAX2 Addgene 12260 
plentiGuide-Puro  Addgene 52963 
His-hSMG1 (WT) Dr.Shigeo Ohno N/A 
His-hSMG1 (DA) Dr.Shigeo Ohno N/A 
GST-p53 Dr. Robert T. Abraham N/A 
siRNAs/gRNAs 
siAMPK α1  Ambion  GAAGATCGGCCACTACATTC 
siAMPK α2  Ambion  GAAGATCGGACACTACGTGC  
siATF4#1 Ambion  S1702 
siATF4#2 Ambion  S1703  
siControl Ambion  Cat#4390846 
sgAMPK α1 IDT GAAGATCGGCCACTACATTC  
sgAMPK α2  IDT GAAGATCGGACACTACGTGC  
sgATF4 IDT AACCTCTTCCCCTTTCCCCA 
Antibodies 
Mouse anti-HA antibody Biolegend Cat#901507  
Mouse anti-β-Actin  Thermo Fisher Scientific Cat#MA5-15739  
Rabbit anti-AMPK α Cell Signaling Technology  Cat#2532  
Rabbit anti pACC1 Ser79 Cell Signaling Technology  Cat#11818  
Rabbit anti-ACC1 Cell Signaling Technology  Cat#3676  
Rabbit anti-SMG1 Cell Signaling Technology  Cat#9149  
Rabbit anti-p53-pS15 Cell Signaling Technology  Cat#9284 
Rabbit anti-GST Raised against GST-GFP N/A 
Rabbit anti-UPF1 Cell Signaling Technology  Cat#12040 
Rabbit anti-SMG6 Abcam Cat#AB87539 
Rabbit anti-UPF2 Novus Biologicals Cat#NB2-20813 
Rabbit anti-UPF3B Bethyl laboratories Cat#A303-688A 
Rabbit anti-SMG5 Abcam Cat#AB129107 
Rabbit anti-SMG7 Bethyl Laboratories  Cat#A302-170A 
Rabbit anti-LC3B Cell Signaling Technology  Cat#2775 
Rabbit anti-ATF4 Cell Signaling Technology Cat#11815  
Alexa Fluor 488-
conjugated goat anti-rabbit  
Thermo Fisher Scientific  Cat#A-11008 
Chemicals 
D-Luciferin Sigma Cat#L9504 
Actinomycin D Sigma Cat#A1410 
Caffeine Sigma Cat#C0750 
Compound C (CC) Sigma Cat#5499 
Thapsigargin   Sigma Cat#T9033 





Cell culture, transfection, lentivirus and adenovirus production and infection 
Human U2OS, HEK293, HEK293T and Calu-6 cells were cultured in DMEM (Sigma, D5796) 
supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 µg/ml 
streptomycin in a 5% CO2 incubator at 37 °C. Human foreskin BJ fibroblasts were cultured in 
70% DMEM (Sigma, D5796), 15% medium 199 (Sigma, M7528), supplemented with 15% FBS, 
100 units/ml penicillin and 100 µg/ml streptomycin and grown in a 5% CO2 incubator at 37 °C.  
siRNA transfection for knockdown of AMPKα or ATF4 was done using TransIT-siQUEST 
transfection reagent (Mirus), according to manufacturer’s protocol. Transfections were done 48 
hours before analysis of NMD and sample collection.  
Lentiviruses expressing Cas9 or gRNAs used to knockout AMPK or ATF4 were generated by 
co-transfecting HEK293T cells with lentiviral vectors and packaging vectors (pCMV-VSVG and 
pPAX2) using TransIT-LT1 transfection reagent (Mirus). Cell culture medium containing 
lentiviruses was collected 48 and 72h after transfection, and used to infect target cells. 
Recombinant adenovirus expressing our NMD reporter was described before[19]. Target cells 
were infected with the reporter adenovirus for 24 hours before NMD analysis (see below). 
NMD Reporter assays 
A dual color bioluminescence-based NMD reporter system described previously was used to 
measure NMD activity in human cells[19]. The reporter in the pBluescript (KS-) vector consists 
of a PTC-containing TCR minigene fused to CBR (CBR-TCRβ(PTC)) and a WT TCR minigene 
fused to CBG (CBG-TCRβ(WT)). NMD activity is measured by the ratios of CBR-TCRβ(PTC) 
to CBG-TCRβ(WT) at the protein and mRNA levels using bioluminescence imaging, western 
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blot or RT-qPCR, as previously described[19, 59]. U2OS cells stably expressing the NMD 
reporter system were described previously[19]. For analysis of NMD activity in Calu-6 and BJ 
cells, a recombinant adenovirus expressing the NMD reporter was used for infection. For 
bioluminescence imaging, cells were incubated with 150 µg/ml D-luciferin for 10 min at 37 °C, 
and bioluminescence signals were measured sequentially using IVIS 100 imager with 
appropriate open, red, green filters. Regions of interest (ROIs) were drawn over the images and 
bioluminescence signals were quantified using Living Image (Caliper) and Igor (Wavemetrics) 
analysis software packages as described previously[19, 60]. Spectral unmixing was performed 
using an Image J plugin. For RNA analysis of CBR-TCRβ(PTC) and CBG-TCRβ(WT), total 
RNA was extracted using a Nucleospin RNA II Kit from Clontech (740955). Reverse 
transcription reaction was performed to synthesize cDNA using PrimeScript RT kit from 
Clontech (RR037A). RT-qPCR was performed using a two-step PCR protocol (melting 
temperature: 95°C; annealing/extension temperature: 60°C; cycle number: 40) on an ABI V117 
real-time PCR system with PowerUp SYBR Green Master Mix (Thermo-Fisher). The mRNA 
levels of the housekeeping genes GAPDH were used for normalization. The sequences of all the 
primers used are listed in Table 3.2. Protein levels of CBR-TCRβ(PTC) and CBG-TCRβ(WT) 
(both of which are N-terminally HA-tagged) were measured by western blot with anti-HA 
antibodies using the Li-Cor Odyssey system. Cells were lysed in 50 mM Tris, 10% glycerol, 2% 
SDS, 5% β-mercaptoethanol. Protein lysates were run on SDS-page gels and transferred to a 
PVDF membrane, blocked with casein buffer and incubated with HA antibody (Biolegend, 
901507). β-Actin detected with an antibody from Thermo-Fisher (MA5-15739) was used as a 
loading control. 
Analysis of the expression and stability of endogenous NMD targets  
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Calu-6 cells expressing a mutant PTC-containing p53 mRNA were first treated with DMSO or 
CC for 24 hours. Subsequently, actinomycin D (5 or 10 µg/mL) was added to inhibit new mRNA 
synthesis. Total mRNA was isolated both immediately before and 6 hours after the addition of 
actinomycin D. mRNA levels of mutant p53 was measured using RT-qPCR. The percent of 
mRNA remaining (stability analysis) was determined as the percent of mRNA remaining after 
actinomycin D treatment, compared to that before actinomycin D treatment. The stability of 
known physiological NMD targets including PISD, UPP1, FRS2, ATF4, PIM3, as well as 
transcripts of NMD factors UPF1, UPF2, SMG1, SMG5, SMG6, SMG7, and UPF3B were 
measured using RT-qPCR[19]. ORCL and HPRT, which are not NMD targets, were used as 
controls. Relative expression of different SC35 splice variants in U2OS cells was also measured 
using RT-qPCR. Sequences of the qPCR primers are listed in Table 3.2. 




p53-F GAGGTTGGCTCTGACTGTACC  
p53-R TCCGTCCCAGTAGATTACCAC  
SC35C-F GGCGTGTATTGGAGCAGATGTA  
SC35D-F CGGTGTCCTCTTAAGAAAATGATGTA   
SC35C and D-R CTGCTACACAACTGCGCCTTTT  
SC35WT-F CGTGCCTGAAACTGAAACCA  


































Knockdown and knockout of AMPKα or ATF4 in human cells 
To deplete the catalytic subunits of AMPK (AMPKα1 and AMPKα2), U2OS cells were 
transfected with mixed siRNAs targeting AMPKα1 and AMPKα2, respectively, using the 
TransIT-siQUEST transfection reagent (Mirus). To knock out AMPKα1 and AMPKα2, a Cas9-
expressing U2OS cell line was first generated by lentiviral transduction with pLenti-Cas9 Blast 
(Addgene 52962) followed by blasticidin selection for 5 days. sgRNAs in plentiGuide-Puro 
 (Addgene 52963) targeting AMPKα1 and AMPKα2 were then introduced into cells for gene 
deletion by lentivirus transduction. Cells were then plated in 96-well dishes and individual 
knockout cell clones were screened and verified by western blot using AMPKα antibodies. 
Knockdown and knockout of ATF4 in U2OS cells were also performed by the siRNA 
transfection and CRISPR-Cas9 methods. Because basal expression levels of ATF4 are below 
detection in U2OS cells, knockdown or knockout was confirmed by western blot analysis after 




Immunoprecipitation and in vitro kinase assay 
His-tagged, wild type (WT) or kinase dead (DA) SMG1 ectopically expressed 293T cells was 
immunoprecipitated using cobalt beads (HisPurä, ThermoFischer) in a buffer containing 300 
mM NaCl, 50 mM Na3PO4 (pH 8.0), 0.02% Tween, 0.25% NP40, and protease inhibitor cocktail 
(EDTA-free, Pierce). A recombinant GST-p53N fusion protein containing a N-terminal segment 
of p53 with the Ser15-phosphorylation site was expressed in E. coli and purified using FPLC 
with a GSTTrap column (GE Healthcare). In vitro kinase reaction was performed by incubating 
His-SMG1 (WT) or His-SMG1 (DA) with the GST-p53 substrate in the presence or absence of 
CC (10 µM) or caffeine (10 mM) at 30°C for 2 hours in a kinase buffer (25 mM Tris HCl, pH 
7.5, 10 mM β-Glycerophosphate, 0.2 mM Na3VO4, 10 mM MgCl2, 0.05 mM DTT). Reactions 
were terminated by the addition of SDS sample buffer. S15-phosphorylation of the GST-p53N 
substrate was detected by western blot using a phosphor-specific antibody (Cell Signaling 
Technology, 9284). 
 
Immunofluorescence staining to detect LC3B foci 
U2OS reporter cells were plated in 3.5 cm glass-bottomed dishes (MatTek corporation) and 
treated with DMSO or CC for 24 hours. Cells were then washed with phosphate buffered saline 
(PBS, pH 7.5), and then fixed using 4% paraformaldehyde (PFA) in PBS for 10 minutes. 
Subsequently, cells were permeabilized using 0.2% Triton X-100 in PBS followed by blocking 
for 1 hour with 10% normal goat serum in PBS. Cells were then incubated overnight with anti-
LC3B antibodies (Cell Signaling Technology, 2775 at 1:200 dilution in PBS with 0.1% Triton X-
100). After washing, cells were incubated with Alexa Fluor 488-conjugated goat anti-rabbit 
secondary antibodies (Thermo-Fisher, A-11008 at 1:500 dilution) to detect LC3B foci. DNA was 
visualized with Hoechst 33342 staining (1 µg/ml). Fluorescence images were acquired using a 
Nikon Eclipse Ti-E inverted microscope with MetaMorph software, as described previously[62].  
 
Electron Microscopy and quantification of autophagosomes 
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U2OS cells were grown on 4 x 4 mm cover slips immobilized in 6 cm dishes. Cells (~70% 
confluent) treated with either DMSO or CC for 24 hours were briefly washed with Mammalian 
Ringer’s solution (155 mM NaCl, 3 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 3 mM NaH2PO4, 
10mM glucose, and 5 mM HEPES pH 7.2), and then fixed with 2% glutaraldehyde in buffer 
containing 100 mM NaCl, 2 mM CaCl2, 30 mM HEPES, pH 7.2 for 1 hour at room temperature. 
The coverslips were then washed with the same buffer 3 times over a period of 1 hour and then 
subjected to a secondary fixation with 1% Osmium tetroxide for 1 hour in the dark. Coverslips 
were washed 3 times with ultrapure water over 30 minutes and then en bloc stained with 1% 
uranyl acetate in H2O for 1 hour in the dark. After staining was complete, coverslips were briefly 
washed in ultrapure water, and dehydrated in a graded acetone series (20%, 40%, 60%, 80%, 
100%) in H2O, with 10 minutes for each dilution. Coverslips were transferred into fresh 100% 
ethanol and then placed in 50% Araldite in ethanol followed by two exchanges of 100% Araldite, 
30 minutes for each. Resin embedding was done by filling BEEM capsules with resin and then 
placing coverslips on top, with sample side facing down. To ensure infiltration of resin, blocks 
were incubated at RT for 2 hours, and then polymerized at 60°C overnight. Coverslips were 
dissolved off polymerized blocks with 42% hydrofluoric acid, followed by extensive water 
washes of the block before sectioning. Sections of 80 nm thickness were generated on an ultra 
microtome and post-stained first with 1% uranyl acetate in H2O for 4 minutes and then with 
Reynold’s lead citrate for 4 minutes.  Images of sections were acquired on a JEOL 1400 
Transmission Electron Microscope (JEOL, Tokyo, Japan) with an attached AMT XR111 digital 
camera (AMT, Woburn, MA, USA).  Autophagosomes were identified as vacuoles containing 
cytoplasmic organelles, such as ribosomes or mitochondria, with a limited membrane as 
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described in standard guidelines[63, 64]. Quantification was achieved by counting the number of 
autophagosomes per cell within two 1.75 mm sections taken from two blocks for each sample. 
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Figure 3.1. CC inhibits NMD in human cells. 
A. Schematic diagram of the dual color bioluminescence-based NMD reporter construct 
containing CBR-TCRβ(PTC) and CBG-TCRβ(WT) transcription units. 
B. Ratios of CBR to CBG bioluminescence signals in U2OS cells stably expressing a dual color 
bioluminescence-based NMD reporter (hereafter referred to as U2OS reporter cells). Cells 
were treated with indicated concentrations of CC, or caffeine for 24 hours before imaging. 
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The CBR/CBG ratio of the DMSO alone control was normalized to 1. Data represent the 
mean ± SD of three independent experiments.  ****p ≤ 0.0001; **p ≤ 0.01; *p ≤ 0.05 (paired 
t-test). 
C. Ratios of CBR to CBG bioluminescence signals in U2OS reporter cells treated with DMSO 
or CC (10 µM) for the indicated times. The CBR/CBG ratio of the 0-hour time point was 
normalized to 1.  Data represent the mean ± SD of three independent experiments. **p ≤ 0.01 
(paired t-test). 
D. Ratios of CBR to CBG reporter mRNAs in U2OS reporter cells treated with DMSO or CC 
(10 µM) for 24 hours. The CBR/CBG mRNA ratio of the DMSO alone control was 
normalized to 1. Data represent the mean ± SD of three independent experiments. *p ≤ 0.05 
(paired t-test). 
E. Western blot result of the NMD reporter proteins (HA-tagged) after 24-hour treatment of 
U2OS reporter cells with DMSO or CC (10 µM). 
F. Ratios of CBR to CBG bioluminescence signals in Calu-6 cells infected with adenoviruses 
expressing the NMD reporter after 24-hour treatment with DMSO or CC (10 µM). The 
CBR/CBG ratio of the DMSO alone control was normalized to 1. Data represent the mean ± 
SD of three independent experiments. **p ≤ 0.01 (paired t-test).  
G. Ratios of CBR to CBG bioluminescence signals in BJ cells infected with adenoviruses 
expressing the NMD reporter after 24-hour treatment with DMSO or CC (10 µM). The 
CBR/CBG ratio of the DMSO alone control was normalized to 1. Data represent the mean ± 




Figure 3.2. CC stabilizes endogenous NMD targets. 
A. Effects of CC on the stability of p53 mRNA containing a PTC in Calu-6 cells. Cells were 
treated with DMSO or CC (10 µM) for 24 hours followed by actinomycin D treatment for 6 
hours to inhibit transcription. Total mRNA was collected before and after actinomycin D 
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treatment. p53 mRNA levels were measured using RT-qPCR. Data represent the mean ± SD 
of three independent experiments. **p ≤ 0.01 (paired t-test). 
B. Effects of CC on the levels of the SC35 mRNA isoforms (SC35C, SC35D, and SC35WT). 
U2OS cells were treated with DMSO or CC (10 µM) for 24 hours followed by total RNA 
isolation and RT-qPCR. The mRNA levels of DMSO-treated cells were normalized to 1. 
Data represent the mean ± SD of three independent experiments. *p ≤ 0.05; ns, not 
significant (paired t-test). 
C. Effects of CC on the stability of known NMD targets PIM3, UPP1, FRS2, and PISD in Calu-
6 cells.  Samples were collected and analyzed as depicted in (A). ORCL and HPRT are non-
NMD target controls. Data represent the mean ± SD of three independent experiments. **p ≤ 
0.01; ns, not significant (paired t-test).   
D. Effects of CC on the stability of the mRNA of NMD factors UPF1, UPF2, SMG1, SMG5, 
SMG6, SMG7, and UPF3B in Calu-6 cells. UPF3B is not a NMD target. Samples were 
collected and analyzed as depicted in (A). Data represent the mean ± SD of three independent 
experiments. ****p ≤ 0.0001; **p ≤ 0.01; *p ≤ 0.05, ns, not significant (paired t-test). 
E. Effects of CC on the steady-state levels of the mRNA of NMD factors UPF1, UPF2, SMG1, 
SMG5, SMG6, SMG7, and UPF3B. Calu-6 cells were treated with DMSO or CC (10 µM) 
for 24 hours followed by total RNA isolation and RT-qPCR. Results represent fold change of 
mRNA levels in CC-treated cells, compared to DMSO-treated cells. ***p ≤ 0.001; **p ≤ 





Figure 3.3. CC inhibits NMD independently of AMPK inhibition. 
A. Effects of AMPKα-knockdown on ACC1 phosphorylation in U2OS reporter cells. Protein 
samples were collected 48 hours after siRNA transfection. 
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B. Relative ratios of CBR to CBG bioluminescence signals in AMPKα-knockdown or control-
knockdown U2OS reporter cells after 24-hour treatment with 10 µM CC or DMSO. The 
CBR/CBG ratio of the siControl DMSO control was normalized to 1. Data represent the 
mean ± SD of three independent experiments. *p ≤ 0.05; ns, not significant (paired t-test). 
C. Knockout (KO) of AMPKα in U2OS cells.  
D. Relative ratios of CBR to CBG bioluminescence signals in AMPKα-KO or control cells after 
24-hour treatment with 10 µM CC or DMSO and infection with adenoviruses expressing the 
NMD reporter. The CBR/CBG ratio of the AMPK WT DMSO control was normalized to 1. 
Data represent the mean ± SD of three independent experiments. *p ≤ 0.05; ns, not 
significant (paired t-test). 
E. Effects of AICAR on ACC1 phosphorylation. Activation of AMPKα by AICAR also caused 
a gel mobility shift. 
F. Relative ratios of CBR to CBG bioluminescence signals in U2OS reporter cells after 
treatment with indicated concentrations of AICAR. The CBR/CBG ratio of untreated control 
was normalized to 1. Data represent the mean ± SD of three independent experiments. **p ≤ 






Figure 3.4. CC reduces protein levels of multiple NMD factors, but does not inhibit SMG1 
kinase activity. 
A. Purified, recombinant GST-p53 protein containing a N-terminal fragment of p53.  
B. Result of in vitro kinase assay for SMG1 with GST-p53 as substrate containing the 
phosphorylation site S15. CC (10 µM) was used to test effects on SMG1 kinase activity. 
Caffeine (10 mM), a known inhibitor of SMG1, was used as a positive control.  
C. Effects of CC on the protein levels of NMD factors UPF1, UPF2, UPF3B, SMG1, SMG5, 
SMG6, and SMG7 in U2OS reporter cells.  
D. Quantification of the effects of CC on the protein levels of NMD factors UPF1, UPF2, 
UPF3B, SMG1, SMG5, SMG6, SMG7. Quantification was performed by measuring signal 
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intensity relative to actin. Protein levels of DMSO-treated cells are normalized to 1. Data 
represent the mean ± SD of three independent experiments. **p ≤ 0.01; *p ≤ 0.05; ns, not 
significant (paired t-test).  
 
 
Figure 3.5. CC induces autophagy independently of the expression and stabilization of the 
NMD target ATF4 
141 
 
A. Effects of CC on LC3BII levels in U2OS cells. Cells were treated with DMSO or CC (10 
µM) for 24 hours and collected at the indicated time points.  
B. Immunofluorescence detection of LC3B foci in U2OS cells after 24-hour treatment with 
DMSO or CC (10 µM). DAPI was used to visualize nuclei. 
C. Representative electron microscopy images of U2OS cells after 24-hour treatment of with 
DMSO or CC (10 µM). The arrow marks an electron-dense autophagosome. N, nucleus.  
D. Quantification of autophagosomes formed after 24-hour treatment with DMSO or CC (10 
µM). Two sections were made from 2 different blocks for each sample. Each section is 80 
nm thick and 1.75 mm long. The number of autophagosomes per cell from the two sections 
was counted for each sample. In total, 89 cells were counted in DMSO control, and 88 cells 
were counted in the CC-treated sample. 
E. Effects of shRNA-mediated knockdown of UPF1 or SMG1 on LC3BII levels in U2OS cells, 
compared to the effects in U2OS cells treated with DMSO or CC (10 µM) for 24 hours.  
F. Effects of CC on ATF4 mRNA expression in U2OS cells treated with DMSO or CC (10 µM) 
for 24 hours. mRNA expression of DMSO-treated cells was normalized to 1. Data represent 
the mean ± SD of three independent experiments. **p ≤ 0.01 (paired t-test). 
G. Effects of CC on ATF4 mRNA stability in U2OS cells. Cells were treated with DMSO or CC 
(10 µM) for 24 hours followed by treatment with actinomycin D for 6 hours. Total RNA was 
collected before and after actinomycin D treatment. ATF4 mRNA levels was measured by 
RT-qPCR. Data represent the mean ± SD of three independent experiments. *p ≤ 0.05 
(paired t-test). 
H. ATF4 protein levels after 24-hour treatment with DMSO or CC (10 µM).  
I. Effects of siRNA-mediated knockdown of ATF4 on LC3BII levels in U2OS cells treated 
with DMSO or CC (10 µM) for 24 hours.  
J. ATF4 protein levels in WT or knockout U2OS cells. Because the basal level of ATF4 is 
below detection, cells were treated with 0.2 µM Thapsigargin (a known ER stressor that 
induces ATF4) for 4 hours before ATF4 western blot.  
K. Effects of ATF4 KO on LC3BII levels in WT or ATF4-KO cells treated with DMSO or CC 




1. Losson R, Lacroute F. Interference of nonsense mutations with eukaryotic messenger RNA 
stability. Proceedings of the National Academy of Sciences of the United States of America. 
1979;76(10):5134-7. PubMed PMID: 388431; PubMed Central PMCID: PMCPMC413094. 
 
2. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Human 
molecular genetics. 1999;8(10):1893-900. PubMed PMID: 10469842. 
 
3. Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC. Nonsense surveillance 
regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. 
Nat Genet. 2004;36(10):1073-8. doi: 10.1038/ng1429. PubMed PMID: 15448691. 
 
4. Tani H, Torimura M, Akimitsu N. The RNA degradation pathway regulates the function of 
GAS5 a non-coding RNA in mammalian cells. PloS one. 2013;8(1):e55684. doi: 
10.1371/journal.pone.0055684. PubMed PMID: 23383264; PubMed Central PMCID: 
PMCPMC3559549. 
 
5. Hwang J, Maquat LE. Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: 
to die or not to die, that is the question. Curr Opin Genet Dev. 2011;21(4):422-30. doi: 
10.1016/j.gde.2011.03.008. PubMed PMID: 21550797; PubMed Central PMCID: 
PMCPMC3150509. 
 
6. Bruno IG, Karam R, Huang L, Bhardwaj A, Lou CH, Shum EY, et al. Identification of a 
microRNA that activates gene expression by repressing nonsense-mediated RNA decay. 
Molecular cell. 2011;42(4):500-10. doi: 10.1016/j.molcel.2011.04.018. PubMed PMID: 
21596314; PubMed Central PMCID: PMCPMC3123134. 
 
7. Gong C, Kim YK, Woeller CF, Tang Y, Maquat LE. SMD and NMD are competitive 
pathways that contribute to myogenesis: effects on PAX3 and myogenin mRNAs. Genes & 
development. 2009;23(1):54-66. doi: 10.1101/gad.1717309. PubMed PMID: 19095803; 
PubMed Central PMCID: PMCPMC2632170. 
143 
 
8. Karam R, Lou CH, Kroeger H, Huang L, Lin JH, Wilkinson MF. The unfolded protein 
response is shaped by the NMD pathway. EMBO Rep. 2015;16(5):599-609. doi: 
10.15252/embr.201439696. PubMed PMID: 25807986; PubMed Central PMCID: 
PMCPMC4428047. 
 
9. Gardner LB. Hypoxic inhibition of nonsense-mediated RNA decay regulates gene 
expression and the integrated stress response. Mol Cell Biol. 2008;28(11):3729-41. doi: 
10.1128/MCB.02284-07. PubMed PMID: 18362164; PubMed Central PMCID: 
PMCPMC2423288. 
 
10. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. Nonsense-mediated decay 
approaches the clinic. Nat Genet. 2004;36(8):801-8. doi: 10.1038/ng1403. PubMed PMID: 
15284851. 
 
11. Keeling KM, Bedwell DM. Suppression of nonsense mutations as a therapeutic approach to 
treat genetic diseases. Wiley Interdiscip Rev RNA. 2011;2(6):837-52. doi: 10.1002/wrna.95. 
PubMed PMID: 21976286; PubMed Central PMCID: PMCPMC3188951. 
 
12. Bordeira-Carrico R, Pego AP, Santos M, Oliveira C. Cancer syndromes and therapy by 
stop-codon readthrough. Trends Mol Med. 2012;18(11):667-78. doi: 
10.1016/j.molmed.2012.09.004. PubMed PMID: 23044248. 
 
13. Nomakuchi TT, Rigo F, Aznarez I, Krainer AR. Antisense oligonucleotide-directed 
inhibition of nonsense-mediated mRNA decay. Nature biotechnology. 2016;34(2):164-6. 
doi: 10.1038/nbt.3427. PubMed PMID: 26655495; PubMed Central PMCID: 
PMCPMC4744113. 
 
14. Martin L, Grigoryan A, Wang D, Wang J, Breda L, Rivella S, et al. Identification and 
characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress 
nonsense p53 mutations. Cancer research. 2014;74(11):3104-13. doi: 10.1158/0008-
144 
 
5472.CAN-13-2235. PubMed PMID: 24662918; PubMed Central PMCID: 
PMCPMC4040335. 
 
15. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, et al. Nonsense-
mediated mRNA decay affects nonsense transcript levels and governs response of cystic 
fibrosis patients to gentamicin. The Journal of clinical investigation. 2007;117(3):683-92. 
doi: 10.1172/JCI28523. PubMed PMID: 17290305; PubMed Central PMCID: 
PMCPMC1783999. 
 
16. Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour immunity by targeted 
inhibition of nonsense-mediated mRNA decay. Nature. 2010;465(7295):227-30. doi: 
10.1038/nature08999. PubMed PMID: 20463739; PubMed Central PMCID: 
PMCPMC3107067. 
 
17. Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS, Bertrand E, et al. 
Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals 
the dynamic of NMD factors in P-bodies. J Cell Biol. 2007;178(7):1145-60. doi: 
10.1083/jcb.200611086. PubMed PMID: 17893241; PubMed Central PMCID: 
PMCPMC2064650. 
 
18. Dang Y, Low WK, Xu J, Gehring NH, Dietz HC, Romo D, et al. Inhibition of nonsense-
mediated mRNA decay by the natural product pateamine A through eukaryotic initiation 
factor 4AIII. The Journal of biological chemistry. 2009;284(35):23613-21. doi: 
10.1074/jbc.M109.009985. PubMed PMID: 19570977; PubMed Central PMCID: 
PMCPMC2749136. 
 
19. Nickless A, Jackson E, Marasa J, Nugent P, Mercer RW, Piwnica-Worms D, et al. 
Intracellular calcium regulates nonsense-mediated mRNA decay. Nat Med. 2014;20(8):961-




20. Bhuvanagiri M, Lewis J, Putzker K, Becker JP, Leicht S, Krijgsveld J, et al. 5-azacytidine 
inhibits nonsense-mediated decay in a MYC-dependent fashion. EMBO Mol Med. 
2014;6(12):1593-609. doi: 10.15252/emmm.201404461. PubMed PMID: 25319547; 
PubMed Central PMCID: PMCPMC4287977. 
 
21. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated 
protein kinase in mechanism of metformin action. The Journal of clinical investigation. 
2001;108(8):1167-74. doi: 10.1172/JCI13505. PubMed PMID: 11602624; PubMed Central 
PMCID: PMCPMC209533. 
 
22. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, et al. Dorsomorphin 
inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 
2008;4(1):33-41. doi: 10.1038/nchembio.2007.54. PubMed PMID: 18026094; PubMed 
Central PMCID: PMCPMC2727650. 
 
23. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of 
protein kinase inhibitors: a further update. The Biochemical journal. 2007;408(3):297-315. 
doi: 10.1042/BJ20070797. PubMed PMID: 17850214; PubMed Central PMCID: 
PMCPMC2267365. 
 
24. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, et 
al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent 
apoptosis. Cell Mol Life Sci. 2007;64(10):1290-302. doi: 10.1007/s00018-007-7080-4. 
PubMed PMID: 17447005. 
 
25. Kim N, Lee JO, Lee HJ, Lee YW, Kim HI, Kim SJ, et al. AMPK, a metabolic sensor, is 
involved in isoeugenol-induced glucose uptake in muscle cells. J Endocrinol. 
2016;228(2):105-14. doi: 10.1530/JOE-15-0302. PubMed PMID: 26585419; PubMed 




26. Gollavilli PN, Kanugula AK, Koyyada R, Karnewar S, Neeli PK, Kotamraju S. AMPK 
inhibits MTDH expression via GSK3beta and SIRT1 activation: potential role in triple 
negative breast cancer cell proliferation. FEBS J. 2015;282(20):3971-85. doi: 
10.1111/febs.13391. PubMed PMID: 26236947. 
 
27. Rios M, Foretz M, Viollet B, Prieto A, Fraga M, Costoya JA, et al. AMPK activation by 
oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer 
research. 2013;73(8):2628-38. doi: 10.1158/0008-5472.CAN-12-0861. PubMed PMID: 
23370326. 
 
28. Liu X, Chhipa RR, Nakano I, Dasgupta B. The AMPK inhibitor compound C is a potent 
AMPK-independent antiglioma agent. Mol Cancer Ther. 2014;13(3):596-605. doi: 
10.1158/1535-7163.MCT-13-0579. PubMed PMID: 24419061; PubMed Central PMCID: 
PMCPMC3954437. 
 
29. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, et al. In vitro metformin 
anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008;110(2):246-50. 
doi: 10.1016/j.ygyno.2008.04.008. PubMed PMID: 18495226. 
 
30. Vucicevic L, Misirkic M, Janjetovic K, Vilimanovich U, Sudar E, Isenovic E, et al. 
Compound C induces protective autophagy in cancer cells through AMPK inhibition-
independent blockade of Akt/mTOR pathway. Autophagy. 2011;7(1):40-50. PubMed 
PMID: 20980833. 
 
31. Egan D, Kim J, Shaw RJ, Guan KL. The autophagy initiating kinase ULK1 is regulated via 
opposing phosphorylation by AMPK and mTOR. Autophagy. 2011;7(6):643-4. PubMed 
PMID: 21460621; PubMed Central PMCID: PMCPMC3359466. 
 
32. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct 
phosphorylation of Ulk1. Nature cell biology. 2011;13(2):132-41. doi: 10.1038/ncb2152. 
PubMed PMID: 21258367; PubMed Central PMCID: PMCPMC3987946. 
147 
 
33. Wengrod J, Martin L, Wang D, Frischmeyer-Guerrerio P, Dietz HC, Gardner LB. Inhibition 
of nonsense-mediated RNA decay activates autophagy. Mol Cell Biol. 2013;33(11):2128-
35. doi: 10.1128/MCB.00174-13. PubMed PMID: 23508110; PubMed Central PMCID: 
PMCPMC3648072. 
 
34. Yamashita A, Ohnishi T, Kashima I, Taya Y, Ohno S. Human SMG-1, a novel 
phosphatidylinositol 3-kinase-related protein kinase, associates with components of the 
mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA 
decay. Genes & development. 2001;15(17):2215-28. doi: 10.1101/gad.913001. PubMed 
PMID: 11544179; PubMed Central PMCID: PMCPMC312771. 
 
35. Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate machinery 
that shapes transcriptomes. Nat Rev Mol Cell Biol. 2015;16(11):665-77. doi: 
10.1038/nrm4063. PubMed PMID: 26397022. 
 
36. Hauer C, Sieber J, Schwarzl T, Hollerer I, Curk T, Alleaume AM, et al. Exon Junction 
Complexes Show a Distributional Bias toward Alternatively Spliced mRNAs and against 
mRNAs Coding for Ribosomal Proteins. Cell Rep. 2016;16(6):1588-603. doi: 
10.1016/j.celrep.2016.06.096. PubMed PMID: 27475226; PubMed Central PMCID: 
PMCPMC4978704. 
 
37. Hu J, Li Y, Li P. MARVELD1 Inhibits Nonsense-Mediated RNA Decay by Repressing 
Serine Phosphorylation of UPF1. PloS one. 2013;8(6):e68291. doi: 
10.1371/journal.pone.0068291. PubMed PMID: 23826386; PubMed Central PMCID: 
PMCPMC3694864. 
 
38. Yepiskoposyan H, Aeschimann F, Nilsson D, Okoniewski M, Muhlemann O. 
Autoregulation of the nonsense-mediated mRNA decay pathway in human cells. RNA. 
2011;17(12):2108-18. doi: 10.1261/rna.030247.111. PubMed PMID: 22028362; PubMed 
Central PMCID: PMCPMC3222124. 
148 
 
39. Huang L, Lou CH, Chan W, Shum EY, Shao A, Stone E, et al. RNA homeostasis governed 
by cell type-specific and branched feedback loops acting on NMD. Molecular cell. 
2011;43(6):950-61. doi: 10.1016/j.molcel.2011.06.031. PubMed PMID: 21925383; PubMed 
Central PMCID: PMCPMC4281029. 
 
40. Ha J, Daniel S, Broyles SS, Kim KH. Critical phosphorylation sites for acetyl-CoA 
carboxylase activity. The Journal of biological chemistry. 1994;269(35):22162-8. PubMed 
PMID: 7915280. 
 
41. Brumbaugh KM, Otterness DM, Geisen C, Oliveira V, Brognard J, Li X, et al. The mRNA 
surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian 
cells. Molecular cell. 2004;14(5):585-98. doi: 10.1016/j.molcel.2004.05.005. PubMed 
PMID: 15175154. 
 
42. Sanduja S, Feng Y, Mathis RA, Sokol ES, Reinhardt F, Halaban R, et al. AMPK promotes 
tolerance to Ras pathway inhibition by activating autophagy. Oncogene. 2016;35(40):5295-
303. doi: 10.1038/onc.2016.70. PubMed PMID: 27041569; PubMed Central PMCID: 
PMCPMC6086350. 
 
43. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 
2010;140(3):313-26. doi: 10.1016/j.cell.2010.01.028. PubMed PMID: 20144757; PubMed 
Central PMCID: PMCPMC2852113. 
 
44. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, et al. 
The unfolded protein response protects human tumor cells during hypoxia through 
regulation of the autophagy genes MAP1LC3B and ATG5. The Journal of clinical 
investigation. 2010;120(1):127-41. doi: 10.1172/JCI40027. PubMed PMID: 20038797; 




45. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFss 
and BMP pathways. Cell Signal. 2011;23(11):1831-42. doi: 10.1016/j.cellsig.2011.06.019. 
PubMed PMID: 21740966. 
 
46. Longman D, Hug N, Keith M, Anastasaki C, Patton EE, Grimes G, et al. DHX34 and NBAS 
form part of an autoregulatory NMD circuit that regulates endogenous RNA targets in 
human cells, zebrafish and Caenorhabditis elegans. Nucleic acids research. 
2013;41(17):8319-31. doi: 10.1093/nar/gkt585. PubMed PMID: 23828042; PubMed Central 
PMCID: PMCPMC3783168. 
 
47. Wang G, Jiang B, Jia C, Chai B, Liang A. MicroRNA 125 represses nonsense-mediated 
mRNA decay by regulating SMG1 expression. Biochem Biophys Res Commun. 
2013;435(1):16-20. doi: 10.1016/j.bbrc.2013.03.129. PubMed PMID: 23583196. 
 
48. Jin Y, Zhang F, Ma Z, Ren Z. MicroRNA 433 regulates nonsense-mediated mRNA decay 
by targeting SMG5 mRNA. BMC Mol Biol. 2016;17(1):17. doi: 10.1186/s12867-016-0070-
z. PubMed PMID: 27473591; PubMed Central PMCID: PMCPMC4966760. 
 
49. Dai RY, Zhao XF, Li JJ, Chen R, Luo ZL, Yu LX, et al. Implication of transcriptional 
repression in compound C-induced apoptosis in cancer cells. Cell Death Dis. 2013;4:e883. 
doi: 10.1038/cddis.2013.419. PubMed PMID: 24157877; PubMed Central PMCID: 
PMCPMC3920957. 
 
50. Yang WL, Perillo W, Liou D, Marambaud P, Wang P. AMPK inhibitor compound C 
suppresses cell proliferation by induction of apoptosis and autophagy in human colorectal 
cancer cells. J Surg Oncol. 2012;106(6):680-8. doi: 10.1002/jso.23184. PubMed PMID: 
22674626. 
 
51. Jin J, Mullen TD, Hou Q, Bielawski J, Bielawska A, Zhang X, et al. AMPK inhibitor 
Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis 
in MCF7 breast carcinoma cells. J Lipid Res. 2009;50(12):2389-97. doi: 
150 
 
10.1194/jlr.M900119-JLR200. PubMed PMID: 19528633; PubMed Central PMCID: 
PMCPMC2781311. 
 
52. Huang SW, Wu CY, Wang YT, Kao JK, Lin CC, Chang CC, et al. p53 modulates the 
AMPK inhibitor compound C induced apoptosis in human skin cancer cells. Toxicol Appl 
Pharmacol. 2013;267(1):113-24. doi: 10.1016/j.taap.2012.12.016. PubMed PMID: 
23274516. 
 
53. Garulli C, Kalogris C, Pietrella L, Bartolacci C, Andreani C, Falconi M, et al. 
Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by 
inhibition of bone morphogenetic protein signaling. Cell Signal. 2014;26(2):352-62. doi: 
10.1016/j.cellsig.2013.11.022. PubMed PMID: 24280125. 
 
54. Madhu V, Dighe AS, Cui Q, Deal DN. Dual Inhibition of Activin/Nodal/TGF-beta and 
BMP Signaling Pathways by SB431542 and Dorsomorphin Induces Neuronal 
Differentiation of Human Adipose Derived Stem Cells. Stem Cells Int. 2016;2016:1035374. 
doi: 10.1155/2016/1035374. PubMed PMID: 26798350; PubMed Central PMCID: 
PMCPMC4699250. 
 
55. Hao J, Daleo MA, Murphy CK, Yu PB, Ho JN, Hu J, et al. Dorsomorphin, a selective small 
molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. 
PloS one. 2008;3(8):e2904. doi: 10.1371/journal.pone.0002904. PubMed PMID: 18682835; 
PubMed Central PMCID: PMCPMC2483414. 
 
56. Li T, Shi Y, Wang P, Guachalla LM, Sun B, Joerss T, et al. Smg6/Est1 licenses embryonic 
stem cell differentiation via nonsense-mediated mRNA decay. The EMBO journal. 
2015;34(12):1630-47. doi: 10.15252/embj.201489947. PubMed PMID: 25770585; PubMed 
Central PMCID: PMCPMC4475398. 
 
57. Lou CH, Dumdie J, Goetz A, Shum EY, Brafman D, Liao X, et al. Nonsense-Mediated 
RNA Decay Influences Human Embryonic Stem Cell Fate. Stem Cell Reports. 
151 
 
2016;6(6):844-57. doi: 10.1016/j.stemcr.2016.05.008. PubMed PMID: 27304915; PubMed 
Central PMCID: PMCPMC4912386. 
 
58. Hu Z, Yau C, Ahmed AA. A pan-cancer genome-wide analysis reveals tumour 
dependencies by induction of nonsense-mediated decay. Nature communications. 
2017;8:15943. doi: 10.1038/ncomms15943. PubMed PMID: 28649990; PubMed Central 
PMCID: PMCPMC5490262. 
 
59. Nickless A, You Z. Studying Nonsense-Mediated mRNA Decay in Mammalian Cells Using 
a Multicolored Bioluminescence-Based Reporter System. Methods in molecular biology. 
2018;1720:213-24. doi: 10.1007/978-1-4939-7540-2_16. PubMed PMID: 29236262. 
 
60. Nickless A, Bailis JM, You Z. Control of gene expression through the nonsense-mediated 
RNA decay pathway. Cell Biosci. 2017;7:26. doi: 10.1186/s13578-017-0153-7. PubMed 
PMID: 28533900; PubMed Central PMCID: PMCPMC5437625. 
 
61. Armstrong JL, Flockhart R, Veal GJ, Lovat PE, Redfern CP. Regulation of endoplasmic 
reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. The Journal of 
biological chemistry. 2010;285(9):6091-100. doi: 10.1074/jbc.M109.014092. PubMed 
PMID: 20022965; PubMed Central PMCID: PMCPMC2825403. 
 
62. Chen X, Paudyal SC, Chin RI, You Z. PCNA promotes processive DNA end resection by 
Exo1. Nucleic acids research. 2013;41(20):9325-38. doi: 10.1093/nar/gkt672. PubMed 
PMID: 23939618; PubMed Central PMCID: PMCPMC3814391. 
 
63. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. 
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 





64. Yla-Anttila P, Vihinen H, Jokitalo E, Eskelinen EL. Monitoring autophagy by electron 
microscopy in Mammalian cells. Methods Enzymol. 2009;452:143-64. doi: 10.1016/S0076-








Chapter 4:  






The quantity and quality of the transcriptome must be regulated to maintain the fidelity of the 
central dogma. Pre-mRNA splicing greatly contributes to the abundance of the transcriptome by 
producing multiple mRNA isoforms, which serve different functions in cells, including tissue-
specific development1. Due to the complexity of the splicing process, errors can occur, which 
may cause defects in development, genetic disorders, and cancer2. Errors in splicing necessitate 
RNA surveillance mechanisms to regulate the transcriptome. Nonsense mediated RNA decay 
(NMD) regulates both the quantity and the quality of the mRNA3. By targeting nonsense 
mRNAs with pre-mature stop codons (PTCs), including those produced by alternative/mis-
splicing, NMD prevents expression of truncated protein products which may possess dominant 
negative effects in the cell4.  Consequently, NMD plays a major role in modifying the phenotypic 
outcomes of many genetic disorders and cancers associated with nonsense mutations5. By 
targeting non-mutant RNAs, NMD fine-tunes the transcriptome to facilitate many biological 
processes including embryonic development, cell differentiation, and cellular response to 
stress6,7,8.  
Previous studies have implicated pre-mRNA splicing in promoting NMD, especially in 
mammalian systems where exon junction complexes (EJCs) deposited during splicing promote 
recognition of PTCs9. However, an EJC-independent model of NMD exists, even in some 
organisms, such as S. pombe (which has EJC homologs), where splicing still promotes NMD10,11. 
It is, therefore, unclear whether splicing per se is required to promote NMD in mammalian 
systems, or whether the spliceosome components themselves promote NMD, perhaps by 
recruiting and maintaining interactions of EJCs with the mRNA. In this dissertation, we have 
explored the intricate relationship between pre-mRNA splicing, including how pre-mRNA 
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splicing can promote NMD, the impact of defective splicing on NMD, and the impact of NMD 
disruption in cells with defective splicing. 
To better understand the process of NMD, including how and whether splicing or splicing factors 
promote NMD, we developed a novel, specific, and convenient NMD reporter system to measure 
NMD in individual cells and used it to perform a genome-wide CRISPR/Cas9 knockout screen to 
identify genes that promote NMD in human cells. Our findings further highlighted the 
importance of splicing in promoting NMD, as the spliceosome was the most enriched pathway 
and several splicing factors were among the top hits. Specifically, we found that the SF3B 
complex promotes NMD in an EJC-dependent manner, without requiring splicing of the target 
mRNA, suggesting that the recruitment of splicing factors to the mRNA, but not splicing per se, 
promotes NMD.  
SF3B1 and other U2 snRNP-related genes are mutated in cancers, such as hematological 
malignancies (MDS, AML, and CMML), and solid tumors, such as uveal melanoma, breast, lung 
and pancreatic cancers12. These mutations cause distinct patterns of mis-splicing. We predicted 
that these mutations may have an impact on NMD, either directly by impairing the role of the 
splicing factors in NMD, or indirectly by mis-splicing NMD factors or over-whelming the NMD 
pathway with too many NMD targets. Our findings suggest that these cancer-associated splicing 
factor mutations partially inhibit NMD. With this observation, we made a prediction that further 
NMD inhibition would make the cells harboring the splicing factor mutations more susceptible 
to cell death. Indeed, cells expressing splicing factor mutations were remarkably sensitive to 
further inhibition of NMD, suggesting that targeting NMD is a potential novel therapeutic 
strategy to treat cancers with defective splicing. 
156 
 
Aberrant R-loops have been suggested as the unifying mechanism for the etiology of cancers 
caused by splicing factor mutations, as the expression of the cancer-associated splicing factor 
mutations increase R-loops13. R-loops, which are co-transcriptional structures consisting of 
RNA:DNA hybrids and displaced single-stranded DNA, can cause genomic instability if 
unregulated14.  While NMD has not been implicated in R-loop regulation before, we found that 
NMD inhibition or the depletion of an NMD factor increases R-loops. We anticipated that the 
combination of splicing factor mutations and NMD inhibition would result in additive R-loops, 
and associated genomic instability. Indeed, we found that cells expressing splicing factor 
mutations had more R-loops, compared to controls, and that inhibition of NMD further increased 
R-loops and genomic instability in these cells. Consistently, reducing R-loops by over-
expressing the R-loop removing enzyme RNase H1, rescued the cell sensitivity to NMD 
inhibition in cells expressing splicing factor mutants. These observations suggest that R-loops 
play a crucial role in the sensitivity of cells with spliceosome mutations to NMD inhibition. 
Because inhibiting NMD is an attractive approach for treating some genetic disorders and 
cancers, including cancers with defective splicing presented here, efforts are needed to identify 
and characterize specific and non-toxic small molecule inhibitors of NMD. In this dissertation, 
we tested a compound that targets SMG1 (SMG1i), and found that SMG1i inhibits SMG1, but 
does not inhibit the related kinases, including ATR. SMG1i also selectively kills cancer cells 
with spliceosome mutations. We also found that the commonly used AMPK inhibitor, compound 
C potently, inhibits NMD, independent of AMPK inhibition. This compound is, therefore, a non-
specific inhibitor of NMD, suggesting that caution is needed when using this drug, and that more 





How does SF3B promote NMD? 
While it is apparent that pre-mRNA splicing enhances NMD, it remains to be determined 
whether and how the spliceosome process itself or the spliceosome factors promote NMD. Our 
finding that the SF3B spliceosomal complex promotes NMD in an EJC-dependent manner, 
without the splicing of the target mRNA, supports a model where the spliceosome process itself 
is dispensable for NMD in mammalian systems. Because EJC is deposited during splicing, our 
model proposes that the SF3B tetrameric complex is involved in EJC recruitment, or stabilization 
during splicing. Moreover, our model suggests that SF3B complex acts upstream of CWC22, a 
spliceosome protein that directly recruits the EJC core protein eIF4A3 during splicing. However, 
more studies are needed to elucidate whether SF3B directly interacts with EJC factors, or 
CWC22 during EJC assembly. Tethering 3 proteins of the SF3B complex individually caused the 
decay of the target mRNA through NMD, which suggests that the complex as a whole is likely 
important for NMD. However, it will be important to determine which one, among the seven 
proteins within the complex interacts with CWC22 or EJC factors. To better understand the 
importance of such interaction for NMD, it will be critical to identify a separation of function 
mutant that retains its splicing function, but loses its NMD function, and vice versa.  
Previous studies have suggested that CWC22 and eIF4A3 recruitment occurs before or during 
the first catalytic step of splicing15. SF3B complex and the other spliceosome factors identified 
as putative NMD factors/regulators in our screen (SF3A3, PRPF19, RNF113A, and 
DGCR34)16,17,18 are recruited before the catalytic steps of splicing, suggesting that the 
spliceosome proteins required for early steps of splicing may also be important for EJC assembly 
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and NMD. Consistent with this notion, tethering SNRNP40 (component of U5 SnRNP that is 
recruited later) did not cause the decay of the target mRNA, suggesting that this protein is not 
important for NMD. SNRNP40 interacts with PRPF8 and may promote exon ligation and the 
unwinding of U4/U6 and U2 snRNA after splicing is completed19. To further support the 
importance of only the early spliceosome factors for NMD, it will be important to determine 
other key splicing factors required for late steps of splicing, after EJC assembly, that are 
dispensable for NMD. It will be important to demonstrate that indeed the late splicing factors 
tested are required and functional for splicing, but do not promote NMD. Completing these 
studies will facilitate a better understanding of the process of NMD and the relationship between 
pre-mRNA splicing and NMD in mammalian systems. 
How do cancer-associated splicing factor mutations attenuate NMD? 
Splicing factors required during early steps of splicing and participate in the 3’ss selection 
(SF3B1, U2AF1, SRSF2, ZRSR2) are commonly mutated in cancer12. Our finding that the 
expression of SF3B1K700E, or U2AF1S34F attenuates NMD is intriguing, but more experiments are 
required to solidify this finding and uncover the underlying mechanisms for the inhibition of 
NMD. The finding that the expression of splicing factor mutations attenuates NMD is consistent 
with the observation that the expression of NMD factors, which are themselves targets of NMD 
in an auto-regulatory pathway, were increased by expression of splicing factor mutants20. Since 
there is now a library of non-mutant mRNA targets of NMD, NMD activity can be assessed by 
measuring the stability of these NMD targets using RNA sequencing. Ongoing RNA sequencing 
experiments will determine whether the expression and stability of known NMD targets are 




There are at least 3 possibilities that may explain attenuation of NMD by the expression of these 
splicing factor mutants. First, since SF3B1 and likely other early spliceosome factors may 
promote NMD, these mutations may impair the function of these proteins in promoting NMD. 
All cancer-associated mutations in SF3B1 are found on the heat domain that contributes to the 
tertiary structure of the SF3B complex. However, the SF3B1K700E mutation does not affect the 
interaction of SF3B complex with U2AF2, or decrease its affinity for RNA21. It will be 
interesting to determine whether the SF3B1K700E mutation somehow affects the conformation of 
the complex in a way that no-longer supports interaction with EJC/CWC22 to promote NMD. 
Second, since the splicing factor mutations cause aberrant splicing of multiple genes, it is 
possible that some key NMD factors are mis-spliced when the splicing factor mutations are 
expressed. In support of this notion, SMG7 was found to be mis-spliced after the expression of 
cancer-associated mutations in SF3B1, U2AF1, and SRSF222. It will be important to directly 
check whether NMD factors are mis-spliced in the conditions used in our experiments, whether 
the resulting mRNAs are stable, and whether the protein products are functional. Lastly, 
expressing splicing factor mutations can generate numerous nonsense mRNAs that need to be 
degraded by NMD that simply over-whelm the NMD machinery, thus slowing down the NMD 
process. Indeed, it was found that about 50% of the aberrantly spliced mRNAs resulting from the 
expression of cancer-associated SF3B1 mutations were NMD targets23. Uncovering the 
underlying mechanisms for NMD attenuation by expression of splicing factor mutants may 
provide some clues on the function of splicing factors in NMD, and perhaps additional methods 
of modulating NMD in human cells. 
How does dysregulated splicing and disruption of NMD increase R-loops? 
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Our finding that cells harboring splicing factor mutations are remarkably sensitive to NMD 
inhibition suggest that NMD is a novel vulnerability for these cells. Our results indicate that 
dysregulated splicing and disruption of NMD independently increase R-loops and genomic 
instability, and that the combination causes additive effects for both phenotypes. Importantly, 
ectopic expression of RNase H1, which removes R-loops, largely rescues the sensitivity of 
spliceosome mutant cells to NMD inhibition. This observation suggests that R-loops play a 
major role in the cell death caused by NMD inhibition in cells expressing spliceosome mutants. 
However, it remains to be determined how each splicing factor mutation increases R-loops, and 
how NMD regulates R-loops. Several studies have implicated splicing factors, including SF3B1, 
in regulation of R-loops24. It is, however, still unclear what impact the mutations may have on 
the roles of the splicing factors in regulating R-loops, as these mutations do not block, but alter 
the splicing process25. A recent study showed that the SRSF2P95H mutation increased R-loops by 
increasing RNA polymerase II pausing, which is associated with the splicing-independent 
function of SRSF2 during transcription13. Since this transcription role is unique to SRSF2, and 
not other commonly mutated splicing factors, it will be important to determine whether other 
splicing factors have a similar role in transcription, or increase R-loops via other mechanisms.  
NMD has not been directly implicated in R-loop regulation before. However, a study showed 
that the depletion of key NMD factors SMG1, UPF1, and SMG6 increased association of 
TERRA RNA (transcribed from the telomeres) with the telomere and increased chromosomal 
breaks at subtelomeric and intrachoromosomal regions26, suggesting that NMD/NMD factors 
may regulate R-loops at the telomeres (caused by association of TERRA with telomeric DNA 
sequence) and at other regions of the chromosome27. The observation that SMG1, UPF1, and 
SMG6 individual depletion caused a similar phenotype is intriguing, because it suggests that 
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perhaps an intact NMD pathway is needed to regulate R-loops. However, the depletion of UPF2 
(another NMD factor) to similar levels, caused a milder phenotype, suggesting that a UPF2-
independent NMD, which reportedly exists in human cells10, is likely the important pathway that 
regulates R-loops. While our results show that SMG1 inhibition and UPF1 depletion increase R-
loops, more experiments involving depletion of other key NMD factors are required to determine 
whether the NMD process itself is important for R-loop regulation. The next step would be to 
determine how NMD may regulate R-loops.  
NMD may regulate R-loops directly or indirectly. Previous observation that the NMD factors 
were present at the telomeres suggest a direct role of NMD/NMD factors at regulating R-loops at 
the telomeres. However, it is hard to explain a direct role of a translation-dependent pathway in 
removing R-loops in the nucleus. It is, therefore, more likely that NMD regulates R-loops 
indirectly. Other mRNA processing factors regulate R-loops by binding to nascent RNA to 
prevent annealing of mRNA to DNA, unwinding RNA:DNA hybrids, and ensuring efficient 
transcription, splicing and mRNA export28. It is possible that NMD reduces R-loops by 
facilitating the degradation of many mRNAs that are usually still bound by RNA binding 
proteins, such as EJCs, which allows for quicker recycling of RNA binding proteins that bind 
RNA and prevent formation of R-loops in the nucleus.  
NMD can also prevent R-loops by reducing features that pre-dispose to R-loop formation. One 
such feature is G-quadruplex (G4) formation, which is often formed at GC-rich chromosomal 
regions, including mammalian telomeres. It was found that G4s form on the displaced ssDNA on 
an R-loop, and that stabilizing G4s, such as by treatment with G4 ligands, increased R-loops29,30. 
There are now many proteins that bind and stabilize G4, such as MYC-Associated Zinc Finger 
Protein (MAZ), nucleolin, and PARP131. Since NMD regulates many non-mutant genes, it is 
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possible that NMD regulates the expression of a gene that stabilizes G4s, so that NMD inhibition 
allows for the expression of such a gene and increases R-loops. It is worth noting that some 
mutant proteins can also promote G4s. A well characterized example is the cancer-associated 
mutant p53 that was shown to bind and stabilize G4s and alter transcription32. It is, therefore, 
tempting to speculate that NMD may regulate R-loops by regulating both physiological and 
mutant mRNAs to prevent expression of proteins that may stabilize R-loop structures. 
While R-loops seem to be important for cell death resulting from inhibiting NMD in cells 
expressing splicing factor mutants, it is likely that this is not the only mechanism involved. 
RNase H1 over-expression is not expected to restore NMD, or reduce the levels of mis-spliced 
mRNAs. What then is the consequence of increased aberrantly spliced mRNAs, due to NMD 
inhibition, in cells with defective splicing that are now viable because R-loops are reduced? It 
will be important to determine if the accumulation of aberrant mRNAs contribute to the cell 
death caused by NMD inhibition and defective splicing.  
Developing small molecule inhibitors of NMD 
Small molecule compounds are crucial tools that facilitate modulation of cellular pathways, 
which promotes a better understanding of the pathways and potential targeting of such pathways 
for therapeutic purposes. In chapter 2, we have tested the use of a ATP-competitive sulfonamide 
compound developed by Amgen (SMG1i). This inhibitor targets SMG1, which is the only kinase 
in the NMD pathway. ATP-competitive compounds are common kinase inhibitors, but their 
specificities are sometimes low. However, SMG1i seems to be a specific inhibitor for SMG1. 
We found that SMG1i potently inhibits NMD and selectively kills cells harboring spliceosome 
mutations, but does not inhibit other PIKK-related kinases, such as ATR. Ongoing studies will 
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further characterize this compound and its derivatives, and evaluate the use of this compound in 
human cells and mouse models to selectively kill cancer cells with defective splicing. In chapter 
3, we describe another new small molecule inhibitor of NMD. We found that Compound C, a 
common AMPK inhibitor, inhibits NMD probably by down-regulating some key NMD factor 
proteins. Because Compound C does not reduce the mRNA levels of these NMD factors, 
evaluating whether Compound C up-regulates micro RNAs that target NMD factors will be one 
avenue of uncovering how this compound inhibits NMD. Since compound C increases 
autophagy, it will be interesting to determine if key NMD factors are regulated by autophagy. 
Identifying specifically how Compound C inhibits NMD may provide more information on how 
to develop different small molecules with similar NMD-inhibiting capabilities. Because this 
compound inhibits AMPK and other kinases, future studies should focus on identifying other 
derivatives of this compound that more specifically inhibit NMD.  
Targeting NMD and other pathways to treat cancers with defective splicing 
Our finding that NMD inhibition preferentially kills cells harboring cancer-associated 
spliceosome mutations has wide-ranging clinical implications, as it provides a new strategy for 
treating many cancers with defective splicing. Since the results presented here were obtained 
from experiments in cell lines, it is important to confirm that inhibiting NMD in vivo will have 
similar effects. Ongoing experiments are now testing whether inhibition of NMD will 
preferentially reduce the viability of cells expressing splicing factor mutants that are implanted in 
mice. The next step would be to develop a mouse model of a cancer, such as leukemia that 




The finding that R-loops play a major role in the sensitivity of spliceosome mutant cells to NMD 
inhibition provides new avenues for combination therapies to treat cancers with defective 
splicing. Combination of NMD perturbation and other chemotherapeutic agents, particularly 
those that impair the DNA repair pathway, may be more effective at treating cancers with 
defective splicing. This is because accumulation of R-loops, caused by NMD inhibition and 
spliceosome mutants, causes replication stress and generates DNA breaks that must be repaired 
to promote cell viability and proliferation33. Therefore, impairing the subsequent repair pathway 
would lead to accumulation of DNA breaks and cell death. In support of this idea, cells 
expressing splicing factor mutants and have higher basal levels of R-loops were sensitive to 
inhibition of the DNA repair protein, ATR34. It will be interesting to directly compare the effects 
of treating with NMD inhibitors and ATR inhibitors (separately and combined) in cells harboring 
splicing factor mutants. 
 Small molecule splicing modulators that bind to SF3B1 have also been shown to cause mis-
splicing and increase R-loops. These inhibitors were also effective at killing cells with defective 
splicing in vitro and in mouse models, although clinical trials with these compounds were 
suspended due to toxicity, or lack of objective clinical response35,36. The rationale for the 
effectiveness of these drugs in killing cells with defective splicing was based on the observation 
that mutations in splicing factors are always heterozygous during tumorigenesis, suggesting that 
some level of normal splicing promotes survival of cells with defective splicing. Therefore, 
further altering the splicing process, and accumulating mis-spliced RNA would lead to cell 
death37. Inhibition of NMD would also increase mis-spliced mRNAs, as a big percent of mis-
spliced RNAs are regulated by NMD. Therefore, it will be interesting to directly test whether 
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combination of splicing modulators and NMD inhibition would be beneficial in treating cancers 
harboring spliceosome mutations. 
Lastly, combination of NMD inhibition and G4 analogs that stabilize G4s and increase R-loops 
may also be an effective strategy for treating cancers with defective splicing. Recently, G4 
ligands have attracted great attention as anti-cancer compounds due to their cytotoxicity in cells 
deficient of DNA repair proteins, such as BRCA230. One G4 ligand (CX-5461) is now in an 
advanced phase I clinical trial for patients with BRCA1/2 deficient cancer (NCT02719977). 
Stabilization of G4s at the telomeres have also been shown to impair telomerase activity, thus 
preventing lengthening of telomeres in cancer cells with activated telomerase38. These effects of 
G4 ligands (increased R-loops, DNA damage, and inhibition of telomerase), combined with the 
role of NMD in regulating R-loops and telomere maintenance, suggest that there may be a 
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